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Abstract
Campylobacter jejuni and Helicobacter pylori are phylogenetically related human gastrointestinal pathogens. C. jejuni colonizes the intestine and is the leading cause of bacterial
gastroenteritis worldwide. H. pylori colonizes the stomach of half the world’s population,
causing gastritis, gastric ulcers and gastric cancer. Both pathogens express glycoproteins and
glycolipids (capsule, lipooligosaccharide or lipopolysaccharide (LPS)) that are important in
pathogenesis. Sugar units from capsule or LPS can modify proteins in several bacteria. We
reasoned that this may occur in C. jejuni and H. pylori as means to diversify their surface
glycosylation and aid in colonization, immune evasion and virulence.
The putative sugar nucleotide dehydratase of C. jejuni NCTC 11168, Cj1319, has predicted
roles in initiating the pathway for capsular heptose modification or participating in
legionaminic acid synthesis for flagellin glycosylation. Alternatively, we propose that Cj1319
may use the GDP-manno-heptose precursor normally used for capsular heptose modification
in a novel protein glycosylation pathway. We determined through enzymatic reactions with
GDP-manno-heptose and compositional analysis of capsule from a cj1319 knockout mutant
that Cj1319 does not use GDP-manno-heptose and does not affect capsule. Furthermore, our
comprehensive mass spectrometry (MS) analysis of flagellin glycopeptides showed that
flagellin glycosylation is highly heterogeneous and includes modification by legionaminic
acid. We determined that the cj1319 mutant glycosylates flagellins with more legionaminic
acid than WT, thus excluding the direct involvement of Cj1319 in legionaminic acid synthesis.
This increase in legionaminic acid correlated with higher colonization of chickens but with
lower virulence in Galleria mellonella larvae.
H. pylori NCTC 11637 expresses Lewis Y (Ley) blood group mimics in the O-antigen of LPS
which is important in immune evasion. We determined that the outer membrane protein HopE
is glycosylated with Ley through a comprehensive MS analysis of outer membrane peptides.
This novel level of host mimicry is likely important for colonization and pathogenicity.

Keywords
Campylobacter jejuni, Helicobacter pylori, Cj1319, capsule, lipooligosaccharide,
lipopolysaccharide, glycoproteins, O-antigen, GDP-manno-heptose, Lewis Y, legionaminic
acid, pseudaminic acid, glycopeptide, mass spectrometry.
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Chapter 1

1

Introduction

Campylobacter jejuni and Helicobacter pylori are two important phylogenetically-related
gastro-intestinal human pathogens, both with major health and economic burdens
(Deltenre, 2012; Kaakoush et al., 2015; Peleteiro et al., 2014; Plummer et al., 2015). Each
of these two bacterial species possess and express glycosylation machineries for the
glycosylation of both lipids and proteins (Day et al., 2012; Rubin and Trent, 2013). This
chapter provides a detailed overview of the glycosylation machineries, the glycolipids and
glycoproteins expressed by each, and their relationship to host colonization and infection.
An overview of mass spectrometry analysis methods for glycoproteins is also presented as
this analysis is complex but integral for the understanding of a significant amount of data
presented in this dissertation.

1.1 Campylobacter jejuni
Discovery and general characteristics
Campylobacters were first reported by Escherich in 1886 who noted spirally shaped
microbes in intestinal contents from 16 of 17 children who had died of diarrheal disease
(Escherich, 1886). Thereafter, it was not until 1913 that these organisms were first isolated
from ovine abortuses whereby the bacteria were referred to as ‘Vibrio’ due to their
similarity with Vibrio cholera (McFadyean and Stockman, 1913). However, it was shown
that these microbes were genetically distinct from other vibrios due to their small genomes,
non-fermentative metabolism and microaerophilic nature. In 1963, the genus
Campylobacter, from the Greek word for curved rod, was created and used to classify these
microbes to distinguish them from the Vibrio genus (Sebald and Veron, 1963; Veron and
Chatelain, 1973). Campylobacter are small microaerophilic spirally shaped gram negative
cells (0.2–0.8 μm × 0.5–5 μm) (On, 2001). They obtain energy from amino acids or
tricarboxylic acid cycle intermediates and do not ferment or oxidize carbohydrates
(Vandamme, 2000). Under unfavourable growth conditions, these bacteria form viable but
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non-culturable cocci whose role is not yet understood as it is not clear if these cells can
revert to a culturable form (Portner et al., 2007). C. jejuni was recognized as one of the
three thermophilic species of Campylobacter, including coli and laridis. The interest in this
strain grew exponentially as it was isolated from children with enteritis in 1973 (Butzler et
al., 1973) and subsequently from 57 of 803 fecal samples collected from diarrheal patients
in Britain over 18 months (Skirrow, 1977).

Clinical manifestations of C. jejuni and treatment
C. jejuni is the leading cause of acute bacterial enteritis in the world, contributing to an
estimated 8.4% of all diarrheal disease worldwide, ranking fourth after rotavirus, typhoid
fever, and cryptosporidiosis (Humphrey; Murray et al., 2012; Weisent, 2010). This human
pathogen is a commensal in poultry, although this has been recently challenged (Humphrey
et al., 2014), and spreads to humans usually by the consumption of contaminated poultry
meat in the developed world and contaminated water in the developing world (Humphrey;
Kaakoush et al., 2015). The economic burden of campylobacteriosis in the United States
has been estimated at $1.6 billion annually (Batz et al., 2012). Additionally, an increase in
Campylobacter incidence was observed from 2006 to 2008, in contrast to other gastrointestinal

pathogens,

cryptosporidium, Listeria,

Salmonella, Shigella,

Shiga-

toxigenic Escherichia coli O157:H7, and Yersinia, whose incidence decreased over the
same timeframe (Batz et al., 2012).
In Canada, it was found that Campylobacter spp., mostly C. jejuni, had the highest
frequency of occurrence among all other pathogenic bacteria in agricultural water basins
across the country, with an overall prevalence of 49% (Khan et al., 2014). In the Waterloo
region of Ontario, an average of 49.69 cases of campylobacteriosis per 100,000 people
were reported from 1990 to 2004 annually (Keegan et al., 2009). In Quebec, 28,521 cases
were reported from 1996 to 2006 (Arsenault et al., 2012). British Columbia was reported
to have an average of 38 cases per year per 100,000 people between 2005 and 2009
(Kaakoush et al., 2015).
C. jejuni doses as low as a few hundred cells may lead to infection after a short incubation
time of 24-48 hours (may be up to 10 days) which is followed by severe symptoms
including watery or bloody diarrhoea, abdominal cramps, and fever (Hara-Kudo and
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Takatori, 2011; Kaakoush et al., 2015; Man, 2011). Typically, the infection is self-limiting
within a median of 6 days (Man, 2011). C. jejuni infection causes severe gastroenteritis
and is a predisposing agent of inflammatory bowel disease and celiac disease (Gradel et
al., 2009; Man, 2011; Verdu et al., 2007). Furthermore, there are many post-infection
complications that may arise following a C. jejuni infection including Guillain-Barŕe
syndrome (31% of cases attributed to C. jejuni), reactive arthritis, and Miller Fisher
syndrome, and recently irritable bowel syndrome (Israeli et al., 2010; Nielsen, 2010;
Poropatich et al., 2010). These clinical symptoms associated with C. jejuni infection are
caused by several virulence factors including: adhesins and numerous toxins,
Campylobacter invasion antigen proteins, a type 4 secretion system, capsule,
lipooligosaccharide (LOS), flagella and associated motility and protein glycosylation
(Dasti, 2010).

Genome and phase variation
C. jejuni NCTC 11168, the first sequenced strain of C. jejuni, has a circular chromosome
of 1,641,481 base pairs (30.6% G+C) which is predicted to encode 1,654 proteins and 54
stable RNA species (Gundogdu et al., 2007; Parkhill et al., 2000). Virtually no insertion
sequences or phage-associated sequences are found and there are very few repeat
sequences in its genome. Importantly, there is an abundance of hypervariable sequences
determined by homopolymeric runs of nucleotides primarily found in genes encoding the
biosynthesis or modification of surface structures, including capsule, LOS, and
glycoproteins, or in closely linked genes (such that phase variation leads to fusion or
separation of these genes) of unknown function.
Hundreds of genomes of C. jejuni strains have been sequenced and, as a result, it was found
that there is a high degree of genetic variation among strains. This made it particularly
challenging to study the pathogenesis of this organism. Much progress has been made in
terms of identifying virulence factors and key interactions with host cells using C. jejuni
strains NCTC 11168 and 81-176 as will be described below, however, to date, it remains
unclear how C. jejuni causes illness in humans while it lives in commensalism in the gut
of birds and livestock. Our laboratory has created numerous glycosylation pathway mutants
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in strain NCTC 11168, a pathogenic strain in humans that was the only strain sequenced at
the onset of our studies, and thus this strain was focused on for the work presented in this
thesis. Importantly, as will be discussed, this strain has more genetic potential for making
novel sugars for protein glycosylation.

Virulence factors of C. jejuni
1.1.4.1

Flagella and motility

Motility is an essential virulence factor of C. jejuni mediated by flagella and cell shape.
Cells can either have a unipolar flagellum or bipolar flagella. The flagella are made of two
polymerized subunits, minor subunit FlaB at the base and major subunit FlaA which makes
up the majority of the flagellum. These flagellins are O-glycosylated as discussed in section
1.1.4.3. It has been shown that FlaA is essential for colonization as a knockout mutant of
flaA results in a truncated flagellum with a motility defect and impaired colonization,
whereas FlaB was not important for colonization and a knockout mutant of flaB resulted
in nearly normal motility (Grant et al., 1993; Guerry et al., 1991; Nachamkin et al., 1993;
Pavlovskis et al., 1991; Wassenaar et al., 1991, 1993).
Unlike rod-shaped bacteria, C. jejuni increases in motility velocity as the viscosity of the
medium increases (Ferrero and Lee, 1988), which is due in part to the spiral shape of the
bacterial cell that has been shown to be important for motility as this shape allows the cell
to drill into the mucosal layer of the intestinal epithelium. The shape is acquired due to the
activity of peptidoglycan synthesis and modifying enzymes that are still under investigation
(Frirdich et al., 2012). Pgp1, a metal-dependent DL-carboxypeptidase cleaving monomeric
disaccharide tripeptides of peptidoglycan to disaccharide dipeptides, is the first enzyme
shown to be directly linked the helical morphology of C. jejuni 81-176 (Frirdich et al.,
2012). Pgp1 is also conserved in other spirally shaped bacteria. A knockout mutant of pgp1
was shown to have lost its helical shape as well as have impaired motility, decreased
biofilm formation, and decreased colonization of chicken caeca. Although no defect in the
ability of this mutant to invade epithelial or macrophage cell lines was detected in vitro
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regardless of the viscosity of the mucus used to coat the eukaryotic cells, there was an
increase in mNOD1 activation and IL-8 secretion.

1.1.4.2

Protein glycosylation in C. jejuni

Protein glycosylation was believed to be a eukaryote-exclusive post-translational
modification until the S layer glycoproteins were discovered in the 1970s (Mescher and
Strominger, 1976; Sleytr and Thorne, 1976). Proteins are glycosylated through the action
of a glycosyltransferase (Lairson et al., 2008). The eukaryotic oligosaccharyltransferase
(OTase) is a multimeric subunit protein, whereby a subunit termed STT3 is highly
conserved among eukaryotes (Yan and Lennarz, 2002). The OTase for N-glycosylation
PglB was discovered in C. jejuni which has significant homology to STT3 and is encoded
in a highly conserved locus adjacent to the LOS biosynthesis cluster (Szymanski, 1999).
This locus was found to encode the biosynthesis machinery for synthesis of a conserved
heptasaccharide used for protein glycosylation and made of GalNAc-α1,4-GalNAc- α 1,4[Glcβ1,3-]GalNAc-α1,4-GalNAc-α1,4-GalNAc-α 1,3-Bac-β1, where Bac is bacillosamine
(2,4-diacetamido-2,4,6-trideoxyglucopyranose) (Figure 1A) (Linton et al., 2005;
Szymanski, 1999; Wacker et al., 2002; Young et al., 2002).
N-glycosylation
The N-glycosylation cluster contains cj1120c, cj1121c, and cj1123c, which encode for a
dehydratase, aminotransferase, and N-acetyltransferase respectively which are responsible
for Bac synthesis (Figure 1B). The N-glycosylation pathway involves the attachment of a
Bac-containing heptasaccharide motif onto the asparagine of the consensus sequence D/EY-N-X-S/T (Y, X≠P) (Kowarik et al., 2006). This sequon was thought to be extended
compared to the eukaryotic N-X-S/T (X≠P), however, new data shows that this is not the
case for all bacteria (Schwarz and Aebi, 2011; Schwarz et al., 2011a). Over 65 proteins
have been reported to be modified by the N-glycan motif (Scott et al., 2011). It has been
reported that disruption of this protein glycosylation pathway leads to decreased adhesion
and invasion of INT 407 cells by C. jejuni 81-176 (Szymanski et al., 2002), in addition to
decreased invasion of Caco-2 intestinal cells in vitro and impaired colonization of chicken
caeca by strain NCTC 11168 (Vijayakumar et al., 2006).
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Figure 1. Schematic of the pgl locus and assembly of the conserved heptasaccharide
for protein N-glycosylation.
(A) Conserved N-glycosylation cluster in C. jejuni. (B) Pathway for heptasaccharide
synthesis. PglE, F, and G (or Cj1120c, Cj1121c, and Cj1123c respectively) function to
synthesize UDP-Bac from UDP-GlcNAc. Next, Bac is transferred to undecaprenyl
pyrophosphate by PglC, and additional GalNAc residues and one glucose residue are added
by the glycosyltransferases PglA, J, H and I. The formed heptasaccharide is transferred
from the cytoplasm to the periplasm through the action of the flippase PglK, followed by
the block transfer of this glycan onto the asparagine of the N-glycosylation consensus
sequence through the activity of the OTase PglB. Adapted from (Kelly et al., 2006).
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Protein O-glycosylation in Campylobacter spp.
Protein O-glycosylation in C. jejuni has been described for the flagellins of strain 81-176
(Thibault et al., 2001). Post-translational modification of its flagellins by pseudaminic acid
(Pse5Ac7Ac) is required for assembly and function (Table 1) (Hitchen et al., 2010).
Flagellins from C. coli VC167 were also shown to be glycosylated with Pse5Ac7Ac in
addition to a related sugar, legionaminic acid (Logan et al., 2002; McNally et al., 2007a).
C. jejuni NCTC 11168 was shown to produce both sugars in its metabolome (Logan et al.,
2009), but it was not until recently that glycopeptide data were generated to show that
pseudaminic and legionaminic acid and their derivatives modify flagellins in this strain
(Ulasi et al., 2015; Zampronio et al., 2011; Zebian et al., 2015).
Recently, the major outer membrane protein (MOMP) of C. jejuni NCTC 11168 was
identified carrying a sugar motif of Gal(β1–3)-GalNAc(β1–4)-GalNAc(β1–4)-GalNAc α1
on Thr268. (Mahdavi et al., 2014). This glycosylation affects the conformation of MOMP
which modulates binding to human histo-blood group antigens and promotes cell-to-cell
binding, biofilm formation, adhesion to Caco-2 cells and is required for optimal
colonization of chickens.
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Table 1. Summary of known sugars produced in C. jejuni NCTC 11168 and 81-176,
and in C. coli VC167 that have been shown on glycopeptides and/or have been
identified in the metabolome.
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Modification

Bacterial species and
strains

References

Pseudaminic acida
(Pse5Ac7Ac)

C. jejuni 81-176

Thibault 2001c; McNally
2006d

C. jejuni NCTC 11168 Logan 2009d; Ulasi 2015e

Acetamido pseudaminic acida
(Pse5Ac7Am)

C. coli VC167

Logan 2002e ; McNally
2007d

C. jejuni 81-176

Thibault 2001c; McNally
2006d

C. jejuni NCTC 11168 Logan 2009d;
C. coli VC167

Logan 2002e ; McNally
2007d

O-acetyl pseudaminic acid
(Pse5Ac7Ac8OAc)

C. jejuni 81-176

Thibault 2001c

N-acetyl glutamic pseudaminic
acid derivative
(Pse5Ac7Ac8-GlnAc)

C. jejuni 81-176

Thibault 2001c

Dihydroxypropionyl pseudaminic C. jejuni 81-176
acid derivative
(PsePr)

Thibault 2001c

Dimethylglyceric derivative of
acetamidino pseudaminic acid
(Pse5AcGriMe7Am)

C. jejuni NCTC 11168 Logan 2009d; Ulasi 2015e;
Zampronio 2011e

Dimethylglyceric derivative of
pseudaminic acid
(Pse5AcGriMe7Ac)

C. jejuni NCTC 11168 Logan 2009d; Ulasi 2015e;
Zampronio 2011e

Acetamidino pseudaminic aciddeoxypentose

C. coli VC167

Logan 2002e

O-acetyl pseudaminic aciddeoxypentose

C. coli VC167

Logan 2002e
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Legionaminic acida
(Leg5Ac7Ac)

C. jejuni NCTC 11168 Logan 2009d; Ulasi 2015e;
Zampronio 2011e
C. coli VC167

Acetamidino legionaminic acida
(Leg5Am7Ac)

C. jejuni NCTC 11168 Logan 2009d; Ulasi 2015e;
Zampronio 2011e
C. coli VC167

N-methylacetimidoyl derivative
of Legionaminic acidb
(Leg5AmNme7Ac)
a

McNally 2007d

McNally 2007d

C. jejuni NCTC 11168 Logan 2009d
C. coli VC167

McNally 2007d

Pse5Ac7Ac and Leg5Ac7Ac share the same mass and could not be distinguished on

peptides by MS but could be distinguished from one another by NMR. The same applies
for Pse5Ac7Am and Leg5Am7Ac. To date, most NMR data were obtained via
metabolomic studies (McNally et al., 2007, McNally et al., 2006, Logan et al., 2009), the
only NMR data showing pseudaminic acid on glycopeptides was obtained for C. jejuni
81-176 (Thibault et al., 2001). No NMR analysis has been conducted on C. jejuni NCTC
11168 or C. coli VC167 flagellin glycopeptides, and thus the definitive assignment of
these sugars on glycopeptides remains undetermined.
b

The modifications present on the Leg5AmNme7Ac derivative were identified in the

metabolome of C. jejuni NCTC 11168 (Logan et al., 2009) but have never been found on
pseudaminic acid. Thus the presence of its oxonium ion in MS analyses indicates
specifically the presence of legionaminic acid. Its sugar oxonium ion was shown by topdown MS in C. coli VC167 (McNally et al., 2007) but not mapped to any peptide.
c

glycopeptide data comprising NMR evidence of sugar identity.

d

metabolomics study comprising NMR evidence of sugar identity.

e

MS study relying on mass of oxonium ions only.

12

Pseudaminic acid and legionaminic acid synthesis
The pathway for pseudaminic acid synthesis has been well characterized (Chou et al., 2005;
Creuzenet, 2004; Goon et al., 2003; Guerry et al., 2006; Obhi and Creuzenet, 2005;
Schoenhofen et al., 2006). In a six-step reaction, UDP-GlcNAc is converted to
pseudaminic acid through the actions of PseB/Cj1293, PseC/Cj1294, PseH/Cj1313,
PseG/Cj1312, PseI/Cj1317, and PseF/Cj1311 enzymes. The first three enzymes dehydrate,
aminate, and acetylate UDP-GlcNAc as described for the synthesis of UDP-Bac from
UDP-GlcNAc, however, the two pathways differ in their dehydratases, whereby the
pseudaminic acid pathway Cj1293 enzyme also has C5 epimerase activity (Schoenhofen
et al., 2006).
Through analysis of the nucleotide-activated sugars in the metabolome of various knockout
mutants, a putative legionaminic acid synthesis gene cluster was identified in C. coli, and
the presence or absence of this cluster has been subsequently used to identify
Campylobacter strains and/or species as producing legionaminic acid or not (Howard et al.
2009; McNally et al. 2007). For example, C. jejuni 81-176 lacks this gene cluster and
consistently does not make legionaminic acid. Legionaminic acid synthesis has also been
explored in vitro for Legionella pneumophila and C. jejuni. A pathway in each organism
was proposed whereby the enzymes from both pathways are homologous and carry out
similar functions, but use different substrates. The first pathway used recombinant C. jejuni
Cj1120c, Cj1121c and Cj1123c enzymes from the general protein N-glycosylation system
to perform successive dehydration, amination and acetylation of UDP-GlcNAc to make
UDP-diNAcBac (Demendi and Creuzenet, 2009; Schoenhofen et al., 2006; Vijayakumar
et al., 2006). This was followed by conversion into CMP-legionaminic acid via hydrolysis
of UDP with concomitant C2 epimerisation, condensation with phosphoenolpyruvate and
finally activation as a CMP derivative by homologues of sialic acid synthesis enzymes
from L. pneumophila (Glaze et al., 2008). The second pathway used recombinant C. jejuni
Cj1319, Cj1320 and Cj1298 enzymes to produce GDP-2,4-diacetamido-2,4,6-trideoxy-αD

-glucopyranose from GDP-GlcNAc, followed by conversion into CMP-legionaminic acid

using sialic acid synthesis homologues Cj1328, Cj1327 and Cj1331 (Schoenhofen et al.,
2009). Specifically, in the GDP-GlcNAc based pathway, Cj1319 is reported to catalyze
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GDP-GlcNAc into GDP-2-acetamido-2,6-dideoxy-α-D-xylo-hexos-4-ulose which is further
modified by Cj1320. However, homologues of these two enzymes were previously
excluded from the legionaminic acid gene cluster in C. coli because the knockout mutant
of the Cj1319 homologue produced more CMP-Leg5Ac7Ac than the wild type (WT) and
the knockout mutant of the Cj1320 homologue showed no defect in CMP-Leg5Ac7Ac
production (McNally et al., 2007a). This contradiction is intriguing and requires addressing
in order to understand the complex flagellin glycosylation machinery in C. jejuni NCTC
11168.

1.1.4.3

Capsule

It was originally discovered during the 1990s that Campylobacter spp. produces surfaceexposed polysaccharides that were thought to be the O-chain of lipopolysaccharide (LPS)
(Aspinall et al., 1992, 1993, 1995a, 1995b, 1995c). However, in the early 2000s, the
structures of these polysaccharides in some Campylobacter species were determined which
indicated that these structures were not associated with LPS, but rather they resembled
capsule polysaccharides (Aspinall et al., 1995c). It was also shown by electron microscopy
and Alcian blue staining that these surface structures were indeed capsule polysaccharides
(Karlyshev et al., 2000). There are currently eight C. jejuni capsule structures known,
whereby they differ in the sugar content or in linkage types (Aspinall et al., 1992, 1995c;
Chen et al., 2008; Hanniffy et al., 1999; Karlyshev et al., 2005a; McNally et al., 2005,
2007b; Michael et al., 2002; Muldoon et al., 2002). Specifically, the capsule of strain
NCTC 11168 that is the focus of this study comprises β-D-Ribp, β-D-GalfNAc, α-DGlcpA6(NGro), a uronic acid amidated with 2-amino-2-deoxyglycerol at C-6, and 6-Omethyl-D-glycero-α-L-gluco-heptose as a sidebranch (Figure 2) (Michael et al., 2002). This
structure is linked to a poly-(3-deoxy-D-manno-oct-2-ulosonic acid) (poly-Kdo) which is
linked to a lipid carrier (Corcoran et al., 2006; Willis et al., 2013). C. jejuni strains have
been classified into 47 serotypes according to a scheme called Penner or heat-stable (HS)
serotyping which sorts on the basis of a combination of their capsule and LOS structures,
although the capsule has a stronger influence on the serotype (Penner, 1983; Penner and
Hennessy, 1980). A recent systematic review revealed that eight serotypes accounted for
more than half of sporadic diarrheal diseases globally, three of which dominated inter-
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regionally and globally, including HS2, the serotype of NCTC 11168 (Pike et al., 2013).
More recently, a genotyping scheme for capsular types was developed based on the
potential of a strain to express a serotype which is not sensitive to variations in capsule
gene expression or affected by genes and gene products outside the capsule locus which
are complications affecting the HS serotyping scheme (Poly et al., 2011). A number of
capsule genotypes have been shown to be associated with Guillain-Barre Syndrome in
combination with certain LOS structures, including HS2 (Heikema et al., 2015).
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Figure 2. Structure of the capsule of C. jejuni NCTC 11168 and the organization of
the capsular gene locus highlighting the three regions.
(A) Schematic of one capsule unit attached to its KDO-phospholipid anchor next to the
structure of the capsule unit. (B) Schematic of the three genetic regions for capsule
synthesis, assembly and export highlighting the heptose modification genes in region 2
and the capsule transporter gene kpsM in region 3. Adapted from (Wong et al., 2015).

16

A

B

17

Capsule is assembled via an ABC transporter mechanism in C. jejuni, similar to the class
2 and 3 capsules of E. coli K1 and K5, Neisseria meningitidis and Haemophilus influenza
(Guerry et al., 2012; Whitfield, 2006). The genetic organization of the capsular genes in C.
jejuni is also similar to their organization in the said organisms, whereby there are three
regions: 1 and 3 are highly conserved and involved in assembly and transport of the capsule
and region 2 is a variable region involved in synthesis of the polysaccharides. Region 1
contains six genes encoding KpsF, E, D, U, C, and S. KpsE and KpsD are involved in the
translocation of the polysaccharide across the periplasmic space, while KpsC and KpsS are
believed to play roles in the attachment of Kdo to the phosphatidic acid, and its subsequent
attachment to the reducing end of the polysaccharide. KpsF has unknown function and
KpsU is a cytidine 5’-monophosphate (CMP)-Kdo synthetase enzyme, responsible for the
generation of the CMP-Kdo required for the ligation step. Region 3 encodes for KpsM and
KpsT, both members of the ATP-binding cassette (ABC) family of transporters, which are
involved in the export of the polysaccharide from the cytoplasmic face of the inner
membrane into the periplasmic space.
The phospholipid anchor of three capsule types (HS3, HS6, and HS23/36) has been
determined to be dipalmitoyl-glycerophosphate with ester-linked hexadecanoic acids
(Corcoran et al., 2006). A distinguishable feature of Campylobacter species capsules is the
presence of a heptose found in an unusual configuration (altro, ido, gulo, talo) which is
also sometimes found dehydrated at C6. This modified heptose may be part of the main
chain or a side branch of the capsule depending on the strain (Aspinall et al., 1992, 1995c;
Chen et al., 2008; Hanniffy et al., 1999; Karlyshev et al., 2005a; McNally et al., 2005,
2007b; Michael et al., 2002; Muldoon et al., 2002). In our strain of interest, it is a side
branch (Figure 2) (Michael et al., 2002). In addition, an O-methyl phosphoramidate
(MeOPN) is linked to different sugars in most Campylobacter strains and its presence
seems to depend on that of the modified heptose in strain NCTC 11168 (Alphen et al.,
2014; McNally et al., 2007b).

18

Modified capsular heptose
The capsule locus of Campylobacter species contains the highly conserved genes gmhA2,
hddA, and hddC encoding enzymes responsible for the biosynthesis of GDP-D-glycero-Dmanno-heptose, the precursor of the capsular modified heptose (Karlyshev et al., 2005a).
In addition to gene product of gmhB (D-glycero-D-manno-heptose 1,7-bisphosphate
phosphatase; shared with the LOS pathway for making heptose) encoded by the LOS
cluster, the gene products of gmhA2 (phosphoheptose isomerase), hddA (putative Dglycero-D-manno-heptose 7-phosphate kinase), and hddC (putative D-glycero-D-mannoheptose 1-phosphate guanosyltransferase) synthesize GDP-D-glycero-D-manno-heptose
from D-sedoheptulose 7-phosphate (Kneidinger et al., 2001), a common precursor for
synthesis of the heptose found in the LOS or LPS of other bacteria (Karlyshev et al., 2005a;
Kneidinger et al., 2002). Noteworthy, gmhA2 is homologous to gmhA which is encoded in
the LOS biosynthesis gene cluster and part of the pathway for making ADP-L-glycero- Dmanno-heptose from D-sedoheptulose 7-phosphate. The two gene products have been
shown to be redundant in function as the heptose of both capsule and LOS remained
produced in either single gene knockout mutant of gmhA or gmhA2, but upon disruption of
both genes, both the capsule and LOS no longer contained heptose (Karlyshev et al.,
2005a).
The pathway for modification of GDP-D-glycero-D-manno-heptose used for capsule
synthesis has been fully characterized in C. jejuni 81-176 (Figure 3A) (McCallum et al.,
2012). The enzymes encoded by cjj1426 (DdahA, C4, C6 dehydratase), cjj1430 (DdahB,
C3 epimerase) and cjj1427 (DdahC, C4 reductase) modify this precursor to form GDP-6deoxy-α-D-altro-heptose. C. jejuni NCTC 11168 has been shown to incorporate D-glyceroα-L-gluco-heptose into its capsule (Figure 2) (Michael et al., 2002). The pathway for
making this sugar has been partially deciphered (Figure 3, right pathway) (McCallum et
al., 2013), whereby the enzymes encoded by cj1430 (MlghB, C3, C5 epimerase) and
cj1428 (MlghC, C4 reductase) have been characterized. However, the proposed C4 oxidase
MlghA of this pathway has yet to be found. This enzyme is expected to be homologous to
the dehydratase DdahA as C4 oxidation also occurs during C4, C6 dehydration. However,
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there are no proteins encoded by the NCTC 11168 capsule locus bearing similarity to
DdahA aside from Cj1319, coded by a gene found in the flagellar glycosylation locus.
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Figure 3. Pathways for the modification of GDP-manno-heptose for incorporation
into capsular polysaccharide.
(A) The fully characterized pathway for capsular heptose modification in C. jejuni 81176. (B) The partially determined equivalent pathway from strain NCTC 11168.
(Adapted from McCallum et al., 2013).
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Cj1319 is predicted to be a sugar nucleotide dehydratase suggesting its involvement in a
glycosylation pathway. Cj1319 is estimated to be encoded by 82% of C. jejuni clinical
strains including NCTC 11168 (Huang et al., 2013). Although Cj1319 is homologous to
GDP-manno-heptose dehydratases and GDP-mannose dehydratases, Cj1319 has been
shown to participate in an in vitro pathway for legionaminic acid synthesis, a sugar that is
predicted to glycosylate the flagellins of some C. jejuni strains, as discussed in section
1.1.4.2.
Some strains of C. jejuni also further methylate the capsular heptose (Karlyshev et al.,
2005a). This modification is variable as, for example, strain NCTC 11168 produces a
modified capsular heptose in a heterogeneous mixture of unmethylated, C3-O-methylated,
C6-O-methylated, or C3, C6-O-methylated D-glycero-α-L-gluco-heptose (Michael et al.,
2002; Wong et al., 2015). The expression of this modified heptose is also negatively
regulated by WcaG, a C4 reductase which reduces GDP-6-deoxy-4-keto-D-lyxo-heptose to
GDP-6-deoxy-D-manno-heptose (McCallum et al., 2011, 2013).
As C. jejuni NCTC 11168 expresses the modified heptose as a sidechain of the capsular
polysaccharide, it was possible to study the role of this modified heptose in the virulence
of C. jejuni specifically as the lack of the incorporation of this heptose still allows for
capsular chain assembly which is in contrast with other strains that express the modified
heptose within the main chain (Wong et al., 2015). This modified heptose was found to
play a role in serum resistance and invasion of intestinal cells and that it is important for
the

colonization

of

chicken

caeca.

Similar

findings

were

obtained

from

Yersinia pseudotuberculosis, which expresses a modified heptose in its LPS, which
showed the lack of this heptose led to an increase in susceptibility to bile salts, polymyxin
and novobiocin, as well as decreased flagellar mediated motility (Ho et al., 2008;
Kondakova et al., 2008).

1.1.4.4

LOS

C. jejuni makes LOS, rather than LPS which is more commonly found in gram negatives.
The LOS is composed of lipid A with a core oligosaccharide and no O-antigen repeat chain
as found in LPS. The structure of the LOS core of strain NCTC 11168 has been determined
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(Figure 4). The lipid A differs from that of Escherichia coli lipid A in that it contains the
disaccharide 2,3-diamino-2,3-dideoxy-D-glucose and D-glucosamine (GlcN3N-GlcN), or
variations

of

GlcN3N–GlcN3N

and

GlcN–GlcN,

phosphorylated

with

pyrophosphorylethanolamine (PPEtn) and this is acylated with palmitic or lauric acid
(Szymanski et al., 2003). These backbones further vary by having different
phosphorylation patterns. WaaC is heptosyltransferase I that attaches the first heptose to
Kdo and WaaF is heptosyltransferase II that attaches the second heptose to the first (Klena
et al., 1998; Oldfield et al., 2002). As mentioned above in section 1.1.4.3, these heptoses
are synthesized from the same precursor, D-sedoheptulose 7-phosphate, used to make GDPmanno-heptose for capsule synthesis, however, through the action of different enzymes.
GmhA (phosphatase), GmhB (kinase), WaaE (pyrophosphorylase) and WaaD (epimerase)
are responsible for the conversion of D-seduloheptulose7-phosphate into ADP-L-glycero-Dmanno-heptose (Karlyshev et al., 2005a). C. jejuni also produces neuraminic acid (sialic
acid) which is incorporated into some of the LOS chains. The outer core of the LOS of
strain NCTC 11168, β-Gal-(1,3)-β-D-GalNAc-(1,4)-β[α-NeuAc-(2,3)]-Gal, is analogous
to the human gangliosides GM1a and GM2 (Michael et al., 2002; Oldfield et al., 2002;
Szymanski et al., 2003). These structural mimics lead to generation of cross-reacting
antibodies against gangliosides which is the pathological basis for the association of
preceding C. jejuni infection with GBS and MFS (Godschalk et al., 2007; Islam et al.,
2012; Nachamkin et al., 1998; Yuki et al., 2004). Other strains have been shown to produce
LOS mimics of other structures such as strain RM1221 which makes LOS mimics of P
blood groups and paragloboside antigens and strain RM1503 which makes LOS mimics of
lacto-N-biose and sialyl-Lewis c units, a pancreatic tumor-associated antigen (Houliston et
al., 2011).
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Figure 4. The biosynthesis and structure of the LOS of C. jejuni NCTC 11168.
The structure of the LOS from strain NCTC 11168, highlighting the transferases known
or predicted to be responsible for addition of each sugar to the LOS core. (Adapted from
Karlyshev et al., 2005b).
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The role of Cj1319 in C. jejuni
As mentioned above, Cj1319 has predicted roles in both synthesis of a modified heptose
for capsule and in legionaminic acid synthesis. The cj1319 gene, encoding a putative sugar
nucleotide dehydratase, is clustered with cj1320 and cj1321, encoding a putative
aminotransferase and an N-acetyl transferase respectively, which is reminiscent of the
genetic arrangement of the N- and O-protein glycosylation pathways (Figure 5) (Creuzenet,
2004; Nothaft and Szymanski, 2010; Obhi and Creuzenet, 2005; Vijayakumar et al., 2006).
This suggests that there is a possibility that these three gene products may be part of a novel
protein glycosylation pathway. Cj1319 belongs to the NDP-sugar modifying subfamily of
short chain dehydrogenases/reductases which have characteristic Rossman-fold structures
with helices on either side and a catalytic tetrad (N-S-Y-K) (Persson et al., 2009). Cj1319
shares similarity to the GDP-manno-heptose dehydratases, DmhA (45 %) and DdahA (41
% ) (Ho et al., 2008; McCallum et al., 2011). DdahA is the first enzyme in the capsular
heptose modification pathway in strain 81-176. This pathway for our strain of interest, C.
jejuni NCTC 11168, is partially characterized, however, the enzyme initiating this pathway
which is predicted to be a C4 oxidase has yet to be found (McCallum et al., 2013). This
oxidase role may be fulfilled by Cj1319 as C4 oxidation is also performed by C4, C6
dehydratases, whereby Cj1319 would have a central role in capsular heptose modification.
Alternatively, Cj1319 may use GDP-manno-heptose as the precursor of a novel protein
glycosylation pathway whereby its product would be further modified by Cj1320 and
Cj1321. This would establish a potential link between capsule synthesis and protein
glycosylation.
Cj1319 and Cj1320 have been implicated in an in vitro pathway for legionaminic acid
synthesis for flagellar glycosylation (Schoenhofen et al., 2009). In contrast, the Cj1319 and
Cj1320 homologues from C. coli were excluded from the legionaminic acid synthesis
pathway based on knockout mutagenesis and metabolic profiling (McNally et al., 2007a).
This contradiction remained unaddressed at onset of this work, mainly due to the lack of
flagellin glycopeptide data showing that legionaminic acid is incorporated onto flagellins
in C. jejuni and also because the effects of inactivating cj1319 and cj1320 have not been
studied in C. jejuni.
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Figure 5. Genetic organization of cj1319 gene locus and the two protein
glycosylation pathway genes.
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Host interactions
C. jejuni has long been considered a commensal colonizer of chickens, however, recently
it has been demonstrated that C. jejuni colonization of chickens does result in inflammation
and affects the well-being of the birds (Humphrey et al., 2014). A major difference
observed between the interaction of C. jejuni with humans and chickens is that more
bacteria invade human epithelial cells compared to those derived from chickens (Byrne et
al., 2007; Larson et al., 2008; Young et al., 2007). The chicken intestinal mucus was shown
to have an important role in inhibiting C. jejuni invasion of both chicken and human
intestinal cells (Byrne et al., 2007). Thus the ability of C. jejuni to adhere to and invade
epithelial cells is key to determine the ability of this organism to act as a pathogen or
commensal. The initial interactions in the intestinal tissues are with mucins, highly
sialylated and mannosylated proteins, such as MUC1 which is a decoy receptor released
from the intestinal epithelium into the lumen upon binding bacteria including C. jejuni, and
MUC2 which is significantly less sialylated compared to MUC1 and found in C. jejuni’s
favoured niche, the intestinal crypts (Linden et al., 2008; McAuley et al., 2007). C. jejuni
was found to be able to bind to the more easily accessible fucosylated and terminal
galactosylated structures found within the crypts, although no C. jejuni lectin has been yet
identified (Day et al., 2009). A number of adhesins have been identified such as CadF and
FlpA which have been demonstrated to bind fibronectin (Flanagan et al., 2009; Monteville
et al., 2003). Whereas the importance of CadF has been demonstrated in a number of
different strains and using different methods (Konkel et al., 1997; Scott et al., 2010; Ziprin
et al., 1999), other identified adhesins, JlpA and PEB proteins have controversial roles in
adherence. JlpA was described as an important adhesin (Jin et al., 2001), however, others
were unable to show a significant defect in invasion of intestinal cells by a jlpA mutant
(Novik et al., 2010). PEB proteins were also originally thought to be adhesins (Pei et al.,
1991), however, they were found to be inner membrane proteins with transporter or
chaperone roles (Del Rocio Leon-Kempis et al., 2006; Kale et al., 2011), whereby they
appear to have an indirect role on cellular adherence to intestinal cells. In addition to their
role in motility, the flagella have also been shown to act as a type III secretion system for
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Campylobacter invasion antigens (Cia) (Konkel et al., 2004). However, it is not clear if the
Cia proteins are secreted into intestinal cells or into the lumen. The role of the flagellar
glycosylation in host cell interactions is also not clear as there still remains limited data on
flagellar glycosylation in C. jejuni strains.
It has also been shown that C. jejuni pre-exposed to oxidative stress are better able to invade
epithelial cells (Šikić Pogačar, 2009). However, it was recently shown that this is strain
specific, as NCTC 11168 for example is unable to adhere to or invade Caco-2 intestinal
cells when exposed to hydrogen peroxide (Koolman et al., 2016). Analysis of gene
expression in 10 strains in response to hydrogen peroxide stress revealed the upregulation
in cadF in all strains, whereas other changes in gene expression were deemed to be strain
specific (Koolman et al., 2016). C. jejuni expresses a highly branched electron transport
chain which allows for both aerobic and anaerobic respiration, whereby it encodes for all
proteins required for a complete oxidative TCA cycle (Kelly, 2008). Aerobic respiration is
preferred, however, this bacterium is also able to use alternative electron acceptors
including nitrate, dimethylsulphoxide, fumarate, and tetrathionate (Liu et al., 2013;
Pittman et al., 2007; Sellars et al., 2002). Fumarate respiration has been shown to be
important for both chicken colonization and intracellular survival of C. jejuni (Liu et al.,
2012b; Weingarten et al., 2009).
Once C. jejuni invades epithelial cells, it is able to avoid the lysosome and gain access to
underlying tissues and reach different cellular receptors and phagocytic cells (Mihaljevic
et al., 2007; Watson and Galán, 2008). It has been reported that C. jejuni can survive within
macrophage for extended periods of time (6-7 days) by some (Hickey et al., 2005;
Kiehlbauch et al., 1985), whereas others report this is not a common occurrence due to the
finding that human derived monocytes/macrophages kill phagocytosed bacteria within 24
to 48 h, as C. jejuni is targeted to the lysosome in macrophages (Wassenaar et al., 1997;
Watson and Galán, 2008). The internal survival of C. jejuni within phagocytes is largely
believed to be strain-dependent. Within macrophages, C. jejuni needs to survive the
reactive oxygen and nitrogen species produced by the host cell and may overcome them at
least in part by the expression of catalase and nitric oxide response regulator (Day et al.,
2000; Gundogdu et al., 2011; Iovine et al., 2008).

31

Role of biofilm formation and interaction with amoeba in
survival during transmission in the environment
Unlike other foodborne pathogens, Campylobacters have fastidious growth requirements
and lack many of the adaptive responses correlated to the resistance of different stress
conditions (Park, 2002). They are highly sensitive to oxygen levels, have a limited pH and
temperature range for growth, and very sensitive to osmotic stress and dryness. Conversely,
these organisms are still able to survive in the environment, allowing for their transmission
among different hosts which leads to the infection of humans. The mechanisms by which
C. jejuni are able to survive outside of their hosts are still under investigation.
Under unfavourable growth conditions, Campylobacter spp. have been shown to enter a
viable but nonculturable (VBNC) form whereby the cells maintain limited metabolic
activity while retaining their spiral shape or degenerating into a coccoid form, but do not
replicate and cannot be cultured (Bronowski et al., 2014; Murphy et al., 2006; Oliver, 2005;
Park, 2002). There remains controversy regarding the role of this cell form, but it has been
suggested that cells may maintain this form to survive unfavourable environmental
conditions, and they may revert back into a replicating viable and culturable form once
they enter a host.
The formation of biofilms by C. jejuni is an important survival mechanism still undergoing
extensive study. These bacteria have been shown to be able to form biofilms in water
systems, on abiotic surfaces, and in natural aquatic environments (Lehtola et al., 2006;
Maal-Bared et al., 2012). C. jejuni has been shown to form three types of biofilm forms,
including a pellicle at the liquid air interface, surface attachment, and free unattached
aggregates termed ‘flocs’ (Joshua et al., 2006). Multiple studies have shown that stressful
conditions, such as exposure to oxygen, detergents and bile, induce and enhance biofilm
formation of C. jejuni (Allen and Griffiths, 2001; Reuter et al., 2010; Svensson et al., 2009,
2014). The extracellular matrix of the biofilm has yet to be fully characterized, as there
have only been a few recent studies aimed at determining its composition. Some studies
have demonstrated that it is composed of extracellular DNA by demonstrating its
sensitivity to Dnase treatment and through the induction of the release of DNA in response

32

to bile which in turn induced biofilm formation (Brown et al., 2015; Svensson et al., 2014).
In contrast, another study demonstrated that the C. jejuni can produce an α-dextran in
response to pancreatic amylase and this dextran represents the exopolysaccharide (Jowiya
et al., 2015). It is possible that both components are required to form the extracellular
matrix.
Whereas C. jejuni encodes very limited metabolic pathways (Kelly, 2001), it has many
transport systems which suggests that the potential this organism may exploit the resources
produced by other organisms (Dorrell and Wren, 2007). As such, although C. jejuni is able
to form biofilms on its own (Joshua et al., 2006), it has been shown that it has enhanced
attachment and survival when co-cultured with Pseudomonas aeruginosa and has been
suggested that C. jejuni are secondary colonizers of pre-existing biofilms sampled from
poultry farm environments (Hanning et al., 2008; Ica et al., 2012; Trachoo et al., 2002).
The interaction of C. jejuni with protozoa in water has also been suggested as a mechanism
for bacterial survival. It has recently been shown that amoeba deprive their local
environment of oxygen, thus creating favourable respiratory conditions for surrounding C.
jejuni (Bui et al., 2012a). It has also been shown that environmental stress factors promote
C. jejuni internalization in amoeba, although the internal survival was reported to be shortlived and limited to several hours (Bui et al., 2012b). Other studies have shown that C.
jejuni can survive within amoeba for several days, whereby live non-replicating C. jejuni
were maintained in non-digestive vacuoles and heat-killed bacteria were found in one large
digestive vacuole (Olofsson et al., 2013). To address the discrepancy found between the
described studies, a modified gentamycin protection assay was performed to remove as
much variability among assays as possible. The results of this study were in support of the
prior studies, suggesting internalization of C. jejuni occurs at a very low negligible rate
(Dirks and Quinlan, 2014). Furthermore, cocultures of C. jejuni and amoeba in
unpasteurized milk and juice prolonged the survival of extracellular C. jejuni (Olofsson et
al., 2015).
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1.2

Helicobacter pylori
Discovery and clinical manifestion

Helicobacter pylori, originally called Campylobacter pylori, was regularly observed in
stomach biopsies and assumed to be related to inflammation nearly 35 years ago (Marshall
and Warren, 1984). Despite this, it was not accepted by the scientific community that a
bacterium would be able to survive the harsh conditions of the stomach and cause disease.
H. pylori was first isolated in 1982 and, through drinking H. pylori cultures which lead to
the development of symptoms of gastritis that could be relieved by antibiotic treatment,
Dr. Marshall was able to prove that this organism is able to cause gastritis (Marshall et al.,
1985). This significant finding later led to Dr. Marshall and Dr. Warren, whom he worked
with, being awarded the Nobel Prize in Physiology or Medicine in 2005. This pathogen is
now considered the leading cause of gastric cancer and gastric ulcers and has been
determined to be a class I carcinogen by the World Health Organization (Malfertheiner et
al.,1994). It is estimated that gastric cancers caused by H. pylori account for ~6% of all
cancers worldwide (Plummer et al., 2015). The prevalence of colonization is currently
estimated to be 70-90% in developing countries and 25-50% in developed countries
(Malfertheiner et al., 2014; Papamichael and Mantzaris, 2012). Colonization rates can vary
drastically within countries, as observed in Canada where prevalence can range from 23%
to 95% across different ethnic groups (Naja et al., 2007).
In order to prevent these H. pylori caused-illnesses, early eradication of this bacterium is
the most effective method and can also reduce the risk of gastric cancer (Ford et al., 2014).
Triple therapy was the popular method of treatment which includes two antibiotics
combined with a proton pump inhibitor, however this strategy has been losing efficacy due
to the increase in antibiotic resistance and thus to overcome this, quadruple therapies are
being used which include an additional antibiotic (Delchier et al., 2014; Gatta et al., 2013;
Ierardi et al., 2013; Jheng et al., 2015; Malfertheiner et al., 2012; Yang et al., 2014).
However, both triple and quadruple therapies result in harsh side effects in a significant
portion of patients (23% for sequential therapies and 46% for concomitant therapies)
(Delchier et al., 2014; Gisbert et al., 2015; Jheng et al., 2015). A number of studies also
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suggest there is a high rate of ineffective treatment (up to 67%) (Masoodi et al., 2015).
Other efforts have been put into combining probiotics with the above treatments in which
some probiotics have been deemed to possibly improve the efficacy of treatment and
reduce some of the negative side effects associated with treatments (McFarland et al.,
2015). Efforts are being put into finding novel treatments other than antibiotic therapy that
would specifically target H. pylori and eradicate it with minimal side effects.

Flagella and other protein glycosylation
As in C. jejuni, the H. pylori flagella are made of the two subunits FlaA and FlaB at a ratio
of 10 to 1 respectively (Josenhans et al., 1995). FlaA is required for motility whereas FlaB
only enhances motility since a flab knockout mutant was found to have impaired motility
(30-40% reduction compared to WT). The flagella of a number of H. pylori strains have
been shown to be O-glycosylated with pseudaminic acid (Josenhans et al., 2002; MerkxJacques et al., 2004; Schirm et al., 2003, 2005). The glycosylation has been shown to be
required for motility, however, since the flagella are sheathed, the sugars are not exposed
to the host and thus it is not apparent that they play a role in host interaction (Geis et al.,
1993; Merkx-Jacques et al., 2004). The sheath is composed of outer membrane (Geis et
al., 1993), thus contains both outer membrane proteins and LPS. The role of this sheath is
not yet well understood, however, it is believed that it may provide a protective barrier for
the flagella, shielding them from the acidic pH of the stomach and preventing
depolymerization of the FlaA and B subunits, shield the antigenic properties of the flagella,
as well as aid in adhesion as some outer membrane protein adhesins are found in the sheath.
Our group identified other glycoprotein candidates through selective biotin-hydrazide
labelling of sugars and detection with fluorescently-labelled streptavidin via Western blot,
in addition to extracting the sugars from glycoproteins and analyzing them by MS (Hopf
et al., 2011). These findings were confirmed by another group who used selective azidelabelling of glycoproteins (by supplementing H. pylori growth media with azide-labelled
free sugars) in conjunction with Staudinger ligation of a FLAG-His-tag to azide-labelled
sugars to purify glycoproteins. β-elimination was used to release O-linked sugars and these
proteins were analyzed by mass spectrometry (Champasa et al., 2013). By doing so, 125
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O-linked glycoproteins were identified through the detection of Staudinger-glycan ligation
adducts which were released only after β-elimination. These proteins localized to different
parts of the cell and are of diverse biological function, some with roles in pathogenesis. Of
these glycoproteins, only the urease proteins UreA and UreB were validated biochemically.
Urease is an important virulence and colonization factor which is secreted by H. pylori to
cleave urea and neutralize the local environment in the stomach to provide a favourable
niche for H. pylori to persist within (Eaton et al., 1991; Scott et al., 1998). Urease also
functions to raise the pH of the periplasm, increase the membrane potential, and induce
protein synthesis at acidic pH (Scott et al., 1998).

Lewis mediated host mimicry of LPS as a virulence factor
1.2.3.1

Lewis-containing O-antigen and host mimicry

Gram-negative bacteria are unique in that they express LPS which cover ~75% of their cell
wall (Lerouge and Vanderleyden, 2002). These negatively charged structures, composed
of lipid A, a core oligosaccharide and a variable O-antigen repeat chain, provide a
permeability barrier to large negatively charged and/or hydrophobic molecules and
contribute to the structural properties of the cell envelope. The H. pylori LPS is unique in
that its O-antigen is composed of host-related Lewis blood group antigens, carbohydrates
that are also expressed by the gastric epithelium in humans (Figure 6). Lewis y (Ley) and
Lewis x (Lex) are the predominant Lewis antigens expressed in H. pylori clinical isolates
(80-90%) (Heneghan et al., 2000; Marshall et al., 1999; Simoons-Smit et al., 1996; Wirth
et al., 1996). In humans, Ley and Lex are tumour-associated markers and these antigens and
their derivatives can interact with selectins, mediating cell-to-cell adhesion (Hakomori,
1992). This pathogen also expresses other related antigens at a lower frequency including
Lewis a, Lewis b, Lewis c, sialyl-Lex and H-antigens (Monteiro et al., 1998, 2000, 2000).
Lewis b, found on gastric epithelial cell surfaces, is an acceptor for the attachment of H.
pylori (Borén et al., 1993). The expression of these Lewis O-antigens by H. pylori is a
mechanism of molecular mimicry, which has two function in pathogenesis. H. pylori can
protect itself from recognition by the host immune system and thus aid in its prolonged
persistence in the host, however, upon recognition by the immune system over time, the
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formation of antibodies towards these antigens results in auto-antibodies towards the Lewis
expressing gastric epithelium and thus resulting in inflammation (Appelmelk et al., 1996,
1997; Moran et al., 1996; Negrini et al., 1996).
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Figure 6. Diagramatic representation of the Lewis antigens O-glycosylating gastric
mucins.
Lewis antigen structures highlighting the different compositions and linkages of the
glycans. Lex, Ley and H-type antigens are also expressed by H. pylori (Adapted from
Juge, 2012).
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Ley and Lex are made by the addition of fucose onto Galβ1-4GlcNAc repeat units of the Oantigen chain (Wang et al., 2000). Three fucosyltransferases, FutA, B and C, are
responsible for O-antigen biosynthesis. FutA and B have α 1,3 and α 1,4 fucosyltransferase
activity for the synthesis of Lex and Lea antigens respectively. FutC is a α 1,2
fucosyltransferase that adds an additional fucose to form Ley and Leb antigens respectively
(Ma et al., 2006; Moran, 2008). H. pylori uses the mechanism of slipped-strand mispairing
to yield the different LPS variants due to the presence of long stretches of C-residues at the
ends of the three genes encoding each of the three fucosyltransferases described
(Appelmelk et al., 1999; Wang et al., 1999). In addition, both FutA and B contain
molecular rulers depicted as heptad repeats of DD/NLRV/INY, whereby the number of
these repeats reflects the number of Galβ1-4GlcNAc repeat units that become fucosylated
(Nilsson et al., 2006). The length of the chains has also been shown to be affected by the
environment and different cells within the same bacterial population can have varying Oantigen chain length as well as different O-antigen types (Appelmelk et al., 1999; Nilsson
et al., 2006, 2008). The expression of Ley and Lex is influenced by both pH and iron
concentrations as well as location in the gastric tissue (Keenan et al., 2008; Moran et al.,
2002; Nilsson et al., 2006; Skoglund et al., 2009). H. pylori is able persist in colonization
by expressing different LPS variants that bind to DC-SIGN of dendritic cells which leads
to modulation of the host T-helper cell immune response (Bergman et al., 2004; Skoglund
et al., 2009).

1.2.3.2

General assembly of LPS

LPS biosynthesis in H. pylori follows a novel mechanism compared to that of other gram
negatives (Hug et al., 2010). The pathway involves glycosyltransferases, a flippase, and an
O-antigen ligase (Figure 7). WecA is responsible for initiating the pathway by transferring
a GlcNAc-phosphate from UDP-GlcNAc to UndP. Next a number of glycosyltransferases,
GalT, GlcNAcT and FucTs, assemble the O-chain by addition of galatose, GlcNAc and
fucose respectively to UndPP-GlcNAc.

As described above, the fucosyltransferases

expressed govern the degree of fucosylation which leads to the determination of the Oantigen Lewis type. The flippase Wzk, which is homologous to protein N-glycosylation
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flippases, translocates the UndPP-O-antigen chain to the periplasm. This chain is then
ligated to the lipid A-core oligosaccharide through the O-antigen ligase WaaL.
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Figure 7. LPS biosynthesis pathway in H. pylori
The H. pylori O-antigen chains are assembled in the cytoplasm onto a polyisoprenoid
membrane anchor. O-antigen synthesis is initiated by the UDP-GlcNAc transferase WecA.
Glycosyltransferases (GalT and GlcNAcT) alternately add Gal and GlcNAc residues,
producing the linear O chain backbone. Fucosyltransferases (FucTs) attach fucose residues
on selected locations of the O-antigen backbone, generating Lewis antigens. The flippase,
Wzk, transfers the O-polysaccharide to the periplasm, where it is attached onto the lipid Acore via the O-antigen ligase WaaL. The LPS molecule can then be transported to the outer
leaflet of the H. pylori outer membrane by Lpt proteins. (Adapted from (Hug et al., 2010)).
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Adhesins
Three major outer membrane adhesins expressed by H. pylori bind to glycoconjugates of
the gastric mucus layer and epithelial cells (Magalhães et al., 2010; Rossez et al., 2014).
BabA is a blood group binding adhesin which recognizes Lewis b blood group antigens
expressed in glycoproteins from the gastro-intestinal tract (Ilver et al., 1998; Magalhães et
al., 2009). SabA is a sialic acid binding adhesin which recognizes α 2,3-sialylated
structures including sialyl-Lewis a and sialyl-Lex found on glycosphingolipids and
glycoproteins (Mahdavi et al., 2002). Most recently, the adhesin LabA has been discovered
which adheres to di-N-acetyllactosamine motifs found on the MUC5AC gastric mucin
(Rossez et al., 2014). All three adhesins function through recognition of sugar motifs and
this glycan-mediated adhesion has been shown to act as an important trigger for
translocation of several virulence factors into host cells as specifically found in the case of
BabA (Ishijima et al., 2011). These factors include CagA and peptidoglycan which
modulate the host signaling NF-κB and NOD1 pathways respectively (Brandt et al., 2005;
Viala et al., 2004).

1.3
Relationship between protein glycosylation and
LPS synthesis
Bacterial protein O-glycosylation and LPS biosynthesis are evolutionarily related. This
stems from the conserved Wzy_C domain for substrate recognition that is found in both
OTases and O-antigen ligases (Power et al., 2006; Qutyan et al., 2007). The link between
the two glycosylation processes was first shown in Pseudomonas aeroginosa 1244
whereby pili were demonstrated to be glycosylated with a single O-antigen unit from the
LPS through the action of PilO, an OTase distinct from the O-antigen ligase WaaL which
is also present in this bacterium (Castric et al., 2001; DiGiandomenico et al., 2002). The
OTase of C. jejuni, PglB, is used for the transfer of the heptasaccharide for protein Nglycosylation but has relaxed substrate specificity such that it can transfer O-antigen of
LPS from E. coli and P. aeruginosa to proteins (Feldman et al., 2005). The capsule units
of Acinetobacter baumaunnii have been shown to glycosylate some proteins (Lees-Miller
et al., 2013). It is possible that the link between protein glycosylation and capsule or LPS
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synthesis is a more common phenomenon and occurs in other bacteria including C. jejuni
and H. pylori.

1.4

Protein glycosylation analysis

Protein glycosylation is the most common and complex post-translational modification as
the process of glycosylation is a non-template driven process that relies on the action of
many enzymes without any proofreading machinery (Lisowska and Jaskiewicz, 2001). The
synthesis of the final glycosylation products relies on several factors including the
availability of the sugar substrates and the production of the enzymes required for
biosynthesis and transfer of the glycan onto a protein which may be expressed at different
growth stages (Raman et al., 2005). These factors allow for several magnitudes of
structural heterogeneity of the glycan and the glycosylation of the recipient protein. The
selectivity of certain proteins for certain glycans relies majorly on the sugar substrate
specificity of the glycosyltransferase and whether this enzyme attaches sugars to
serine/threonine or asparagine residues (Ielmini, 2011; Lundborg, 2010). Furthermore,
asparagine residues need to be within a minimum consensus sequence of N(X)S/T (X≠P)
for N-glycosylation in eukaryotes (Bause, 1983). This sequence was thought to be extended
to D/E-Y-N-X-S/T (Y, X≠P) in bacteria, however, this is not true in most cases (Kowarik
et al., 2006; Nita-Lazar et al., 2005; Schwarz et al., 2011b). Glycosylation sites are
restricted even more based on their accessibility to the glycosyltransferase which is
governed by the glycoprotein’s structure (Slynko et al., 2009; Zielinska et al., 2010). These
factors aid in analysis of glycoproteins and predicting sites of glycosylation.

Challenges of glycoprotein analysis
There are several challenges for glycoprotein analysis which have largely lead to the slow
progression of the glycoproteomics field. Bacteria produce unconventional sugars
synthesized through complex sugar pathways. This heterogeneity likely contributes to
immune evasion due to the structural diversity provided by the glycosylation. Bacteria
produce more simple glycan structures compared to eukaryotes which use limited types of
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well-known

conventional

sugars

(including

mannose,

fucose,

galactose,

N-

acetylglucosamine and N-acetylgalactosamine) to form large complex glycan chains
(Stanley et al., 2009). More than 70% of eukaryotic proteins are estimated to be
glycosylated, whereas in bacteria, it is not currently known what the extent of protein
glycosylation is, though it is now thought to be a normal occurence rather than a rare event
(Dell et al., 2011). The large size of the glycan, low abundance of many glycoproteins, the
poor ionization of glycoproteins and glycopeptides in mass spectrometers, the size of some
glycans (particularly eukaryotic glycans), the branched nature of glycan chains and the
heterogeneous nature of glycosylation all contribute to the difficulty in glycoprotein
analysis (Liu et al., 2014). These factors lead to poor detection of glycoproteins by mass
spectrometry, the gold standard for glycopeptide characterization, and thus a number of
strategies have been employed to overcome this problem.

Strategies to simplify and improve the analysis of
glycoproteins
In order to simplify glycoprotein analysis, many studies have used the strategy of
deglycosylation of glycoproteins either chemically or enzymatically (Edge, 2003; Wilson
et al., 2002). Upon deglycosylation, the deglycosylated peptides and released
sugars/glycans are analyzed separately by mass spectrometry. To facilitate the sugar
analysis, the sugars are typically derivatized by permethylation or other stabilizing
signature tags (Morelle and Michalski, 2007). The information from the peptide and sugars
are combined to infer the glycosylation of the protein from which these glycopeptides were
released. This approach is lacking in its ability to demonstrate unarguably that the sugars
detected were indeed linked to the peptide identified as no linkage information is produced.
Other approaches focus on methods for glycoprotein/glycopeptide enrichment to increase
their detection by mass spectrometry. Enrichment methods may be targeted toward certain
glycoproteins, whereby lectins with specific sugar binding preferences may be used
(Ongay et al., 2012). Other untargeted methods make use of the hydrophilic nature of the
sugars on proteins which allows their enrichment through reverse phase chromatography
(Calvano et al., 2008; Scott et al., 2011; Yu et al., 2009). It is also possible to label sugars
with a number of tags, for example with biotin hydrazide based on a Schiff-base reaction
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after oxidation that specifically labels sugars (Ruhaak et al., 2010). Affinity
chromatography targeting the incorporated tags can then be used to purify the
glycoproteins/glycopeptides.

Mass spectrometry analysis of glycoproteins and
glycopeptides
Mass spectrometry is considered the gold standard for glycoprotein analysis, whereby this
technique allows for the determination of the identities of the protein and sugar(s) in
addition to being able to map the site(s) of glycosylation. There are two methods of MS
analysis for proteins including glycoproteins: ‘top-down’ and ‘bottom-up’ (Chait, 2006).
Top-down MS describes the fragmentation of intact glycoproteins by MS and tandem MS
(MS2), providing protein sequencing ladders and in situ localization of the glycosylation
without prior extensive separation or proteolytic digestion (Hanisch, 2011; Schirm et al.,
2005). This method has been applied to studying the glycosylation of flagellins of some
bacterial pathogens (Schirm et al., 2005). The bottom-up MS approach is the most widely
used strategy for glycoprotein analysis which differs from the top-down approach in that it
requires extensive preprocessing of samples prior to MS analysis, including proteolytic
digestion and chromatography techniques (Zhang et al., 2013). The glycoproteins may be
chemically or enzymatically deglycosylated and the resulting peptides and sugars can be
analyzed as described above. Alternatively, and more popular with recent MS advances,
the glycoproteins can be treated with a protease and the resulting glycopeptides may be
enriched if needed and analyzed by MS directly in order to simultaneously obtain peptide,
sugar, and glycosylation site information.
Two major ionization technologies are employed for glycoprotein and glycan analysis:
electrospray (ESI) and matrix-assisted laser desorption ionization (MALDI) (Han and
Costello, 2013). ESI is able to generate multiply charged ions of glycopeptides, which is
advantageous when studying intact glycoproteins although increasing the complexity of
the data generated. Furthermore, ESI can be coupled with liquid chromatography (LC)
which allows for online LC-MS analysis. The advantage in MALDI is that it generates
singly charged species when analyzing glycoproteins which simplifies the analysis.
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Derivatization of the glycan by permethylation, for example, can help stabilize the labile
glycosidic bonds and aid their detection when using either ionization type.
Different mass analyzers are used for the analysis of glycoproteins, including the orbitrap
and Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometers which are
now commonly used for glycoprotein analysis (Han and Costello, 2013; Patrie et al., 2013;
Zhou and Håkansson, 2011). The FT-ICR-MS has the highest mass accuracy and ultrahigh
resolution, but comes at a high monetary cost. The orbitrap also has ultrahigh resolution
and is compatible with LC and can be used for three different fragmentation modes
including collision-induced dissociation (CID), higher collision-induced dissociation
(HCD), and electron transfer dissociation (ETD). Orbitraps have been combined with linear
ion traps for the analysis of glycoproteins, whereby the MS occurs in the linear ion trap
and MS2 is set up to take place in the orbitrap, thus leading to rapid and accurate mass
detection of peptide and sugar fragments (Ye et al., 2013).

1.4.3.1

Fragmentation methods

In CID, the peptide ions are accelerated by an electrical potential to high kinetic energy
and then collided with neutral molecules (helium, nitrogen or argon) (Mitchell Wells and
McLuckey, 2005). Some of the kinetic energy is converted into internal energy which
results in bond breakage and ions are detected in the linear ion trap. In HCD, peptide ions
are injected into a collision cell and fragment ions are then analyzed by an orbitrap analyzer
where more accurate mass/charge (m/z) for the fragment ions can be measured (Olsen et
al., 2007). Peptide fragmentation patterns and nomenclature of fragment ions are
represented in Figure 8. Two types of fragment ions, b- and y-ions (peptide fragments
originating from sequential losses of amino acids from the C- and N-terminus respectively),
are frequently observed in MS2 spectra obtained by CID and HCD fragmentation.
Glycosylation typically decreases the fragmentation efficiency of peptide backbones when
these fragmentation methods are used. As the collision energy is mostly absorbed by the
glycan, glycosidic bonds usually break first, leading to inefficient peptide bond breakage
if any. This results in different fragmentation patterns of glycopeptides compared to their
non-glycosylated counterparts. This issue has been resolved through the use of HCD,
which supplies sufficient energy for peptide bond breakage even in the presence of a glycan
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and also results in the release and detection of sugar oxonium ions which are signatures of
sugar release (Olsen et al., 2007). HCD can be used to map glycosylation sites as has been
demonstrated in the case of peptides modified by GlcNAc (Segu and Mechref, 2010).
On the other hand, ETD produces fragment ions dominantly by breaking peptide bonds
while the glycan/sugar or other post-translational modification remains attached (Kim and
Pandey, 2012; Mikesh et al., 2006). Electrons are transferred to a multiply protonated
peptide or protein, or radical cations are generated in the case of a multiply protonated
peptide or protein, which leads to the cleavage of the N–Cα backbone bonds to generate cand z-ions (Figure 8) (Syka et al., 2004).
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Figure 8. Peptide fragmentation pattern and nomenclature of major ions formed by
mass spectrometry.
Nomenclature is based on the Roepstorff Nomenclature Scheme (Roepstorff and Fohlman,
1984). Fragment ions arising from the charge being retained on the N-terminus are denoted
as a, b, and c. Fragments arising from the charge being retained on the C-terminus are
denoted as x, y, and z. (Adapted from Maleknia and Johnson, 2011).
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1.4.3.2

Data analysis

Once the raw spectral data is generated by the mass spectrometer, the data can be analyzed
using specialized software in order to determine peptide sequences and their protein origin.
Database search and de novo sequencing are the two mainly used computational
approaches for spectral data interpretation, whereby the major difference between the two
approaches is the requirement of protein databases. In the first approach, the protein
sequences in a protein database are digested in silico to generate peptides, then an MS2
spectrum is compared with each possible peptide to calculate a peptide-spectrum match
(PSM) score, a calculated measurement of the similarity between a peptide and a spectrum.
The peptide from the database with the top PSM score is determined to match the MS2
spectrum. As protein databases do not incorporate post-translational modification (PTM)
data, database searching misses the identification of modified peptides. De novo
sequencing is a recent advance in spectral analysis which constructs the peptide sequence
directly from an MS2 spectrum, thus it is often used for novel protein identification. De
novo searches all amino acid combinations to find the optimal peptide sequence. PEAKS
and PepNovo are two state-of-the-art de novo software tools (Frank and Pevzner, 2005;
Ma, 2003). Accurate de novo sequencing, accompanied by different enzymatic digestions,
has been proven to be able to calculate the whole sequence for a purified protein sample
(Liu et al., 2009). However, the accuracy of the peptide sequence obtained from de novo
sequencing approaches is often lower than the one obtained from database search
approaches, although the two combined approaches have resulted in superior results than
either alone (Zhang et al., 2012). PEAKS software also allows to search for fixed or
variable PTM modifications whose corresponding mass can be manually inputted by the
user to facilitate analysis of modified peptides.

Mass spectrometry analysis of C. jejuni flagellins
A detailed description of Campylobacter flagellin glycosylation is presented here as an
example of bacterial glycoprotein analysis where a combination of the various MS methods
described above needed to be implemented to overcome the challenges presented by the
complex and highly heterogeneous flagellin glycosylation. This information is imperative
to the understanding of the work presented in sections 3.3.5 and 3.3.6.
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The glycopeptides of C. jejuni 81-176 flagellins have been mapped (Thibault et al. 2001),
whereby 19 of the 107 Ser/Thr residues were shown to be O-glycosylated with Pse5Ac7Ac,
Pse5Ac7Am, Pse5Ac7Ac8OAc, and Pse5Pr7Pr (Table 1). The glycopeptides of C. coli
VC167 flagellins have been mapped by MS and contain both Pse5Ac7Ac (316.127 Da)
and its acetamidino derivative, Pse5Ac7Am (315.143 Da), and two unknown sugars with
masses 431 Da and 432 Da (Table 1) (Logan et al., 2002). Additionally, it was shown by
metabolome analysis that this bacterium makes CMP-legionaminic acid (CMPLeg5Ac7Ac), its acetamidino derivative (CMP-Leg5Am7Ac), and a N-methylacetimidoyl
derivative (CMP-Leg5AmNMe7Ac). This was the first report of legionaminic acid being
produced in Campylobacter (McNally et al., 2007a), but it was not known whether these
legionaminic acid derivatives contributed to flagellin glycosylation in C. jejuni.
Interestingly, many chicken, bovine, and ovine livestock isolates of C. jejuni encode the
putative legionaminic acid synthesis cluster derived from C. coli analyses, including strain
NCTC 11168 (Champion et al. 2005).
Early attempts at characterizing the flagellin glycopeptides of C. jejuni NCTC 11168 were
unsuccessful (Thibault et al. 2001), but metabolomics data indicate that this strain makes
CMP-linked Pse5Ac7Ac, Pse5Ac7Am, two dimethylglyceric derivatives of pseudaminic
acid (Pse5AcGriMe7Ac, 390.164 Da and Pse5AcGriMe7Am, 389.180 Da), and, consistent
with the presence of the putative legionaminic acid synthesis gene cluster, it also makes
CMP-linked Leg5Ac7Ac (316.127 Da), Leg5Am7Ac (315.143 Da) and Leg5AmNMe7Ac
(329.159 Da) (Table 1) (Logan et al. 2009). Pse5AcGriMe7Ac and Pse5AcGriMe7Am
were further shown to glycosylate flagellins in two independent studies, one identifying
two peptides (residues 203-222 and 463-479), although the precise glycosylation sites were
undetermined (Logan et al., 2009), and the other showing that S181 and S207 were each
modified by Pse5AcGriMe7Ac or Pse5AcGriMe7Am and that T465 or T464 was modified
by Pse5AcGriMe7Am (Zampronio et al. 2011). It is also important to note that the
5AcGriMe7Ac and 5AcGriMe7Am modifications are unique to pseudaminic acid and have
not been found associated with legionaminic acid to date, and thus can be used to
unambiguously show that pseudaminic acid is glycosylating the flagellins. No
glycopeptide evidence of flagellin modification by legionaminic acid was demonstrated in
these studies. This is because pseudaminic acid and legionaminic acid are both structurally
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related to sialic acid and have the same mass (Table 2) and cannot be distinguished by mass
spectrometry, preventing assignment of either legionaminic acid or pseudaminic acid to
flagellin glycopeptides based on detection of their oxonium ions. The same problem applies
to their acetamidino derivatives. In contrast, the 5AmNMe7Ac modification has only been
found associated with legionaminic acid and not with pseudaminic acid to date, which
allows assignment of legionaminic acid to the flagellins upon detection of the unique
oxonium ion of Leg5AmNMe7Ac at m/z 330.167 during glycopeptide analysis. This
principle was used to demonstrate by top-down MS that the C. coli flagellins are indeed
modified by legionaminic acid (McNally et al. 2007).
Very recently, improved methodology allowed a more thorough characterization of the
flagellin glycopeptides (Ulasi et al., 2015). The use of collision induced dissociation (CID)
and electron capture dissociation (ETD) with high field asymmetric waveform ion mobility
spectrometry (FAIMS), combined with either trypsin or proteinase K treatment, resulted in
detection of multiple glycopeptides within the amino acid region 387 to 463 of flagellin A.
This highly glycosylated region had been missed in previous work. Overall 16
glycosylation sites were identified in addition to those found in the previous studies, several
of them presenting a high level of heterogeneity in glycosylation. However, even in this
study, no glycopeptide evidence showing specifically the presence of legionaminic acid
via the unique 329.159 Da Leg5AmNMe7Ac modification was obtained. The reported
presence of legionaminic acid was only based on detection of ions that are common to
pseudaminic and legionaminic acids. Thus the presence of legionaminic acid on flagellins
of C. jejuni NCTC 11168 remained hypothetical. Recently, as a result of the work presented
in this dissertation (Section 3.3.5), legionaminic acid was conclusively found to glycosylate
the flagellins of this strain (Zebian et al., 2015).
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Table 2. Monoisotopic and oxonium ion masses of sugars produced by C. jejuni
NCTC 11168 based on metabolome analysis (Logan et al., 2009).

55

Sugars

Monoisotopic Oxonium
Mass (Da)

Ion Mass
(Da)

Pseudaminic acid OR Legionaminic acid

316.127

317.136

315.143

316.151

390.164

391.172

389.180

390.188

329.159

330.167

(Pse5Ac7Ac OR Leg5Ac7Ac)

Acetamidino pseudaminic acid OR Acetamidino legionaminic
acid (Pse5Ac7Am OR Leg5Am7Ac)

Dimethylglyceric derivative of pseudaminic acid
(Pse5AcGriMe7Ac)
Dimethylglyceric derivative of acetamidino pseudaminic acid
(Pse5AcGriMe7Am)

N-methylacetimidoyl derivative of Legionaminic acid
(Leg5AmNme7Ac)
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1.5

Rationale and hypothesis

As discussed, C. jejuni NCTC 11168 has several glycosylation pathways that have been
extensively studied. However, there are still missing links in these pathways, including the
OTases for flagellin glycosylation, and many genes within the annotated glycosylation
islands are of yet unknown functions. Cj1319 is a putative sugar nucleotide dehydratase
which has potential roles in both protein glycosylation and capsule synthesis.
In H. pylori, we and others have shown that novel glycoproteins other than the well
characterized flagellin glycoproteins exist (Champasa et al., 2013; Hopf et al., 2011).
Additionally, the pathway for LPS synthesis has been recently deciphered and signifies an
evolutionary connection between N-protein glycosylation and LPS biosynthesis (Hug et
al., 2010). Combined with the fact that the H. pylori LPS O-antigen represents human
Lewis blood group mimics and this O-antigen has an important role in both host evasion
and immune modulation through molecular mimicry, it would not be surprising if H. pylori
used these host mimicking structures for protein glycosylation as well.
Based on the above, we hypothesize that there are links between the machineries used for
glycosylation of lipids and proteins in C. jejuni and H. pylori, whereby the sugar precursors
of glycolipids or O-units can serve for protein glycosylation to generate glycoproteins that
have not been identified to date. These novel glycoproteins may have important roles in
virulence and would also contribute to the heterogeneity of glycosylated structures found
on the cell surface.
To address this main hypothesis, we have two major objectives. Our first goal is to
investigate a relationship between capsule synthesis and protein glycosylation in C. jejuni
through the study of the enzyme Cj1319, a sugar nucleotide dehydratase, which has
predicted roles in both protein glycosylation and capsule synthesis. We also aim to
determine the contribution of this enzyme and its predicted glycosylation pathway in
colonization and virulence. Secondly, our purpose is to show that H. pylori can glycosylate
proteins with the O-antigen of its LPS by MS analysis of glycoprotein candidates to show
that their glycopeptides contain O-antigen in addition to identifying the glycosylation
site(s).
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In chapter 3 of this thesis, sections 3.1-3.4 aim to examine the role of Cj1319 in C. jejuni
and its contribution to colonization and virulence. Our hypothesis is Cj1319 is sugar
nucleotide dehydratase participating in a novel protein glycosylation pathway with a link
to capsule modified heptose synthesis through the use of a common precursor and
contributes to the virulence of C. jejuni NCTC 11168. To address this specific hypothesis,
we have three main objectives:
1) To determine the enzymatic function of Cj1319 by determining its substrate
and product.
Determining the enzymatic function of Cj1319 is a key piece of information that
will aid greatly in determining which glycosylation pathway(s) this enzyme
functions within. We assessed its activity on GDP-manno-heptose to determine if
it has a role in capsular heptose modification or if it shares the said precursor of this
pathway. Additionally, we tested its activity on GDP-mannose, as there is
functional similarity between heptose and hexose modifying enzymes. We
controlled positively for its activity using GDP-GlcNAc which was described as
the substrate of Cj1319 within the in vitro legionaminic acid synthesis pathway
(Schoenhofen et al., 2009).
2) To show legionaminic acid decorates WT flagellins and investigate its presence
in the cj1319::CAT mutant to determine if Cj1319 is involved in legionaminic
acid synthesis.
Here we address the controversial role of Cj1319 in legionaminic acid synthesis
through mass spectrometry analysis of flagellin glycopeptides from the WT, a
cj1319::CAT mutant, and its complemented strain. Since limited flagellin
glycopeptide data was available for our strain of interest at the onset of our work
and legionaminic acid was only implied but not demonstrated to glycosylate the
flagellins of C. jejuni, we performed a comprehensive flagellin glycopeptide
analysis using LC-HCD-MS2 with an emphasis on determining the presence of
legionaminic acid on the flagellins of our strains.
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3) To determine phenotypes associated with the cj1319::CAT mutant to shed light
on its biological activity.
In order to understand the importance of Cj1319 and the role of the glycosylation
pathway this enzyme may participate in on C. jejuni and on its interactions with
host cells, we examined the composition of the capsule and LOS of cj1319::CAT
mutant, in addition to this mutant’s glycoprotein profile compared to WT. We
further investigated functions of C. jejuni that are affected by glycosylated
structures including motility. In addition, we studied the interaction of the WT and
our mutant strain with several eukaryotic cells. Lastly, we examined the role of
Cj1319 in vivo, specifically in chicken colonization and infection in an insect
model.
Chapter 3, section 3.5 aims to identify a novel glycoprotein from H. pylori NCTC 11637
that is modified by a Lewis O-antigen. We hypothesize that H. pylori synthesizes the Oantigen Ley for protein glycosylation, specifically for outer membrane proteins which can
interact with the host, in addition to incorporation into its LPS. For this we have three
specific objectives:
1) To isolate Ley-modified peptide candidates from outer membranes.
Previous preliminary data from our laboratory indicates that at least one Leymodified protein is found in the outer membrane. Since the outer membrane
proteins copurify with LPS by ultracentrifugation during cell fractionation, we
trypsinolyzed the outer membranes to release soluble peptides and glycopeptides
into the supernatant. These peptides were passaged through a fucose binding lectin
column to enrich for Ley containing peptides.
2) To analyze glycopeptides by mass spectrometry for the Ley modification.
In order to identify the Ley-modified protein, we analyzed the peptide samples with
LC-HCD-MS2. Upon identification of the glycopeptide, we continued to analyze
the sample with LC-CID/ETD-MS2 in order to map the glycosylation site(s).

59

3) To verify Ley-modified glycoproteins identified by mass spectrometry through
knockout mutagenesis and Western blot analysis using anti-Ley.
To verify that the glycoprotein identified in objective 2 is the Ley-modified protein
candidate observed in our preliminary data, we constructed a knockout mutant of
the gene encoding the glycoprotein identified. Anti-Ley Western blot was used to
verify that the Ley glycoprotein candidate originally found in the WT is not present
in the mutant.
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Chapter 2

2

Methods

2.1 Bacterial strains and culture conditions
C. jejuni NCTC 11168 was grown in a microaerobic atmosphere (85% N2, 10% CO2 and
5% O 2) at 37°C on trypticase soy agar (TSA) supplemented with 5% sheep blood
(Cedarlane) and 10 μg mL−1 vancomycin and 5 μg mL−1 trimethoprim as background
antibiotics. Where appropriate, the medium was supplemented with 15 μg mL−1
chloramphenicol and/or 30 μg mL−1 kanamycin. The cells were grown overnight from
freezer stocks on TSA containing appropriate antibiotics. Cells were harvested and
normalized to an OD600nm=0.1 and 100 µL were spread onto TSA blood plates containing
only the background antibiotics using glass beads and strains were allowed to grow for 20–
24 h. The cells were harvested and normalized to the same OD600nm before use for
phenotypic analyses unless otherwise specified. The viability of the bacterial suspensions
that were used as the inoculum for phenotypic assays was assessed by colony forming unit
(CFU) measurements.
H. pylori NCTC 11637 cells were grown under microaerobic conditions, as indicated
above, for approximately 48 h on agar plates containing 37 g L−1 Brain Heart Infusion
(BHI) media (EMD), 2.5 g L−1 yeast extract (Bioshop), and 0.05% sodium pyruvate,
supplemented with 7.5 % horse serum (Gibco), 4 μg mL−1 amphotericin B (Calbiochem),
5 μg mL−1 trimethoprim (Sigma) and 10 μg mL−1 vancomycin (EMD Biosciences). Cells
were revived from freezer stocks on standard BHI plates in the case of the wild type strain
and BHI supplemented with 15 μg mL−1 chloramphenicol in the case of the hopE::CAT
mutant strain. After 48 h of growth, the bacteria were spread to a new plate using a sterile
cotton swab soaked in BHI and grown for another 48 h. The full plates were each expanded
to 8 plates and grown for 48 h. Standard BHI plates (without chloramphenicol) were used
in the final expansion of both wild type and mutant strains whereby each plate was further
expanded to another 8 plates. The bacteria were harvested in 1 mL of sterile 0.85 % saline
solution per plate of confluent growth. The harvested bacteria were centrifuged at 4,000 g
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for 30 min at 4˚C in a 5810 R centrifuge (Eppendorf). The supernatant was discarded and
the pellet was frozen at -20˚C until further use.
E. coli was routinely grown on Luria Bertani (LB) agar (Fisher Scientific) in a 37˚C
incubator. Alternatively, E. coli was grown in LB broth in a shaking incubator (200 rpm)
at 37˚C. Antibiotics were supplemented where appropriate at the following concentrations:
100 μg mL−1 ampicillin, 30 μg mL−1 kanamycin, 34 μg mL−1 chloramphenicol and 4
μg mL−1.

2.2

Preparation of chemically competent E. coli and

transformation of these cells
A 3 mL overnight culture of E. coli grown in LB broth was used to inoculate 100 mL LB.
The bacteria were incubated until an OD600 of 0.6 was reached. The bacteria were pelleted
at 5,000 g (Eppendorf 5415D, Eppendorf) for 10 min at 4˚C, resuspended in 20 mL of cold
50 mM calcium chloride solution and incubated on ice for 30 min. The cells were then
pelleted as described above and resuspended in 5 mL of 50 mM calcium chloride solution
and incubated on ice for 5 h. The cells were resuspended in 5 mL of 50 % cold glycerol in
50 mM calcium chloride and aliquoted for storage at -80˚C.
The competent E. coli cells were thawed on ice and 100 μL were added to 10 μL of plasmid
DNA (~25 ng μL−1) or a ligation mixture was added and mixed gently into the competent cells
and incubated on ice for 30 min. The cells were heat shocked for 90 s at 42˚C and then placed
on ice for 1 min. Then 600 μL of LB broth was added to the cells prior to incubation for 1.5 h
at 37˚C in a shaking incubator. The cultures were then plated on LB agar plates supplemented
with the appropriate antibiotics for selection. The plates were incubated at 37˚C for up to 16 h
and colonies were patched onto LB plates and screened by colony PCR. Positive clones were
grown in 3 mL of LB overnight and freezer stocks were prepared in 25% glycerol for storage
at -80˚C. Plasmids were extracted with a plasmid extraction kit (Froggabio) as per

manufacturer’s instructions for sequencing.
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2.3
Construction of His-tagged and GST-tagged
recombinant enzymes
NHis-Cj1319 was made by cloning cj1319 into a pET23 derivative vector using CJ1319P1
and CJ1319P2 (Appendix B, Table 9). Cj1319-CHis was made by cloning cj1319 into a
pET30a

vector

using

CJ1319P9

and

CJ1319P10

(protein

start

sequence

MDGKGEKVRNIL) or using CJ1319P23 and CJ1319P24 (protein start sequence
MVRNIL). NGST-Cj1319 was created by cloning cj1319 into a pGEX-2T vector using
CJ1319P13 and CJ1319P14. NHis-Cj1320 was made by cloning cj1320 into a pET23
derivative vector using CJ1320P1 and CJ1320P2. NHis-Cj1419 and NHis-Cj1426 were
created by cloning cj1419c and cj1426c into a pET23 derivative vector using primer pairs
CJ1419P1 and CJ1419P2 or CJ1426P1 and CJ1426P2 respectively. The primers used for
making all constructs contained sequences cleavable by restriction enzymes, such that the
PCR products and the plasmids were digested accordingly and ligated with T4 DNA ligase
(NEB Biolabs). The constructs were transformed into E. coli DH5α and clones were
selected by growth on LB agar supplemented with the appropriate antibiotics and screened
by colony PCR and verified by DNA sequencing (Robarts Sequencing).
pNRC173.1, pNRC136.1, and pNRC175.1 were generously provided by Ian Schoenhofen
(National Research Council, Canada) for the expression of PgmL, PtmE and GlmU
respectively. These plasmids were constructed as detailed in (Schoenhofen et al., 2009).
NGST-HP0044 and DdahA-CHis were constructed as detailed previously (Butty et al.,
2009; McCallum et al., 2011).

2.4

Protein expression and purification

Protein expression was performed in E. coli BL21(DE3) for His-tagged clones and E. coli
DH5α for GST-tagged clones. Unless specified otherwise, cells were grown in LB broth
shaking at 200 rpm at 37ᵒC until an OD600nm=0.6 was reached and then recombinant protein
expression was induced for 3 h at 37ᵒC (or overnight at room temperature for GST-tagged
clones) by the addition of 0.15 mM isopropyl β-D-1-thiogalactopyranoside. The cells were
pelleted at 14,000 g for 15 min and stored at -20ᵒC until needed.
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For purification of over-expressed His-tagged proteins, cell pellets were re-suspended in
30 mL cold binding buffer (5mM imidazole, 0.1 M NaCl, 50 mM sodium phosphate pH
7.5). The cells were lysed by passaging through a cell disruptor (Constant Systems LTD
IS6/40/BA/AA model) at 25,000 psi. The cellular debris and insoluble proteins were
removed by centrifugation at 14,000 g for 30 min at 4˚C, followed by the removal of
membranes by ultracentrifugation (Beckman) at 100,000 g for 1 h at 4˚C. The His-tagged
proteins were purified by nickel chelation chromatography using Fast Protein Liquid
Chromatography (FPLC) system with a POROS 1.6 mL column (Applied Biosciences).
The column was washed initially with 5 column volumes (CV) of water before being
charged with 30 CV of 0.1 M nickel sulphate. After the column was charged, the column
was washed with 7.5 CV of 0.1 M NaCl and 5 CV of water. The column was equilibrated
with 10 CV binding buffer that was adjusted to pH 7.5 for Cj1319 purifications and pH 8
for Cj1419 and Cj1426 purifications. After loading the sample, the column was washed
with 10 CV of 1X binding buffer to remove proteins that were non-specifically bound to
the column. Bound proteins were eluted with an imidazole gradient from 50 mM to 1.0 M
in 0.1M NaCl and 50 mM sodium phosphate that was adjusted to the same pH as the 1X
binding buffer. Elution fractions were collected and separated by SDS-PAGE to determine
which fraction contained the protein of interest. Purified proteins were stored in 50 %
glycerol at -20ᵒC.
The GST-tagged proteins were purified by affinity chromatography using a 1 mL GSTrap
FF column (GE Healthcare) that had been equilibrated in PBS binding buffer. The cell
pellets obtained after overexpression of the GST-tagged proteins were resuspended in 30
mL of PBS binding buffer, pH 8 (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4). The cells were disrupted using a cell disruptor (Constant Systems LTD
IS6/40/BA/AA model) at 25,000 psi. Cellular debris and insoluble proteins were removed
by centrifugation for 30 min at 14,000 g and by filtration through a 0.2 μm filter. GST
affinity purification was completed on an FPLC system using a 1 mL GSTrap FF column
(GE Healthcare) that had been equilibrated in PBS binding buffer. The column was washed
with 10 CV of binding buffer. The GST-tagged proteins were eluted with 3 CV of 0.01 M
reduced glutathione. The glutathione was removed from the sample by overnight dialysis
(cutoff of 3500 Da) in 50 mM Tris-HCl, pH 8, at 4ᵒC. For HP0044, the GST tag was

64

removed by on-column incubation with thrombin for 2 h at 37ᵒC, and the protein was eluted
in 5 CV of 50 mM Tris-HCl buffer, pH 8. The purified proteins were analyzed by SDSPAGE and Coomassie staining and were stored in 50% glycerol at -20ᵒC.

2.5

Enzymatic reactions and analysis

Enzymatic reactions for making GDP-GlcNAc from D-glucosamine-6-phosphate were
performed as described previously (Schoenhofen et al., 2009).
GDP-manno-heptose substrate was prepared enzymatically from sedoheptulose 7phosphate (GlycOTeam) using overexpressed and purified GmhA/B/C and D enzymes
from Aneurinibacillus thermoaerophilus as described previously (Butty et al., 2009).
GDP-manno-heptose was purified by anion-exchange chromatography using a 5 ml High
Q Econopac column (Bio-Rad Laboratories) and a linear gradient of 20 CV of TEAB
(triethylammonium bicarbonate), pH 8.5, (50 mM–1 M) at 1 ml min−1 as described
previously (Obhi and Creuzenet, 2005). After freeze-drying, substrate quantification was
performed using a NanoDrop spectrophotometer and using ϵGTP=12000 mol−1·l·cm−1.
Reactions were typically performed by incubating 50 ng–2 μg of enzyme with 0.1 mM
substrate (GDP-manno-heptose or GDP-GlcNAc prepared as described above or
commercial GDP-mannose (Sigma)) in a final volume of 10 μl of 200 mM Tris/HCl pH 8.5
for DdahA and HP0044 or 25 mM sodium phosphate, pH 7.3, 25 mM NaCl for Cj1319 and
other enzymes. Coenzymes were added at a concentration of 0.1 mM each. For reactions
with Cj1320, 0.8 mM PLP, 8 mM L-Glu, and 1.2 mM acetyl-CoA were added. Reactions
with Cj1419 and Cj1426 additionally contained 1 mM S-adenosylmethionine (SAM).
Reactions were normally incubated for 3 h at 37°C. The reaction products were analysed
by capillary electrophoresis.

2.6
Capillary electrophoresis (CE) of sugar
nucleotides
CE was performed on a Beckman Gold instrument using the 32 Karat software and a 75
cm inner diameter bare silica capillary. The initial conditioning of the capillary was
performed by washing the capillary with 0.1 N HCl for 30 min at 20 psi, followed by 10
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min of water. For sample analyses, the capillary was washed for 2 min with 200 mM borax,
pH 9, buffer. The sample was injected by pressure for 4 s and separation was performed by
applying 26 kV to both ends of the capillary that were maintained in the borax buffer.
Migrating compounds were monitored at 254 nm in a window placed at 50 cm from the
beginning of the capillary. The capillary was washed 2 min with water, 2 min with 0.1 M
NaOH, and 2 min again with water between each run. Substrate conversion was estimated
by integration of the areas under the substrate and product peaks using the 32 Karat
software.

2.7

Extraction of chromosomal DNA from C. jejuni and

H. pylori
For chromosomal DNA extraction from total cells, half a plate of confluently grown bacteria
were harvested into 1 mL of 0.85 % saline solution and pelleted at 14,000 g for 1 min and
washed once prior to resuspension in 500 µL of cetyltrimethylammonium bromide (CTAB)
buffer (100 mM Tris-HCL pH 8.8, 1.4 M NaCl, 0.02 M EDTA, 1% (w/v) CTAB). A solution
of phenol:chloroform:isoamyl alcohol (25:24:1) was added to the cell suspension (1:1) and the
mixture was vortexed until an emulsion formed following by centrifugation at 14,000 g for 5
min. The aqueous phase was collected and added to 500 µL of chloroform-isoamyl alcohol
(24:1) and centrifuged at 14,000 g for 5 min to remove residual phenol. The aqueous phase
was recovered and 0.08 volumes of cold 7.5 M ammonium acetate and 0.54 volumes of chilled
isopropanol were added to precipitate the DNA. The contents were mixed by inversion 30 times
and incubated at room temperature for 10 minutes. The precipitated DNA was collected by
centrifugation at 14,000 g for 10 min at 4ᵒC. The DNA pellet was washed once with cold 70
% ethanol and air dried. The final DNA pellet was resuspended in 50 μL of autoclaved distilled

water and stored at 4ᵒC.
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2.8

Construction of knockout mutant and complement

strains
Construction of cj1319::CAT knockout mutant
Construction of the cj1319::CAT knockout mutant was performed as previously described
for the cj1294::CAT mutant using a CAT cassette for selection and natural transformation
(Vijayakumar et al., 2006). Primers CJ1319P1 and CJ1319P2 were used to clone cj1319
into the pET23 vector derivative (Newton and Mangroo, 1999) and primers CJ1319P3 and
CJ1319P4 were used for inverse PCR (Appendix B, Table 9). The CAT cassette was
amplified from pRYIII vector using primers CATCOLIP3 and CATCOLIP2 (Vijayakumar
et al., 2006; Yao et al., 1993). The knockout mutant was checked by PCR with primers
flanking outside the gene.

Construction of cj1319 complement strains
Complementation was performed by chromosomal integration in the 16S–23S rRNA
region as reported previously (Karlyshev and Wren, 2005) and detailed by (Wong et al.,
2015). Briefly, cj1319 was fused together with the promoter of ompE and a downstream
kan resistance cassette using primers CJ1319P16, CJ1317, CJ1319P18, and CJ1319P19 by
the primer overlap extension method (Heckman and Pease, 2007) (Appendix B, Table 9).
The final construct was cleaved with NheI and inserted into the XbaI site of the pBluescript
plasmid, generating pBSK-cj1319comp_RSP. This was sequenced (Robarts Sequencing
Facility, London, Ontario) and transformed into the cj1319::CAT mutant by natural
transformation.
Alternatively, primers 1318Pr-Bglll and Cj1319p25-NdeI were used to amplify cj1319
with two upstream predicted promoter sequences based on RNA-seq data (Dugar et al.,
2013). The kan resistance cassette was amplified with primers Aph3-For-His-NdeI and
Aph3-p3. The two PCR products were digested with NdeI and ligated together. The blunt
ended product was ligated into blunt ended pBSK-16S-23S cut with SmaI to generate
pBSK-cj1319comp_RSP. To generate pBSK-cj1319comp_ONP, the blunt ended product
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and pET23-cj1320 were digested with BglII and NcoI and the two digested products were
ligated together.

Construction of hopE::CAT mutant
The 500 bp upstream of the hp0706 gene was PCR-amplified from chromosomal DNA
from H. pylori strain NCTC 11637 and the CAT cassette and 500 bp downstream of hopE
were amplified by PCR from the hopEHisCat PCR SOEing product. The upstream and
CAT downstream products were blunt-end ligated using T4 ligase (New England Biolabs).
The ligated product was finally inserted into pUC18 digested with PstI and EcoRI forming
phopE::CAT. Proper integration of the CAT cassette is verified by PCR. The knockout
hopE mutant of strain NCTC 11637 was generated using this construct by electroporationmediated allelic exchange, with selection on 12 µg mL−1 chloramphenicol. Potential
transformants were analyzed for gene integration by PCR amplification of the gene
knockout using primers that hybridize to DNA that was outside of the fragment used for
recombination. Finally, correct insertion was confirmed by sequencing of the amplicons
generated from the chromosomal DNA of selected mutants.

2.9

Purification of BambL, PAII-L and BC2L-A

pET25-BambL, pET25pa2l, and pRSETbcla were generously obtained from Dr. A.
Imberty (CERMAV-CNRS, Grenoble, France) and constructed as described previously
(Audfray et al., 2012; Lameignere et al., 2008; Mitchell et al., 2005). The plasmids were
transformed into E. coli BL21(DE3) cells. The transformed cells were grown in LB broth
containing 100 μg ml−1 ampicillin to an OD600nm=0.6 and induced with 0.5 mM IPTG for
5 h at 30ᵒC. The cells were centrifuged at 7,000 g for 15 min and resuspended in
equilibration buffer (20 mM Tris pH 7.5, 100 µM CaCl2, 0.15 M NaCl) followed by
passaging through a cell disruptor (Constant Systems LTD IS6/40/BA/AA model) at
25,000 psi. The lysate was centrifuged at 14,000 g for 30 min to pellet cellular debris and
insoluble proteins. The supernatant was further centrifuged at 50,000 g for 30 min, and the
resulting supernatant was filtered through a 0.45 µm filter. Affinity chromatography on a
mannose-agarose column (Sigma-Aldrich) was performed on the supernatant, whereby 1
mL of resin was loaded into a column and the beads were washed with 10 CV milliQ water
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and 10 CV equilibration buffer. The purified lectins were allowed to bind to immobilized
mannose in equilibration buffer and after washing with (20 mM Tris-HCl pH 7.5,
1 M NaCl), they were eluted with 2 CV of 100 mM mannose in equilibration buffer.
Purified protein was dialyzed extensively using a 3.5 kDa MW cutoff against ultrapure
water overnight, lyophlized and stored at 4 °C.

2.10

Labelling lectins with biotin

Pure BambL, PA-IIL, and BC2L-A was resuspended in 0.1 M sodium carbonate, pH 9.5,
0.1 % NaN3 at a concentration of 20 mg mL−1. Biotin-hydroxysuccinimide ester in DMSO
was added to each lectin at a ratio of 10 mol biotin/mol of lectin and the mixture was
allowed to incubate for 4 h at room temperature. To quench the reaction, 20x phosphate
buffer (10 mM sodium phosphate, 150 mM NaCl pH 7.4, 0.1 % NaN3) was added to the
mixture and the sample was dialyzed extensively against phosphate buffer using a 3.5 MW
cutoff.

2.11 Coupling BambL to sepharose for purification of
glycopeptides
Lyophilized BambL (3 mg) was resuspended in 1 mL of coupling buffer (0.1 M NaHCO3
pH 8.3, 0.5 M NaCl) and added to sepharose (1 mL/0.2g dried sepharose). The column was
washed with 4 CV of coupling buffer and the sepharose was blocked by adding 5 CV of
0.1 M Tris-HCl pH 8.0. The column was equilibrated in 10 CV of equilibration buffer (20
mM Tris pH 7.5, 0.15 M NaCl, 100 uM CaCl2). The soluble outer membrane tryptic
peptides were allowed to bind to immobilized BambL in equilibration buffer and after
washing with (20 mM Tris-HCl pH 7.5, 1 M NaCl), glycopeptides were eluted with 2 CV
of each of 100 mM and 200 mM mannose in equilibration buffer.

2.12

Agarose gel electrophoresis

Agarose gel electrophoresis was used to separate DNA fragments. For most DNA
fragments, a 0.7 % agarose gel was prepared in TAE buffer (40 mM Tris-acetate pH 8.0, 1
mM EDTA), and ethidium bromide was added to a final concentration of 0.01 %. For
smaller fragments (~200 bp), a 1.4 % agarose gel was prepared in a similar manner as
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above. Samples were mixed with DNA loading buffer (4x TAE buffer, 50 % glycerol, 0.01
% bromophenol blue) before loading and sizes were compared to a 1 kilobase pair DNA
ladder standard (Invitrogen, Frogga). Electrophoresis was carried out at 80 volts until
proper separation was achieved. DNA bands were visualized using UV light (254 nm).

2.13

Natural transformation of C. jejuni and H. pylori

C. jejuni were grown under microaerobic conditions as described above and the cells were
harvested into TSB and adjusted to an OD600=0.2. A total of 2 g of plasmid DNA was
added to the cells to a final volume of 80 L. A negative transformation control consisted
of 70 L of cells and 10 L of water. The transformation mixtures were diluted by the
addition of 300 L of TSB. Four spots of 75 L each were placed onto TSA plates
supplemented with 5% sheep blood and cells were allowed to recover for 8 hours under
microaerobic conditions at 37C. The spots were resuspended in 300 L of TSA broth and
75 L plated onto TSA agar plates containing the appropriate antibiotics for selection using
glass beads. Plating onto TSA plates, with no antibiotics, to ensure viability after
transformation, was also done in parallel. These plates were grown for 2-3 days under
microaerobic conditions at 37C until colonies were observed.
Similarly, H. pylori were transformed according to the above protocol with the following
modifications: Transformation mixtures were done in BHI and cells were grown on BHI
agar supplemented with 7.5% horse serum. Plates were allowed to incubate for 5-7 days
until colonies were observed.

2.14

Growth curves of C. jejuni strains

C. jejuni was grown as described above and re-suspended in MH broth to an OD600 of 1.0.
A sidearm flask containing 20 mL MH broth and background antibiotics was first
equilibrated under microaerobic conditions overnight. The MH broth was then inoculated
with 1.5 mL of the bacterial suspension to achieve a starting OD600 of 0.075. Nitrogen gas
was injected into the flask for approximately 1 min through a sterile Pasteur pipette which
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was inserted into the flask, and partially sealed with a rubber stopper, to allow gas to fill
the remaining volume of the flask, creating a microaerobic environment. The flasks were
then sealed and incubated under agitation (120 rpm) at 37˚C for up to 24 h. Growth was
monitored using a Klett colony meter (600 nm filter) over 24 h.

2.15

SDS-PAGE and Western blotting

Bacterial proteins were denatured in SDS loading buffer (0.625 M Tris pH 6.8, 2% SDS, 2
% β-mercaptoethanol, 10 % glycerol, and 0.002 % bromophenol blue) and incubated for 5
min at 100⁰C, unless otherwise indicated. Proteins were separated on 12% SDS
polyacrylamide gels by the Laemmli system (Bio-Rad, mini-gel system). Electrophoresis
was performed at 12 mA. Proteins were visualized by Coomassie blue staining (10% acetic
acid, 25% ethanol, 0.001% (w/v) Brilliant Blue R-250), silver nitrate staining or Western
blotting.

LPS preparations were separated by 12 % SDS-polyacrylamide gels. Carbohydrates were
visualized by silver nitrate staining or Western blotting.
The antibodies and Western blot conditions used in this study are summarized in Table 3.
Western blotting was performed after electrophoretic transfer of proteins or LPS to
nitrocellulose (Bio-Rad). Wet transfer was performed for 90 min for membrane protein
samples and 60 min for all other protein and LPS samples in Tris-Glycine Transfer buffer
(192 mM glycine, 25 mM Tris, 20 % methanol, 0.01 % SDS) with a constant current of
180 mA (Bio-Rad transblot system). After transfer, the membrane was rinsed in distilled
water and stained with Ponceau S (0.1% (w/v) Ponceau S (Sigma-Aldrich) in 1 % (v/v)
acetic acid) to visualize the transfer of proteins to the membrane. The Ponceau S stain was
removed from the membrane by two 20 mL washes with phosphate buffered saline (PBS)
buffer (137 mM NaCl, 2.7 mM KC1, 8 mM Na2HPO4, 1.46 mM KH2PO4, pH 7.2). The
membrane was blocked overnight at 4⁰C followed by an hour at room temperature with
gentle shaking on a gel surfer (Dia-med) in 2.5 % skim milk, Odyssey Blocking Buffer
(Licor), or 10 % Horse Serum (Gibco), as appropriate for the antibodies to be used (Table
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3). After blocking, all steps were performed at room temperature and with gentle shaking
on the gel surfer. The membrane was washed twice in 20 mL PBS-Tween-20 (PBS with
0.1 % Tween-20) and once in PBS buffer for 5 min each and then incubated with primary
antibody for 1 h at room temperature. After incubation, the membrane was washed four
times in PBS-Tween-20 and once in PBS for 5 min each and then incubated with secondary
antibody for 30 min in the dark. The membrane was washed in the dark with PBS-Tween20 and PBS as above. All antibodies were centrifuged at 6,300 g for 10 min prior to use.
Proteins or LPS were detected by the Licor Infrared Imaging system at wavelengths of 700
nm or 800 nm.
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Table 3. Antibodies and Western blotting conditions used in this thesis
Epitope
detected

Blocking
buffer

Primary
antibody /label
and dilution

Biotin

10% horse
serum

Glycoprotiens
labelled with
biotinhydrazide

6xHistag

2.5% skim
milk

Fucose

Secondary
antibody and
dilution used
Streptavidin
conjugated to
AlexaFluor 680
(Invitrogen),
1μg/mL

Wavelength
detected (nm)

700

AntipolyHistidine
(mouse)
(Sigma),
1/3000

Anti-mouse (goat)
conjugated to
IRDye 680 (Licor),
1/10000

10% horse
serum

Biotinconjugated
PAII-L or
BambL lectins

Streptavidin
conjugated to
AlexaFluor 680
(Invitrogen),
1μg/mL

Heptose

10% horse
serum

Biotinconjugated
BC2L-A lectin

FlaA and
FlaB

2.5% skim
milk

Anti-FlaA/B
(rabbit),
1/2500

Lewis Y

2.5% skim
milk

Streptavidin
700
conjugated to
AlexaFluor 680
(Invitrogen),
1μg/mL
Anti-rabbit (goat)
800
conjugated to
IRDye 800
(Rockland
Immunochemicals),
1/5000
Anti-mouse (goat)
700
conjugated to
IRDye 680 (Licor),
1/10000

Anti-Lewis y,
clone F3
(mouse)
(Calbiochem),
1/100

700

700
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2.16

RNA extraction and cDNA synthesis

C. jejuni was grown for 20-24 h under microaerobic conditions at 37˚C on one TSA plate.
For RNA isolation, approximately 5.0  109 cells were resuspended in 200 L TE buffer,
as recommended by the manufacturer, prior to lysis. RNA was isolated using the RNA midi
spin kit (GE Health Sciences) as per the manufacturer’s instructions. The final elution step
was done in 500 μL of RNAse free water, following the manufacturer’s instructions. In
addition to the on column DNAse I treatment as suggested by the manufacturer, the
samples were treated using 60 units of DNAse I (Roche, Canada) for 40 minutes at 37C.
Following the reaction, the DNAse was inactivated via the addition of 8.4 μL 100 mM
ethylenediaminetetraacetic acid (EDTA) and heating at 70˚C for 10 minutes. The amount
of RNA was quantified using a ND-1000 Nanodrop spectrophotometer (Nanodrop, USA).
RNA samples were diluted in RNAse free water to a final concentration of 10.5 ng/μL.
cDNA was generated using iScript reverse transcriptase (BioRad, Canada). Each reaction
contained 30 μL of DNAse-treated RNA, 8 μL 5x iScript reaction mix, and 2 μL of iScript
reverse transcriptase. Negative control samples contained 10 μL of the iScript reaction
mix and 30 μL of RNA. The reverse transcription reaction was carried out using a BioRad
thermocycler (BioRad, Canada) and the program used was as follows: 5 minutes at 25˚C
for annealing of the random primers, 30 minutes at 42˚C for extension, 5 minutes at 85˚C
for inactivation of reverse transcriptase, and a final 4˚C hold. Following the generation of
cDNA, the samples were stored at -20˚C until use.

2.17

qPCR analysis

Real-time PCR analysis was carried out using the Rotor-Gene 6000 (Corbett Life Science,
Canada) to measure the transcription levels of the cj1141, cj1142, cj1143, cj1426c,
cj1427c, cj1428c, cj1429c, cj1430c, cj1120c, cj1121c, cj1293, cj1294, cj1318, cj1319,
cj1320, and cj1321 genes in the wild type and mutant strains. The gene cj1537c encoding
an acetyl CoA synthetase (a housekeeping gene) was used as a reference for normalization
within each strain (intrastrain). C. jejuni chromosomal DNA was used as a positive control
for the amplification of each fragment. When determining the expression level of each gene
of interest, samples were set up in triplicate. For determination of gene expression, 2 μL of
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cDNA were added to 2 μL of the appropriate primer mix (1 μL of each primer, at 7 pmol/μL
(see Appendix B Table 9 for primer sequences)), 10 μL SYBR green mix, containing all
necessary components for qPCR, (BioRad, Canada), and 6 μL of water. Negative controls
for the qPCR contained cDNA but did not contain the SYBR Green mix. An additional
negative control consisted of the SYBR Green mix and RNA which did not undergo reverse
transcription. This control was used to ensure there was no chromosomal DNA
contamination.
Reactions were carried out as follows: 95˚C (initial denaturation) for 5 minutes, 95˚C
(denaturation) for 45 seconds, 59.5˚C (annealing) for 30 seconds, and 72˚C (elongation)
for 20 seconds. Steps 2-4 were repeated for 40 cycles.
For each primer pair, efficiencies were determined using the dynamic range of
chromosomal DNA and amplifying the desired fragments. Following amplification, the
data were plotted and a standard curve was generated based on the CT (the cycle number at
which enough amplified product accumulates to yield a detectable fluorescence signal
above a set threshold) values for the amplification from the different chromosomal DNA
concentrations covering the dynamic range. The primer amplification efficiency was
determined from the slope of the standard curve by performing the following calculation:
E (efficiency) = 10-1/slope, which was converted into a percentage using the following:
%Efficiency = (E-1) x 100.
The dynamic range of cDNA for downstream qPCR analysis was determined using varying
concentrations of cDNA. For this, DNA fragments were amplified from serial dilutions of
cDNA. The CT value for each reaction was determined and a standard curve was generated
by plotting CT against the cDNA concentration. The cDNA concentrations yielding the best
standard curve (i.e. the CT values were evenly spaced and a linear standard curve results in
a slope indicative of the maximum amplification efficiency (i.e. a doubling of DNA per
cycle)) were used in each experiment to determine gene expression.
Two methods of comparison were used to determine differences in gene expression:
intrastrain and interstrain comparisons. In intrastrain comparisons, the fold difference of
expression of each gene was normalized to an internal housekeeping gene, cj1537c (a gene
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which encodes acetyl CoA synthetase). For interstrain comparisons, the ΔCT of each gene
compared to the housekeeping gene was calculated. The ΔΔCT between the WT and
mutant genes was calculated and the fold change compared to WT was calculated as such:
fold = 2ΔΔCT. The standard deviation (SD) of the CT values of biological replica was
determined for each gene and the propagated error incorporated into the fold change
calculation was determined using the following equation 𝐸 = √(𝑆12 + 𝑆22 ), where S1 is
the SD of the gene of interest and S2 is the SD of the housekeeping gene. This error is
calculated within the WT to give E1 and in the mutant strain to give E2. The final
propagated SD is calculated by 𝑆𝐷 = √(𝐸12 + 𝐸22 ).

2.18

Motility assay

Campylobacter jejuni strains were adjusted to OD600nm of 1.0. Motility plates (0.3 % agar
in TSA) were stabbed in triplicate with the wild type or mutants and incubated under
microaerobic conditions at 37°C. The diameter of the motility halo was recorded after 48
h.

2.19

Electron microscopy

Electron microscopy was performed at the Biotron at Western University led by Dr. R.
Gardiner with uranyl acetate staining as previously described (Merkx-Jacques et al., 2004).

2.20

Flagellin purification

C. jejuni strains were grown as described above and cells were harvested from four petri
dishes and washed in 0.85 % saline. The cells were resuspended in 10 ml of 0.85 % saline
and surface appendages were sheared off using a tissue homogenizer for 4 x 30 s with
cooling on ice in between shearing. The cells were pelleted twice at 4,000 g for 20 min at
4°C. The supernatant containing the extracted flagella was centrifuged at 100,000 g for 1
h at 4°C. The pelleted flagella were resuspended in water for further analyses.
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2.21

Capsule, LOS, and LPS extraction and purification

Crude extraction
Crude CPS, LOS and LPS samples were prepared by SDS-solubilization as previously
described by Hitchcock and Brown (Hitchcock and Brown, 1983). Briefly, C. jejuni from
one TSA plate (or H. pylori from one BHI plate) was resuspended into 1 mL of PBS and
pelleted at 14,000 g (Eppendorf 5415D, Eppendorf). The resuspended bacteria were diluted
to an OD600 of 0.375 and 1 mL aliquoted. This aliquot was respun at 14,000 g to pellet the
bacteria. The bacterial pellet was resuspended in 200 μL of SDS solubilization buffer (2 %
SDS, 4 % 2-mercaptoethanol, 10 % glycerol, 1 M Tris pH 6.8, pinch of bromophenol blue)
and boiled for 10 min. To each sample, 5 L of 20 mg mL−1 Proteinase K was added and
incubated for one hour at 60 C. Samples were run on a SDS-PAGE gel as described above.

Ultra-pure extraction and separation of C. jejuni capsule and
LOS
For the purification of capsule from C. jejuni NCTC 11168 wild type, cj1319::CAT,
cj1427::CAT, cj1428::CAT, cj1430::CAT, and KpsM mutants, and cj1319 complement
strains, cells were grown on TSA plates as aforementioned and approximately 4 TSA plates
were used to inoculate 600 mL of Brucella broth (BBL Sciences, Canada), containing 7.5%
horse serum and 25 mM sodium pyruvate to an OD600 of approximately 0.05. After 24 h
of growth (OD600 approximately 0.3), the bacteria were spun down at 4,200 g (Avanti J25I, Beckman-Coulter) for 30 min. Purification of capsule was performed using the hot
water/phenol extraction method (O. Westphal, 1964). Briefly, wet cell pellets of
approximately 1 g were re-suspended in 20 mL of MilliQ water pre-heated to 68°C. An
equal amount of liquified phenol (Fisher) preheated to 68°C was added to the pellet and
sealed in a 50 mL phenol resistant centrifuge tube. The samples were incubated in a 68°C
water bath for 10 minutes with intermittent rigorous vortexing. The sample was allowed
to cool to 10°C on ice and centrifuged for 30 min at 6,300 g (Eppendorf 5810R, Eppendorf),
and 10°C. The aqueous (top) phase was collected, and an equal amount of water was added
to the remaining organic phase. The procedure was repeated and the aqueous phases were
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pooled. The aqueous phases were dialyzed (molecular weight cut off 12-14000 Da,
Spectra/Por, Spectrum Labs) against running water for 2-3 days until no phenol remained.
The

sample

was

lyophilized

and

re-suspended

in

double

distilled

water.

Ultracentrifugation of the sample for 30 h at 4°C and 100,000 g (Optima Max-XP
Ultracentrifuge, Beckman-Coulter) pelleted most of the LOS, while CPS remained in the
supernatant. The sample was lyophilized and resuspended in 500 μL double distilled water.
Treatment with 200 mg of Proteinase K (Biobasic, Markham, Canada) was carried out for
2 h at 60°C to degrade any remaining proteins that may not have been removed during the
hot water/phenol procedure. Capsule samples were stored at -20°C until further required.
For compositional analysis of the capsule and LOS, the procedure was performed on 6 L
of cell cultures, whereby all volumes were adjested accordingly. In addition to the above,
the samples were further treated twice with both DNase I and RNase and twice more with
Proteinase K to ensure the removal of peptides and nucleic acids. In between treatments,
the samples were centrifuged at 100,000 g for 10 h and the pellet was recovered. To
separate the LOS from capsule, isopropanol was added to a final concentration of 50 %
(v/v) and the samples were spun at 14,000 g for 10 min. The supernatant containing the
capsule was removed and speedvaccuumed to drynesss and resuspended in water. The
pellet containing the LOS was resuspended in the same volume of water as the capsule.
Samples were frozen at -20ᵒC until further use.

2.22

Silver staining of carbohydrates

The silver staining protocol of Fomsgaard et al was followed (Fomsgaard et al., 1990).
Briefly, carbohydrates were first separated on a 10% SDS-PAGE and then oxidized in a
solution of 0.7% periodic acid, 40% ethanol and 5% acetic acid in milliQ water with
shaking for 20 min. The oxidation was followed by five washes over 15 min in milliQ
water. The gel was then stained with silver nitrate in a staining solution with the following
final concentrations: 0.19% (v/v) 10 N NaOH, 1.3% (v/v) ammonium hydroxide, 0.7%
(w/v) silver nitrate. Gels were stained for 10 min, followed by five washes over 15 min in
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milliQ water. Following the wash, the gels were developed using 0.005% (w/v) citric acid
and 0.05% (v/v) formaldehyde (37%) in milliQ water until bands became visible. The gels
were then washed several times with milliQ water and scanned.

2.23

Compositional analysis of capsule and LOS

Glycosyl composition analysis was performed by combined gas chromatography/mass
spectrometry (GC/MS) of the per-O-trimethylsilyl (TMS) derivatives of the
monosaccharide methyl glycosides produced from the sample by acidic methanolysis.
Between 300 µg and 400 µg was used for the analysis. The samples were placed into test
tubes and 20 µg of inositol was added. Methyl glycosides were then prepared from the dry
samples by methanolysis in 1 M HCl in methanol at 80°C (16 h), followed by re-Nacetylation with pyridine and acetic anhydride in methanol (for detection of amino sugars).
The samples were then per-O-trimethylsilylated by treatment with Tri-Sil (Pierce) at 80°C
(0.5 hours). These procedures were carried out as previously described in (Merkle and
Poppe, 1994; York et al., 1986). GC/MS analysis of the TMS methyl glycosides was
performed on an Agilent 7890A GC interfaced to a 5975C MSD, using an Supelco Equity1 fused silica capillary column (30m ´ 0.25 mm ID).

2.24

Cell fractionation by differential centrifugation

The cell pellet was resuspended in 30-40 mL of 50 mM sodium phosphate pH 7.2, 0.3 M
NaCl to a final OD600 of 6-10. The cells were subsequently lysed by passage through a cell
disrupter (Constant Systems LTD IS6/40/BA/AA model) at 25,000 psi. All centrifugation
steps were performed at 4⁰C. Cellular debris and unlysed cells were pelleted by
centrifugation at 5,000 g for 30 min. Insoluble proteins were removed from the supernatant
by centrifugation at 13,000 g for 1 h. Membrane proteins were pelleted by
ultracentrifugation (Optima-XL 100K ultracentrifuge, Beckman Coulter, 70-Ti rotor) at
100,000 g for 1 h at 4⁰C. The supernatant recovered containing soluble proteins underwent
a second ultracentrifugation spin at 100,000 g for 1 h. The initial membrane pellet was
washed in 500 μL 50 mM sodium phosphate pH 7.2, 0.3 M NaCl, and pelleted by
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ultracentrifugation in a micro-ultracentrifuge (Optimax ultracentrifuge, Beckman Coulter,
TLA-110 rotor at 100,000 g). The supernatant was discarded and the total membrane pellet
was used for separation of inner and outer membrane proteins.

2.25 Separation of inner and outer membrane proteins
by differential solubilization in N-laurylsarcosine
Differential solubilization of inner and outer membrane by lauryl sarcosine has been
documented as an efficient method to separate both types of membranes in various bacteria
(Creuzenet and Lam, 2001; Filip et al., 1973). To solubilize inner membrane proteins, the
washed total membrane pellet was resuspended in 500 μL of solubilization buffer (50 mM
sodium phosphate pH 7.2, 0.3 M NaCl, with 1% N-lauryl sarcosine (w/v) (Sigma-Aldrich))
and mixed on nutator for 1 h at room temperature and overnight at 4⁰C. Outer membrane
proteins were pelleted by ultracentrifugation at 100,000 g (Optimax ultracentrifuge,
Beckman Coulter, TLA-110 rotor) for 1 h at 4⁰C. To further enhance the separation, the
supernatant containing inner membrane proteins was ultracentrifuged at 100,000 g for 1 h
at 4⁰C three more times until no pellet was visible. Similarly, the original outer membrane
pellet was resuspended and washed in solubilization buffer, mixed for 1 h at room
temperature, and pelleted again by ultracentrifugation at 100,000 g for 1 h at 4⁰C. The final
outer membrane pellet was resuspended in 50 mM sodium phosphate pH 7.2, 0.3 M NaCl
for protein analysis by SDS-PAGE.
The membrane fractions were analyzed by SDS-PAGE (12% polyacrylamide) (Laemmli,
1970). Proteins were visualized directly by Coomassie blue staining or silver nitrate
staining, or after transfer onto nitrocellulose membrane by Ponceau S Red staining, biotinhydrazide labelling or Western blotting. To ascertain proper separation of inner and outer
membranes, the samples were tested for lactate dehydrogenase activity (inner membrane
marker) according to published procedures (Osborn et al., 1972).

2.26

Digestion of outer membrane proteins

Outer membranes were resuspended the in equilibration buffer (20 mM Tris pH 7.5, 0.15
M NaCl, 100 µM CaCl2) and trypsin was added at a ratio of 1:100 to the weight of the
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outer membranes and the sample was incubated at 37ᵒC overnight. Ultracentrifugation at
100, 000 g was performed for 1 h in order to separate the soluble released peptides from
the membranes. Further digestion was performed in the presence of 1 % Tween-20 for 18
h at 37ᵒC.

2.27

Chemical labelling of glycoproteins

The protein content of sample fractions was assessed by Bradford assay and normalized to
1 µg µL-1. From each fraction, 20 µL was used for the labelling reaction. To oxidize the
carbohydrates of the glycoproteins, 2 µL of 100 mM sodium periodate were added to the
sample and allowed to incubate in the dark for 20 min at room temperature. To quench the
oxidizing reaction, 2 µL of 200 mM of sodium bisulphite in 200 mM sodium acetate pH
5.5 was added to the reaction and allowed to incubate for 5 min at room temperature. The
samples were split into two tubes each of equal volume, where one received an addition of
2.5 µL of 5 mM biotin-hydrazide (Sigma) in dimethylformamide (DMF) and the other was
mock labelled with 2.5 µL of DMF. The samples were incubated for 1 h at room
temperature. The reaction was stopped by adding SDS-PAGE loading buffer to final
concentration of 1X.
The biotin hydrazide-labelled and mock labelled samples were boiled for 2 min at 100˚C
and loaded onto a 15-well 12 % 1D SDS-PAGE gel and run at 12 mA. The gel was blotted
onto a nitrocellulose membrane (BioRad) and protein transfer occurred at 180 mA for 45
min. Total proteins were stained by PonceauS Red on the membrane and then scanned. The
membrane was de-stained in Tris-buffered saline (TBS) (10 mM Tris-HCl pH 7.5, and 150
mM NaCl) for 10 min and was blocked overnight in 10 % horse serum in water at 4˚C. The
membrane was then washed in TBS-Tween-Triton (50 mM Tris, 140 mM NaCl, 2 % Triton
X-100, 0.5 % Tween-20, pH 7.5) for 10 min twice and once in TBS for 10 min. The
membrane was probed with 15 ml of 1 µg ml-1 streptavidin-AlexaFluor-680 conjugate
(Molecular Probes) in 0.01 M Potassium Phosphate pH 7.5, 0.8% NaCl for 30 min in the
dark. It was then washed in TBS-Tween-Triton for 10 min three times and once in TBS for
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10 min. The membrane was scanned at 700 nm on a Licor (Odyssey) infra-red scanner to
detect the fluorescent streptavidin conjugate.

2.28

Adhesion and Invasion assay of C. jejuni to Caco-

2 cells
Caco-2 cells (kindly given by D. McKay, University of Calgary) were routinely grown on
75 cm2 tissue culture flasks in DMEM medium containing high glucose (25 mM) and
supplemented with 10% fetal bovine serum (FBS, Gibco), 1.5 g L-1 sodium bicarbonate,
0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 100 U ml-1 penicillin, and 100
μg/ml streptomycin. Caco-2 cells were grown in a CO2 incubator containing 5% CO2 and
37˚C until confluent, and passaged every 4-5 days. Passage of Caco-2 cells was carried out
by releasing the cells from the flask surface via the addition of 0.25% Trypsin-EDTA
(Gibco), followed by incubation in the CO2 incubator at 37˚C for 2-3 min. Once released,
the trypsin-EDTA was neutralized via the addition of fresh DMEM. Cells were then
centrifuged at 200 g (Eppendorf 5702, Eppendorf) for 5 minutes to remove any excess
trypsin.
Caco-2 cells were grown for three days until they formed a confluent monolayer
(approximately 6.5 x 105 cells per well in 24-well plates). Approximately 6.5 x 107 CFU
of C. jejuni were added to the Caco-2 cells for a multiplicity of infection (MOI) of 100:1
and the cells were allowed to incubate for 5 h. The plates were spun briefly (300 g
(Eppendorf 5870R, Eppendorf) for 5 min at room temperature) to maximize contact
between the bacteria and the cell monolayer. To determine total bacterial cell association
(adherent and internalized bacteria), Caco-2 cell monolayers were washed three times,
lysed with 0.1 % Triton X-100 for 10 min and viable bacterial counts were determined by
plating the serial dilutions. To determine the number of internalized bacteria, the Caco-2
cell monolayers were treated with 200 μg mL-1 gentamicin for two hours to kill
extracellular bacteria. The cells were then washed and treated as above to determine
bacterial viable counts.
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2.29

Internal survival of C. jejuni in A. castellanii

A. castellanii ATCC 30234 was obtained from the American Type Culture Collection. The
protozoa were maintained in PYG medium in 75 cm2 tissue culture flasks (BD,
Mississauga, ON, Canada) at 25°C without aeration and routinely subcultured every 5
days. Amoeba cells were seeded at a density of ~2.5 x 105 cells mL-1 in a 24-well plate in
a media free of nutrients and that does not support the replication of the amoeba cells and
allowed to attach for 2 h. The C. jejuni strains are added to the wells at an MOI of 100:1
and allowed to incubate for 2 h, followed by 1 h of incubation with 300 µg/mL gentamycin
at 25°C under aerobic conditions. For 0 h post infection, amoeba were lysed in Triton-X
solution and a sample was taken and serially diluted for enumerating intracellular surviving
bacteria. For 2.5 h and 5 h post infection, ameoba were fed heat inactivated E. coli to
prevent them from starving during the time of incubation following the gentamycin
treatment, and then similarly the amoeba were lysed and a sample was taken to enumerate
surviving bacteria. Serial dilutions for each experiment were done in duplicate per well and
3 spots of 10 µl per dilution were plated for CFU mL-1 enumeration. Controls included
amoeba only to ensure no contaminating bacteria were present, amoeba only for
enumerating amoeba cells post infection time, bacteria only to determine the number of
viable bacteria, bacteria only with gentamycin, and bacteria of the viability control treated
with Triton-X to determine the effect of Triton-X on the bacteria.

2.30

Adhesion, invasion and internal survival of C.

jejuni in Raw macrophages
RAW 264.7 macrophages (ATCC) were grown in 75 cm2 tissue culture flasks (BD Falcon)
in DMEM (Invitrogen) containing high glucose (25 mM), 10% FBS, 0.1 mM non-essential
amino acids, 100 U/ml penicillin, and 100 μg/ml streptomycin in a CO2 incubator
containing 5% CO2 and at 37˚C. They were grown from freezer stocks until 80% confluent
and then passaged every 3-4 days to a maximum of 5 passages. Passaging involves
washing the macrophages in 1x PBS (Wisent) and detaching them by the addition of 5 mL
0.25% Trypsin/EDTA (Gibco) and incubation in a CO2 incubator for 2-3 min. The cells
were detached by allowing 15 mL of fresh DMEM to run over them. Cells were then
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centrifuged at 200 g (Eppendorf 5702, Eppendorf) for 5 minutes to remove any excess
trypsin. To seed new cells, 1 mL of cells was taken and added to 19 mL of fresh DMEM
medium in a 75 cm2 flask and incubated in a CO2 incubator until needed.
Freezer stocks of RAW 264.7 macrophages were made with 45% cells, 45% FBS and 10%
dimethyl sulfoxide (DMSO, Sigma-Aldrich). Cells were aliquoted into 2 mL cryotubes and
stored at -80˚C until required.
Cells were seeded at approximately 2.1  105 cells per well of a 24 well plate and incubated
overnight in DMEM without antibiotics. C. jejuni wild type or mutants were added at a
MOI of 100. The plates were centrifuged for two minutes at 300 g (Eppendorf 5870R,
Eppendorf) to synchronize bacteria-macrophage interaction.
For adhesion experiments, the plates were incubated with bacteria at 4°C for 30 min,
washed with cold PBS five times and the cells were lysed in sterile double distilled water.
The bacteria were then serially diluted and plated for CFU counts.
For intracellular survival experiments, cells were seeded as above and infected with
bacteria at an MOI of 100 for two hours in a CO2 incubator. The cells were washed three
times using PBS and incubated with fresh DMEM containing 225 μg/mL gentamicin for
one hour to kill extracellular bacteria. Macrophages were then washed and incubated in
fresh DMEM for the times indicated. At each time point, the macrophages were washed
three times with PBS and lysed using sterile double distilled water. Samples were serially
diluted and plated for CFU counts.
For infection time course experiments, macrophages were seeded as above and infected
with bacteria at an MOI of 100 for the times indicated. The macrophages were washed
three times in PBS and incubated in fresh DMEM containing 225 μg/ml gentamicin for one
hour, followed by lysis as described above and surviving bacteria were enumerated by CFU
counts.
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2.31

Biofilm assay

C. jejuni was grown as usual and cells were resuspended in TSB at an OD600nm=1 and
incubated for 24 h at 37ᵒC. The strains were normalized to an OD600nm=1 (~109 cell/mL) in
TSB and 1 mL was added to borosilicate glass tubes. The tubes were allowed to incubate
at 37ᵒC over 6 days. At days 3, 4, 5 and 6, three tubes per strain were washed extensively
in water and dried. Attached biofilms were stained with 1 % (w/v) crystal violet in water
for 30 min and then washed extensively and dried and then treated with 1 mL 30% (v/v)
acetic acid to dissolve the stain. The biofilms were quantified through transfer of 200 µL
of the solution to 96-well microtest plate and absorbance was measured at 590 nm.

2.32

Nitrosative and oxidative stress assays

For nitrosative stress assays, C. jejuni were grown as described and harvested in BHI and
normalized to an OD600nm=0.1. To promote the production of reactive nitrogen species,
sodium nitrite was dissolved in BHI pH-adjusted to 5.0 at different concentrations
(Gundogdu et al., 2011; Iovine et al., 2008). The acidified media was added to the cells in
96-well plates (Sarstedt) and they were allowed to incubate for 30 min under static
microaerobic conditions at 37ᵒC. Each strain was treated in duplicate with each
concentration of sodium nitrite and cells serially diluted after incubation. The serial
dilutions were plated in triplicate for CFU enumeration.
In order to compare the susceptibility of strains to oxidative stress in the short term, 100
µL of bacteria at an OD600=0.1 were incubated with different concentrations of H2O2 (15,
1.5, 0.15, or 0 mM) in a 96-well plate for 30 min at 37°C under microaerobic conditions
and then serially diluted and plated on TSA blood plates. CFUs were counted after 2 days.
In order to compare the sensitivity of our strains to oxidative stress in the long term, 100
µL of bacteria at an OD600=2 were spread onto TSA blood plates and allowed to dry. Sterile
filter discs treated with 10 µl of 3%, 10%, or 30% H2O2 and dried were aseptically placed
onto the agar. The plates were incubated under microaerobic conditions for 24 h at 37ᵒC
and the zone of inhibition was measured.
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To determine the sensitivity of strains to serum, 10 μL of bacteria at an OD600nm=0.1 was
added to wells of a 96-well plate dish and 90 μL of serum diluted in BHI broth to a final
concentration of 25 % (v/v). The plates were then incubated for 1.5 h in microaerobic
conditions at 37°C. Following incubation, samples were serially diluted and plated for
CFU counts.

2.33 SDS and polymyxin B minimum inhibitory
concentration (MIC) determination
To determine the MIC SDS and polymyxin B on our strains, 10 μL of bacteria at an
OD600nm=0.1 was added to wells of a 96-well plate dish containing SDS or polymyxin B
serially diluted from 0.02 to 0 % (w/v) SDS or 100 to 0 µg/mL polymyxin B. The plates
were incubated for 48 h at 37°C and a spectrophotomer was used to measure the OD600nm.

2.34

Infection of Galleria mellonella

Final instar G. mellonella larvae (Recorp Inc.) were maintained on wood chips at 15°C. C.
jejuni strains were grown as usual followed by resuspension in 1.5 mL of Brucella broth
supplemented with 0.25 mM sodium pyruvate and incubation at 37ᵒC for 4 h with shaking
at 120 rpm. The cells were spun down gently and resuspended in 0.85% saline at an
OD600nm=3. Larvae were infected with C. jejuni strains in 10 μL inocula by microinjection
(Hamilton) in the right foreleg. The larvae were incubated at 37ᵒC and survival was
recorded after 24 h of infection. Saline-injected and uninjected controls were used. The
bacterial input was measured by serially dilutions and CFU enumeration 2 days later.

2.35

Structural modeling

Homology modeling approach was used to model the structure of HopE. SWISS-MODEL
workspace (http://swissmodel.expasy.org/) was used to build the structure model (Arnold
et al., 2006). The model was exported from SWISS-MODEL as a protein data bank file
(PDB). The 3D structure was then visualized and analyzed using PyMol software
(https://www.pymol.org/).
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2.36

Statistical analysis

Raw data was input into Graphpad Prism 6 software following templates provided for
each statistical test. All calculations including means and standard errors and statistical
analyses were performed using this software.

2.37

Mass spectrometry analysis of glycoproteins

In-gel trypsin digest
Samples for mass spectrometry were prepared according to the procedure outlined by the
University of Western Ontario Biological Mass Spectrometry Laboratory (BMSL). Briefly,
after separation of proteins by SDS-PAGE and protein staining with Coomassie Blue stain,
the protein band of interest was excised from the polyacrylamide gel and cut into 1mm3
pieces and combined in a 1.5 mL eppendorf tube. The gel pieces were washed with 1
volume of autoclaved and filtered distilled water with occasional vortexing throughout.
The distilled water was removed and the gel pieces were treated three times with 1 volume
of 1:1 distilled water and acetonitrile for 15 min. The liquid was removed and the gel pieces
were incubated with enough acetonitrile to just cover the gel pieces until the gel pieces
visibly shrunk in size, appeared white in colour, and stuck together (approximately 5-10
minutes). The gel pieces were subsequently spun down in a microcentrifuge and the
acetonitrile was removed. The gel pieces were rehydrated in 1 volume of 0.1 M ammonium
bicarbonate for 5 min. One volume of acetonitrile was added, resulting in a 1:1 mixture of
acetonitrile and 0.1 M ammonium bicarbonate, and the gel pieces were incubated for an
additional 15 min. The liquid was removed and the gel pieces were dried in a vacuum
centrifuge (Eppendorf) on the organic phase setting. Once completely dry, the gel pieces
were rehydrated in 1 volume of 10 mM DTT, 0.1 M ammonium bicarbonate, and incubated
for 45 min at 56ᵒC to reduce the protein. The remaining liquid was removed and 1 volume
of 55 mM iodoacetamide, 0.1 M ammonium bicarbonate was added. The gel pieces were
incubated in the dark for 30 min and then washed with 1 volume of 0.1 M ammonium
bicarbonate for 5 minutes and 1 volume of 50 % acetonitrile in distilled water for 15 min.
The wash solution was removed and 1 volume of acetonitrile was added and incubated
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until the gel pieces became white and sticky (approximately 5-10 min). The liquid was
removed and an additional 0.1M ammonium bicarbonate and acetonitrile washing cycle
was performed to remove residual Coomassie stain. The samples were completely dried in
a vacuum centrifuge. The gel pieces were rehydrated in 1 volume of trypsin digestion
buffer (50 mM ammonium bicarbonate, 5 mM CaCl2, 10 ng/μL trypsin) and incubated for
45 min on ice. The gel pieces were spun down in a microcentrifuge and the supernatant
removed. The gel pieces were covered with digestion buffer minus trypsin (50 mM
ammonium bicarbonate, 5 mM CaCl2) and incubated overnight at 37⁰C. To extract
peptides, the gel pieces were spun down in a microcentrifuge and the supernatant removed
to a clean 1.5 mL eppendorf tube. One volume of 25 mM ammonium bicarbonate was
added to the gel pieces until they were completely covered. The gel pieces were incubated
for 15 min with vortexing every 2-3 min. One volume of acetonitrile was added to make a
1:1 solution of 0.1 M ammonium bicarbonate and acetonitrile and the gel pieces were
incubated for an additional 15 min. The supernatant was removed and combined with the
initial supernatant following overnight digestion. To the gel pieces, 1 volume of 5% formic
acid was added and incubated for 15 min. The same volume of acteonitrile was added and
incubated for an additional 15 min. The gel pieces were spun down and the supernatant
was combined with the earlier steps. An additional extraction cycle with 5% formic acid
and acetonitrile was performed and the supernatant combined. To the pooled supernatant,
DTT was added to a final concentration of 1 mM. Lastly, the combined supernatant was
completely dried in a vacuum centrifuge and submitted to the BMSL facility for mass
spectrometry analysis. All steps were performed at room temperature unless otherwise
stated.

Analysis of C. jejuni flagellins
Two rounds of proteolytic digestion were performed, the first with trypsin, the second with
trypsin and chymotrypsin, and peptides were collected and processed separately for each
round. The first set of peptides (trypsin digest) was subjected to reversed phase ultra
pressure liquid chromatography (LC) using a Waters nanoAcquity system coupled to a
fourier transform (FT) Thermo Scientific Orbitrap Elite mass spectrometer using a
Nanoflex source. The samples were trapped and then eluted onto a Waters BEH C18 75
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um x 25 cm column using a gradient of 5% to 40% buffer B (Acetonitrile + 0.1% formic
acid) over 90 minutes. The MS mass range was set at 400 to 1800 m/z with a high resolution
set at 120,000 and the MS2 scans were set using a fixed first mass of 100 Da using a
FT/FT/HCD data dependant acquisition scheme. HCD scans were detected in the Orbitrap
with a three step collision energy of 38 +/- 20% to optimize fragmentation data generated
from glycopeptides. The second set of peptides (trypsin/chymotrypsin digest) were treated
similarly using the same column but using a gradient of 5% to 37.5% buffer B over 80
minutes and using the Thermo Scientific QExactive mass spectrometer with the MS mass
range set at 400 to 1500 m/z. The MS2 scans were set using a fixed first mass of 100 Da
using a FT/FT/HCD data dependant acquisition scheme. HCD scans were detected in the
orbitrap with a normalized collision energy of 23%. For targeted MS 3 experiments, data
were acquired using FT/IT(CID)/FT(HCD) (MS/MS2/MS3) with an FT Orbitrap Elite mass
spectrometer with a resolution set at 60,000 using a normalized collision energy of 50%.
MS3 was set to trigger from MS2 scans generating the 373.160 m/z ion, with a preferential
MS2 fragmentation of ions 704.3585 m/z and 772.7425 m/z (+3 charge ions previously
found carrying the 372.145 modification). Raw data were visualized with the Qual Browser
feature of the Thermo Scientific XCalibur software, and data analysis was performed using
PEAKS 7.0 (Bioinformatic Solutions Inc.) software and peptide sequences were generated
by de novo sequencing. The data were also searched against the NCBI database to match
unmodified peptides. Unmatched peptides were further analyzed by manual addition of the
mass of each sugar found in the metabolome of C. jejuni NCTC 11168, summarized in
Table 2, and those found to be modifying flagellins of C. jejuni 81-176 into the variable
modification list of the PEAKS software. Matches and partial matches were manually
inspected to validate glycopeptides and to remove false hits.

Analysis of H. pylori outer membrane tryptic peptides
The tryptic peptides released from the outer membranes of H. pylori NCTC 11637 were
separated on a Tris-glycine based gel (4%-16%-20%) in a Tris-Tricine system (run at 80
V till sample gets into separating, and 200 V till the end. The sample is run 30 min after
the dye has run off the gel for best resolution of lower masses) and then the gel is stained
with Coomassie Brilliant Blue. The area of 9-12 kDa containing anti-Ley reactive bands
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was carefully excised from the gel and the peptides were digested further with trypsin and
extracted from the gel as described above for MS analysis. The peptides were separated by
reversed phase ultra high pressure liquid chromatography (UPLC) using a Waters
nanoAcquity system coupled to a Thermo Scientific Orbitrap Elite™ Hybrid Ion TrapOrbitrap Mass Spectrometer, using a Nanoflex source. The peptides were trapped and then
eluted onto a Waters BEH, 1.7 um, C18, 75 um x 25 cm column using a gradient of 5% to
40% buffer B (Acetonitrile + 0.1% formic acid) over 90 min. The MS mass range was set
at 400 to 1800 m/z with resolution set at 120,000 and the top five most abundant precursor
ions were selected for MS2 by HCD fragmentation using a FT/FT/HCD data dependent
acquisition scheme. HCD scans were detected in the orbitrap with a stepped collision
energy of 38 ± 20%.
Peptides were also analyzed using alternating CID/ETD fragmentation. The MS mass
range was set at 400 to 2000 m/z with a high resolution set at 120,000 and the top two most
abundant precursor ions were selected for MS2 using a FT/FT/ETD/CID data dependant
acquisition scheme. ETD and CID scans were detected in the orbitrap with a normalized
collision energy (NCE) of 40% and 35% respectively. Raw data were visualized with the
Qual Browser feature of Thermo Scientific XCalibur software, and data analysis was
performed using PEAKS 7.5 (Bioinformatic Solutions Inc.) software and peptide
sequences were generated by de Novo sequencing then searched against the NCBI database
to match unmodified peptides. Unmatched or DeNovo only peptides were further analyzed
by manual addition of the mass of Ley and related sugars presented in Table 4, into the
variable modification list of the PEAKS software. Matches and partial matches were
manually inspected to validate glycopeptides and to remove false hits.
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Table 4. Masses of LeY and its fragments ions arising from glycosidic bond
breakage.

Sugar/glycan

Monoisotopic mass (Da) of

Oxonium ion

sugar/glycan residues
released from peptide

(m/z)

Fucose

146.0579

147.0658

Gal

162.0528

163.0607

GlcNAc

203.0794

204.0873

GlcNAc + Fucose

349.1373

350.1452

Gal + GlcNAc + Fuc

511.1901

512.1980

Gal + Fucose

308.1107

309.1186

Full Ley

657.2480

658.2515

Gal + GlcNAc

365.1322

366.1401
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Chapter 3

3

Results

In this chapter, we investigated links between protein glycosylation and different
glycolipids. We first examined the role of Cj1319 in the modification of GDP-mannoheptose to determine if this enzyme participates in heptose modification for capsule and/or
protein glycosylation. We show through enzymology studies and a compositional analysis
of the capsule from a cj1319::CAT knockout mutant that this enzyme is not involved in
heptose modification. We further addressed the controversial role of Cj1319 in
legionaminic acid synthesis, whereby we show it is not required for making this sugar. To
determine an alternative role for this enzyme in non-heptose related protein glycosylation,
we compared the cj1319::CAT mutant to mutants of each of the two known protein
glycosylation pathways in phenotypes related to survival in the environment, host
colonization and virulence. Through this, we determined Cj1319 has an important role in
serum resistance, biofilm formation and infection of Galleria mellonella. Although we did
not find a link between glycoproteins and glycolipids in C. jejuni, we expanded our study
to its close relative H. pylori. We present data showing that an outer membrane porin is
glycosylated with the Ley O-antigen of the LPS, thus providing direct evidence that protein
glycosylation is related to LPS synthesis in H. pylori.

3.1 Investigating the function of Cj1319 via an enzymology
approach
Rationale: Cj1319 is a putative sugar biosynthetic enzyme which we hypothesize has a
role in protein glycosylation in Campylobacter jejuni via a GDP-manno-heptose
dehydratase activity. This is based on the homology of the enzyme to other GDP-mannoheptose dehydratases, DmhA and DdahA (Ho et al., 2008; McCallum et al., 2011), and on
the fact that cj1319 is clustered with a putative aminotransferase and an N-acetyl
transferase, Cj1320 and Cj1321, which is reminiscent of the genetic arrangement found in
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the two known protein glycosylation pathways (Nothaft and Szymanski, 2010;
Vijayakumar et al., 2006). GDP-manno-heptose is the precursor of a dedicated pathway
for the creation of a modified heptose that is incorporated into the capsule of C. jejuni
strains and this heptose is important in virulence and chicken colonization (Karlyshev et
al., 2005a; Wong et al., 2015). This pathway for our strain of interest, C. jejuni NCTC
11168, is partially characterized, however, the C4 oxidase needed to initiate this pathway
has yet to be found (Figure 3) (McCallum et al., 2013). The oxidase role may be fulfilled
by Cj1319 as C4 oxidation is also performed by C4, C6 dehydratases, whereby Cj1319
would have a central role in this pathway, or Cj1319 may use GDP-manno-heptose as the
precursor of a novel protein glycosylation pathway which would be a potential link
between capsule synthesis and protein glycosylation. It has been shown in other bacteria
that O-antigen from the LPS or capsule units can serve as the glycosylation motif for
protein glycosylation (Castric et al., 2001; DiGiandomenico et al., 2002; Lees-Miller et
al., 2013).

Expression of various tagged forms of Cj1319
Previous laboratory members have attempted to express and purify Cj1319 to study its
function enzymatically. Both C- and N-terminal His-tagged Cj1319 (Cj1319-CHis and
NHis-Cj1319) were cloned and transformed into E. coli BL21(DE3)pLysS, however, little
to no soluble expression of either recombinant protein was reported. As such, N-terminal
GST-tagged Cj1319 (NGST-Cj1319) was cloned and transformed into E. coli DH5α in
order to increase the solubility of Cj1319. Although induction of soluble NGST-Cj1319
was successful, the fusion protein was not found to be active on either GDP-manno-heptose
or GDP-mannose. As the lack of activity could be explained by the presence of the GST
tag which could interfere with the binding of Cj1319 to its substrate, the GST tag was
removed through digestion by thrombin. However, thrombin digestion was largely
inefficient and still no activity was found on either substrate. It is possible that the enzyme
may be unstable and lost activity during thrombin digestion. Therefore, we expressed and
purified NGST-Cj1319 to produce untagged Cj1319 following thrombin digestion under
modified digestion conditions to resassess the activity of this enzyme (Appendix B, Figure
46D).
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In addition, we sought to determine conditions for expression of soluble His-tagged Cj1319
in order to avoid GST tag cleavage. We transformed both NHis-Cj1319 and Cj1319-CHis
constructs into BL21 (DE3) without pLysS, and analyzed them for inducible expression of
Cj1319. The Cj1319-CHis clone showed the most inducible expression and thus was
chosen for purification by nickel affinity chromatography (Appendix B, Figure 46A, B and
C).
Since the Cj1319-CHis construct was made with a slightly longer starting sequence
(MDGKGEKVRNIL) due to the ambiguity of the start codon at the time of its design (gtg,
coding for valine, rather than atg), the full enzyme was recloned with a shorter starting
sequence (MRNIL), as the additional starting amino acids may have caused a change in
Cj1319’s structure, rendering it inactive. This new clone matched exactly what was used
by Schoenhofen et al. 2009, who showed that Cj1319 is active on GDP-GlcNAc, although
activity was limited.
Testing Cj1319 on GDP-GlcNAc
It has been shown that Cj1319 is active on GDP-GlcNAc and Cj1320 is active on GDP-2acetamido-2, 6-dideoxy-α-D-xylo-hexos-4-ulose generated by Cj1319 (Schoenhofen et al.,
2009). Thus, in order to show that Cj1319 and Cj1320 were active prior to testing on our
two predicted substrates, we tested both enzymes on GDP-GlcNAc. As this sugar
nucleotide is not available commercially, we needed to synthesize GDP-GlcNAc. We
accomplished this using commercial 6-glucosamine-1-phosphate and enzymes PgmL,
PtmE, and GlmU according to Figure 9. Constructs for expression of these enzymes were
obtained from (Schoenhofen et al., 2009). We expressed and purified these three enzymes
and followed the reaction conditions described in (Schoenhofen et al., 2009). PgmL and
PtmE were used to make GDP-GlcN from 6-glucosamine-1-phosphate. This sugar
nucleotide was then purified by anion exchange chromatography and the pure sugar
nucleotide is shown in Figure 10, trace A. GlmU was then reacted with GDP-GlcN to make
GDP-GlcNAc shown is trace B. Once GDP-GlcNAc was obtained, reactions with Cj1319CHis and NHis-Cj1320 were performed. After 4.5h incubation with Cj1319-CHis, no
evidence of product formation was detected in trace C. We additionally monitored the
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reaction at 8 h, and still no product had formed. However, after extending the reaction
overnight (~20 hours), almost 100% of GDP-GlcNAc is converted to GDP-2-acetamido2, 6-dideoxy-α-D-xylo-hexos-4-ulose in trace D. This extended incubation time was also
reported by (Schoenhofen et al., 2009). To confirm that the new peak that emerged was
GDP-2-acetamido-2, 6-dideoxy-α-D-xylo-hexos-4-ulose, Cj1320 was added to the
reaction and the emergence of GDP-4-amino-4, 6-dideoxy-α-D-GlcNAc is observed in
trace D, although the yield is very limited, and concomitant decrease in the Cj1319 product
was observed. The peak identification is based on direct comparison to the peaks reported
by (Schoenhofen et al., 2009). The slow reaction kinetics of Cj1319 and Cj1320 on these
intermediates of this pathway suggest that these substrates are unlikely to be the native
substrates of these enzymes. Thus we continued to pursue the potential of Cj1319 to act on
GDP-mannose and GDP-manno-heptose. The activity on GDP-GlcNAc was used to
positively control for enzyme activity.
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Figure 9. In vitro pathway for the synthesis of legionaminic acid adapted from
(Schoenhofen et al., 2009) showing only the first few steps of GDP-GlcNAc synthesis
and subsequent enzymatic steps carried out by Cj1319 and Cj1320.
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Figure 10. Analysis of the synthesis of GDP-GlcNAc by CE and the limited activity
of Cj1319-CHis on this substrate.
Trace A shows GDP-GlcN made using PgmL and PtmE from 6-glucosamine-1-phosphate.
Trace B shows the formation of GDP-GlcNAc from GDP-GlcN by the activity of GlmU.
Trace C represents 4.5 h after addition of Cj1319-CHis to B. Trace D represents C
incubated for 20 h. Trace E represents NHis-Cj1320 added to D for 20 h.
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Testing activity of Cj1319 on GDP-manno-heptose and GDP-mannose
The purified enzymes were incubated with GDP-manno-heptose or GDP-mannose and
coenzymes (NAD+ and NADP+) under different buffering conditions (pH 6-11 in 0.5 unit
increments). Control reactions with equivalent amounts of either DdahA (GDP-mannoheptose dehydratase) and HP0044 (GDP-mannose dehydratase) were performed in
parallel. All reactions were analyzed by capillary electrophoresis (CE) using UV detection.
Representative traces of reaction results are shown in Figure 11. No activity on either GDPmanno-heptose was observed regardless of the buffer, pH or coenzyme used. Neither
dialysis following purification to remove excess NaCl and imidazole nor the use of βmercaptoethanol (Schoenhofen et al., 2009) had an affect on the activity of Cj1319.
Different growth conditions for protein expression were tested (temperature and media) in
addition to testing the supplementation of the cell lysate with the required coenzyme NAD+.
No condition had any apparent advantage over the other as no activity from Cj1319 was
detected in any case. To address if there was an inhibitory artifact within the reactions
containing Cj1319, we added either DdahA or HP0044 dehydratases to Cj1319 reaction
cocktails which had been analyzed by CE and reincubated them. These two enzymes
performed their activities as usual, thus demonstrating the reaction conditions were
appropriate for these dehydratases.
Reactions were also performed on Cj1319-CHis prior to Ni2+ affinity purification to
determine if the enzyme was active before purification. This was done by adding cell free
extract containing overexpressed Cj1319-CHis to the reaction mixture containing both
NAD+ and NADP+ and either of GDP-mannose or GDP-manno-heptose. As a control,
cell free extract from E. coli Bl21(DE3) containing no plasmid was added to the same
combinations of reaction mixes. No product was observed in this case compared to the
control.
Testing Cj1319 in the presence of downstream reductase and aminotransferase to
stabilize its product
Enzymatic reactions with Cj1319 were also tested with WcaG, a GDP-4-keto-6-deoxymanno-heptose reductase that we hypothesized could stabilize the Cj1319 4-keto
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intermediate product (McCallum et al., 2011). This also did not lead to detectable activity
from Cj1319. In case Cj1319 is an unstable enzyme that loses activity rapidly and cannot
withstand freeze thaw cycles, the NGST-Cj1319 expressing strain was grown and the
enzyme was purified in a single day without any freezing steps, and enzymatic reactions
were performed immediately following purification. This included reactions performed on
the GST-trap column during thrombin digestion. Despite this, the enzyme displayed no
activity on either substrate.
Furthermore, we cloned, expressed and purified NHis-Cj1320, the next proposed enzyme
of the Cj1319-initiated pathway, in order to determine if Cj1319 requires an interaction
with Cj1320 in order to complete its function. In this pathway, Cj1320 is anticipated to
aminate the 4-keto product of Cj1319. No activity was observed when both enzymes were
present in the reaction mixture. In case no activity from Cj1320 was detected because
Cj1319 was not active, control reactions with DdahA and HP0044, together with Cj1320
were performed. The dehydrated intermediates are proposed substrates of Cj1320
following the hypothesis that Cj1319 is C4, C6 dehydratase working upstream of Cj1320,
however, Cj1320 was not active on the dehydrated intermediates. However, if Cj1319 only
utilizes its potential as a C4 oxidase, then the products of DdahA and HP0044 would be
surrogate substrates of the pathway and thus Cj1320 may not be active on these
intermediate sugar nucleotides.
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Figure 11. Cj1319 has no activity on GDP-manno-heptose or GDP-mannose.
(A) Trace A is a negative control reaction where no enzyme was added, showing GDPmanno-heptose and the two coenzymes, NAD+ and NADP+. Trace B is a representative
trace of reactions with Cj1319 alone (NGST-Cj1319 cleaved or Cj1319-CHis) or both of
Cj1319-CHis and NHis-Cj1320. Trace C is a representative trace of reactions with DdahA
alone, a known GDP-manno-heptose dehydratase, or both of DdahA and NHis-Cj1320,
showing the formation of the DdahA product which was not used by Cj1320. (B) Trace A
is a negative control reaction where no enzyme was added, showing GDP-mannose and the
two coenzymes, NAD+ and NADP+. Trace B is a representative trace of reactions with
Cj1319 alone (NGST-Cj1319 cleaved or Cj1319-CHis) or both of Cj1319-CHis and NHisCj1320. Trace C is a representative trace of reactions with HP0044 alone, a known GDPmannose dehydratase, or both of HP0044 and NHis-Cj1320, showing the formation of the
HP0044 product which was not used by Cj1320.
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Testing if Cj1319 uses methylated substrates of the capsular heptose modification
pathway
As the heptose found in the capsule of our strain of interest can be O-methylated at C3
and/or C6 (Michael et al., 2002; Wong et al., 2015), we investigated the possibility that
Cj1319 may use a methylated heptose intermediate, namely GDP-3(and/or 6)-O-Memanno-heptose, as a substrate. However, at the onset of the study, the identity of the 3- and
6-O-methyltransferases were unknown. Knockout mutagenesis of cj1426c later revealed
that Cj1426 is responsible for 6-O-methylation, although it was never confirmed
enzymatically (Sternberg et al., 2013). By examining the capsule cluster for putative
methyltransferases that have not been studied, we identified cj1419 as a tentative 3-Omethyltransferase. Both cj1419c and cj1426c were cloned with an N-terminal His-tag and
expressed and purified from E. coli and enzymatic reactions were carried out on GDPmanno-heptose and intermediates of the heptose modification pathway. Neither enzyme
showed activity on GDP-manno-heptose, while Cj1419 was found active on GDP-4-keto6-deoxy-lyxo-heptose, the C4-oxidized surrogate intermediate generated by DdahA
(Figure 12). Since the product of Cj1419 elutes in the same time range as does GDPmanno-heptose, we coinjected GDP-manno-heptose with the product of Cj1419 and
ascertained that this was a new product. Although it was not confirmed by MS or NMR,
since the surrogate intermediate is dehydrated at C6, we presume that Cj1419 methylated
at C3 and thus the product formed is GDP-3-O-Me-4-keto-6-deoxy-lyxo-heptose which
would follow the logic of the pathway for making the modified heptose expressed by our
strain and determined by NMR (McCallum et al., 2013; Wong et al., 2015). Therefore, we
could conclude that Cj1319 is not active on GDP-3-O-Me-manno-heptose since this
product is not made in vivo. Since the surrogate intermediates of this pathway are
dehydrated at C6, we did not expect to find activity from Cj1426 on these sugar
nucleotides, and thus we could not conclude whether or not Cj1319 can use GDP-6-O-Memanno-heptose.
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Attempt to identify the Cj1319 substrate using a cj1319 knockout mutant
In the absence of Cj1319 in a cj1319 knockout mutant, we presume that there could be an
accumulation of the substrate of this enzyme assuming that there is no negative feedback
regulatory mechanism at play that would prevent its buildup. Therefore, in an attempt to
find the substrate of Cj1319, we extracted the metabolites of the WT and cj1319::CAT (see
section 3.2 for details) using perchloric acid (PCA), methanol or acetone extraction and
analyzed the metabolites by CE. We did not find any difference in the traces (data not
shown) that would allude to an accumulation of an intermediate. However, we also
compared this to a PCA extract of the cj1430::CAT mutant, whereby Cj1430 is the MlghB
epimerase acting after the oxidase in the heptose modification pathway in our strain of
interest (Figure 3B). The PCA extract of this mutant also showed no difference compared
to that of the WT. Thus we concluded that either not all the metabolites were extracted with
PCA or no accumulation of the metabolites occurred due to feedback regulation on the
glycosylation pathways. In conclusion, we were unable to identify any other potential
substrate of Cj1319.

105

Figure 12. Cj1419 methylates an intermediate of the capsular modification pathway.
A schematic of the reaction is shown to facilitate understanding of the traces. Trace A is a
negative control with GDP-manno-heptose with no enzymes added. Trace B shows the
formation of P1 after the addition of DdahA. Trace C shows the formation of P7 after the
addition of Cj1419 to P1, although complete conversion was not achieved. Trace D shows
coinjection of trace C with GDP-manno-heptose.

106

107

3.2

Generation and characterization of mutant and

complements to explore the function of Cj1319
Rationale: This section introduces all the knockout and complement mutant strains used in
this study in order to facilitate the readability of the thesis. Schematic representations of
these strains are summarized in Figure 13. All constructs for strain generation were
analyzed by PCR and confirmed by sequencing prior to transformation of C. jejuni. Strains
were also verified by PCR analysis and sequencing.
Mutants used in this study
C. jejuni NCTC 11168 was chosen for this study since it was the first sequenced strain and
our laboratory has already constructed protein glycosylation and capsular heptose mutants
in this strain (Wong et al., 2015). It also encodes for Cj1319 which we had surmised could
initiate the capsular heptose synthesis pathway. Cj1319 is not found in all strains of C.
jejuni, but has been found in 82% of isolates (of 151 strains tested, 3 from chickens and
the rest from patients) (Huang et al., 2013). In addition, this strain has one of the most
complex protein glycosylation islands compared to other C. jejuni strains (Gundogdu et
al., 2007; Parkhill et al., 2000). The cj1319 knockout mutant, cj1319::CAT, was
constructed by disruption of the gene with a chloramphenicol resistance cassette (Zebian
et al., 2015).
For analysis of capsule related phenotypes, we compared the cj1319::CAT mutant to
mutants of the capsule heptose modification pathway, cj1427::CAT, cj1428::CAT,
cj1429::CAT and cj1430::CAT, as well as the capsuless mutant KpsM (Wong et al., 2015).
Cj1427 or WcaG, is a negative regulator of the pathway (McCallum et al., 2011). Cj1430
and Cj1428 are the MlghB epimerase and MlghC reductase of this pathway respectively
(Figure 3B) (McCallum et al., 2013). Cj1429 is thought to be a regulator of capsule
synthesis, but its function is unknown (Wong et al., 2015). We also compared the
cj1319::CAT mutant to a protein N-glycosylation pathway mutant, cj1121c::CAT, whereby
Cj1121c is the aminotransferase of this pathway (Vijayakumar et al., 2006), and a mutant
of the protein O-glycosylation pathway, cj1294::CAT, whereby Cj1294 is the

108

aminotransferase of this pathway (Obhi and Creuzenet, 2005; Vijayakumar et al., 2006) in
order to investigate if Cj1319 is related to either of these two pathways or if it could be part
of an independent protein glycosylation pathway. These studies also complemented our
laboratory’s previous studies on the role of protein glycosylation in virulence.

109

Figure 13. Schematic summary of strains used and created for this study.
For each strain, cj1319 and its flanking genes are shown as well as the three copies of 16S
and 23S rRNA genomic regions used for complementation as the site for chromosomal
integration. Drawing not to scale. ‘R’ indicates that the complementation construct
integrated into a copy of 16S 23S rRNA genomic region. ‘O’ indicates the
complementation construct replaced the genes in the original cj1319 locus. ‘SP’ denotes
‘strong promoter’ and corresponds to the use of the constitutive strong promoter of OmpE
to drive expression of the genes in the complementation construct. ‘NP’ denotes ‘native
promoter’ whereby the native promoter of cj1319 was cloned into the complementation
construct. The CAT and KAN antibiotic resistance cassettes are in the same orientation as
cj1319.
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Generation and qRT-PCR characterization of complements
In this study, we originally complemented the cj1319 knockout mutant according to a
published method for C. jejuni chromosomal integration-based complementation
(Karlyshev and Wren, 2005). Due to the instability of shuttle vectors in C. jejuni, this
method of chromosomal integration of the complement construct into one of the three
copies of 16S-23S rRNA genomic regions was chosen. Briefly. we cloned the strong
constitutive promoter of the outer membrane protein, OmpE, as described by (Karlyshev
and Wren, 2005) upstream of cj1319 and inserted a kanamycin resistance cassette
downstream of cj1319. This was done using gene splicing by overlap extension (SOEing).
This construct was flanked by a region of 16S rRNA upstream and 23S rRNA downstream.
This construct was transformed into both the cj1319 knockout mutant and the WT by
natural transformation and homologous recombination into a 16S-23S rRNA genomic
region, generated cj1319comp_RSP and WTcj1319comp_RSP respectively where ‘RSP’
indicates that the complement construct integrated into a redundant 16S 23S region and
that cj1319 at this site is under the control of the strong constitutive promoter of OmpE.
This complement was used in the majority of the work in this thesis. Similarly, complement
constructs using cj1121c and cj1294 instead of cj1319 were made and transformed into
either cj1121c::CAT or cj1294::CAT and WT, yielding cj1121ccomp_RSP and
WTcj1121ccomp_RSP as

well

as

cj1294comp_RSP

and

WTcj1294comp_RSP

respectively.
As cj1319comp_RSP was able to complement some phenotypes, but not others, we
hypothesized that this complement may be overexpressing Cj1319, and thus not restoring
the phenotype to that of WT. We determined by qRT-PCR that the level of cj1319 gene
expression in cj1319comp_RSP was ~7 fold higher compared to that of the WT (Figure
14). Therefore, at the latest stages of this work, we altered the complement construct to
encode the native promoter of cj1319 rather than that of ompE. This construct was
transformed into the cj1319 knockout mutant and WT as described above, yielding
cj1319comp_RNP and WTcj1319comp_RNP respectively, where ‘RNP’ indicates that the
complement construct integrated into a redundant 16S 23S rRNA region and that cj1319
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at this site is under the control of its nature promoter (Figure 13). The cj1319comp_RNP
expressed WT levels of Cj1319 (Figure 14).
To determine if secondary mutations occurred in the cj1319::CAT mutant that contribute
to the phenotypes that we tested, we constructed a third complement, whereby we replaced
the cj1319 gene disrupted with CAT in the knockout mutant with a complete cj1319 gene
under its native promotor. We inserted a KAN cassette downstream of cj1319 in order to
select for the new complement. This construct was introduced into the cj1319::CAT mutant
and

WT

as

described

above

resulting

in

strains

cj1319comp_ONP

and

WTcj1319comp_ONP respectively, where ‘ONP’ indicates the complement construct
replaced the knockout construct and cj1319 is under the control of its native promoter. As
these two new strains are theoretically genetically identical, they should not differ in
phenotypes.
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Figure 14. Fold change of cj1319 locus in cj1319comp_RSP and cj1319comp_RNP
compared to WT as determined through qRT-PCR.
Genetic organization of the genes targeted for the qRT-PCR analysis is depicted (not drawn
to scale). The interstrain change in gene expression is reported in the table shown as a heat
map of low to high gene expression compared to the WT. The fold change in expression
was determined from two biological replicates, each tested in duplicate. The brackets
indicate 2(ΔΔCT-SD) and 2(ΔΔCT+SD), where SD represents the standard error propagated
through the fold calculations. No significant difference was determined by Student’s t test.
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3.3

Effect of inactivation of cj1319 on C. jejuni and

comparison to other glycosylation knockout mutants
Rationale: In section 3.1, we determined that Cj1319 was not part of the pathway for
making a modified heptose for capsule and likely not able to use a methylated intermediate
of this pathway. Thus, we hypothesis that Cj1319 is initiating a protein glycosylation
pathway independent of GDP-manno-heptose. Therefore, in order to explore alternative
functions for Cj1319, we examined phenotypes of a cj1319 knockout mutant compared to
WT. For a more comprehensive analysis, we also compared this mutant to mutants of the
protein glycosylation pathways or capsular heptose modification pathway as described in
the previous section (3.2).

Effect of cj1319 on growth rate

To determine if any of the mutations introduced for the creation of our strains affected the
fitness of the cells under normal laboratory growth conditions, we assessed the growth rates
of all strains. Cells were grown in MH broth preconditioned in microaerobic conditions in
a closed system and growth was monitored using a Klett spectrophotomer until cells
reached stationary phase. We determined that all the knockout mutants and their respective
complement strains grow at approximately double the rate of the WT (Table 5). The
complement constructs did not affect the growth rate of the WT with the exception of
WTcomp_ONP which also grew at double the rate of the WT. Thus we concluded that
none of our strains suffered from detrimental growth defects as a result of the engineered
mutations. However, we noted the increased growth rate of the mutants and complement
strains.
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Table 5. Growth rates of C. jejuni strains used in this study.
Strain

Growth rate constant (g/h)a

Significantly different from
WT?b

WT

0.37 ± 0.04

na.

cj1319::CAT

0.75 ± 0.04

Yes (***)

cj1319comp_RSP

0.84 ± 0.05

Yes (****)

WTcj1319comp_RSP

0.53 ± 0.01

No

cj1319comp_RNP

0.88 ± 0.04

Yes (****)

WTcj1319comp_RNP

0.56 ± 0.06

No

cj1319comp_ONP

0.83 ± 0.11

Yes (****)

WTcj1319comp_ONP

0.83 ± 0.03

Yes (****)

cj1121c::CAT

0.71 ± 0.02

Yes (**)

cj1121ccomp_RSP

0.72 ± 0.05

Yes (**)

WTcj1121ccomp_RSP

0.43 ± 0.07

No

cj1294::CAT

0.76 ± 0.05

Yes (***)

cj1294comp_RSP

0.82 ± 0.08

Yes (***)

WTcj1294comp_RSP

0.46 ± 0.09

No

a

g represents the number of generations.

b

na. for not applicable. (**) indicates P<0.01, (***) indicates P<0.001, (***) indicates

P<0.0001.
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Effect of cj1319 inactivation on capsule and LOS

We did not find a role for Cj1319 in the capsular heptose modification pathway as per
enzymatic assays. To further investigate this in our cj1319 knockout mutant, we analyzed
the gene expression of the capsular heptose modification genes, including cj1419c (which
we showed codes for the 3-O-methyltransferase in this pathway) and cj1426c (which codes
for the predicted 6-O-methyltransferase of this pathway (Sternberg et al., 2013)) in the WT
and cj1319::CAT (Figure 15). We did not find any change in the expression of these genes,
signifying that they are not affected by the absence of Cj1319. This further supports that
Cj1319 does not play a role in heptose modification for capsule synthesis.
To ascertain that Cj1319 does not play a role in heptose modification for capsule synthesis,
we extracted and analyzed the capsules of cj1319::CAT, cj1319comp_RSP, and
WTcj1319comp_RSP and compared them to those of the WT, acapsular mutant, KpsM,
and three mutants lacking modified heptose as determined by NMR, cj1427::CAT,
cj1428::CAT and cj1430::CAT (Wong et al., 2015). We used a hot water and phenol
extraction method for capsule purification that is compatible with downstream mass
spectrometry and NMR analysis (Westphal, 1964). Since the LOS copurifies with capsule,
we used ultracentrifugation to separate capsule from the LOS, as the latter was reported to
pellet and the former was reported to remain soluble (Michael et al., 2002). In order to
maximize resolution of the capsule/LOS species by SDS-PAGE, gel compositions
developed for resolving peptide and small proteins using a tris-tricine buffering system
were exploited (Schägger, 2006). We found that using these gel compositions (now on
refered to as ‘peptide gels’) in a tris-glycine buffering system increased the resolution of
the capsule.
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Figure 15. Fold change in capsular heptose modification genes in the cj1319::CAT
mutant compared to WT as determined by qRT-PCR.
Genetic organization of the genes targeted for the qRT-PCR analysis is depicted (not drawn
to scale). The interstrain change in gene expression compared to the WT is reported in the
table shown. The fold change in expression was determined from two biological replicates,
each tested in duplicate. The brackets indicate 2(ΔΔCT-SD) and 2(ΔΔCT+SD), where SD
represents the standard error propagated through the fold calculations. No significant
difference was determined by Student’s t test.
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Separation and identification of capsule and LOS by ultracentrifugation and SDS-PAGE
We analyzed both the pellet and supernatant following ultracentrifugation by SDS-PAGE
and silver staining (Figure 16). The smallest species is the LOS, mostly found in the pellet
as expected, but is also found in small amounts in the supernatant. The intermediate
molecular weight species is capsule based on its absense in the KpsM mutant. Against
expectation a significant amount of capsule was recovered in the pellet. High molecular
weight species with a ladder-like appeareance very reminiscent of LPS were recovered
mostly in the pellet along with the LOS.
As C. jejuni strains generally do not produce LPS, it was initially intriguing that we
observed this regularly spaced high molecular weight species that no one has described
previously in our strain. However, it has been published that the LOS of other strains of C.
jejuni form aggregates above a certain concentration which gives rise to the visualization
of regular ladder repeating units by SDS-PAGE and silver staining (Logan and Trust,
1984). Therefore, to test if this was the case for our strain, we separated the pelleted
capsule/LOS sample on a 12.5% peptide gel. Part of the gel was silver stained and used as
a ruler to accurately excise specific bands from the unstained gel. These gel slices were
then inserted into the wells of a second 12.5% peptide gel and re-separated by SDS-PAGE
and silver stained. The resulting gel (Figure 17A) shows that these higher molecular weight
bands are indeed LOS aggregates, as they give rise to low molecular weight LOS.

Effect of cj1319 inactivation on LOS as assessed by SDS-PAGE

Importantly, cj1319::CAT and cj1319comp_RSP showed downshifted bands indicative of
truncated repeat units of this high-molecular weight species compared to the WT and the
other strains. As our results indicate that the high molecular weight species is LOS, this
infers that cj1319 affects the LOS. To show this, we performed serial dilutions of the WT
and cj1319 mutant pellet capsule/LOS samples and resolved them on a 16% peptide gel
(Figure 17B). The diluted sample allowed the visualization of two LOS bands distinctly,
corresponding to the full LOS structure (top band) and LOS lacking the branched sialic
acid residue (bottom band) (Linton et al., 2000), showing the truncation occurs at the level
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of the LOS core of the cj1319 mutant. Thus this truncation of the core LOS would
consistently give rise to LOS aggregates of smaller size compared to those of WT.
The effect of cj1319 inactivation on capsule as assessed by SDS-PAGE
The cj1319::CAT mutant also showed a higher abundance of the high molecular weight
capsule bands compared to WT. This phenotype was not reversed back to WT levels in
cj1319comp_RSP, signifying this phenotype is likely due to a secondary mutation or due
to

the

high

expresion

of

cj1319

by

the

strong

promoter.

Interestingly,

WTcj1319comp_RSP showed reduced capsule production compared to WT. Trace
amounts were detected if any. The spacing between the repeat units does not appear altered
compared to WT, however, the heptose modification mutants also do not appear different
compared to WT even though we have shown they lack the modified heptose by NMR
(Wong et al., 2015). So it is possible that the capsule composition in the cj1319 mutant
differs from that of WT.
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Figure 16. Analysis of the supernatant and pellet by SDS-PAGE of a 16% peptide
gel stained with silver following ultracentrifugation of the total capsule/LOS
extracted samples.
(A) Supernatant showing semi-pure capsule. (B) Pellet showing LOS, second capsule
species not previously reported, and high molecular weight species.
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Figure 17. Analysis of high molecular weight species reveals it is LOS and highlights
the truncation of the LOS core.
(A) SDS-PAGE of bands excised from a 12% peptide gel showing the high molecular
weight species are LOS aggregates. (B) Serial dilutions of WT and cj1319 knockout mutant
pellet capsule/LOS samples on a 16% peptide gel stained with silver highlighting the
truncation of the inner core of the LOS in the mutant.
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Effect of cj1319 inactivation on capsule and LOS as assessed by compositional analysis
To aid the interpretation of the band shifts observed by SDS-PAGE, a compositional
analysis of the samples was performed at the Complex Carbohydrate Research Center
(CCRC), Athens, GA. The bulk of the capsule and LOS pelleted following
ultracentrifugation, thus this sample was used for the compositional analysis (Figure 16).
To simplify the analysis, we separated the capsule from the LOS by taking advantage of
the different solubility tendencies of the two species in alcohol. Isopropanol and ethanol
were tested at different concentrations, and it was determined that isopropanol was the best
solvent in separating the LOS from capsule at an optimal concentration of 50%, whereby
the LOS pellets at a low speed spin and the capsule remains soluble (Figure 18). Both the
corresponding CPS and LOS samples of the WT and cj1319 knockout mutant were
processed by per-O-trimethylsilylation and GC-MS for compositional analysis at the
CCRC and the results are summarized in (Appendix B, Table 10). The structures of the
LOS and capsule which have been published for our strain are presented in (Figure 2A and
Figure 4B).
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Figure 18. Separation of capsule from LOS by differential solubility in 50%
isopropanol.
Pellet samples shown in Figure 16B separated into insoluble LOS and soluble CPS
following addition of isopropanol to a final concentration of 50% (v/v).
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No change in the capsule composition of the cj1319::CAT mutant
As shown in Table 10 (Appendix B), there was no difference in the capsule composition
between the WT and mutant. Since cj1319::CAT still makes the modified heptose, this is
in line with our enzymology work, where we excluded Cj1319 from this heptose
modification pathway.
Furthermore, the enhanced capsule phenotype observed in the cj1319::CAT mutant could
not be complemented (data not shown). In light of this, we concluded that the enhanced
expression of higher molecular weight capsule chains is likely due to a secondary mutation
rather than due to the disruption of cj1319. Five genes in the capsule locus of our strain
contain hypervariable sequences, four of which code for methyltransferases, including
cj1426c which encodes the probable C6-O-methyltransferase for heptose modification
(Sternberg et al., 2013), and one of unknown function, cj1429c (Parkhill et al., 2000). We
did not expect that methylation would affect the amount of capule produced because
previous studies of capsule methylation phase variants did not show that there were
differences in capsule abundance among variants (Szymanski et al., 2003). However, since
cj1426c is of interest in our study, we examined this gene for phase variation. We
determined through sequencing that cj1426c did not phase vary from WT by slipped-strand
mutagenesis in its phase variable poly-G tract, however, we did find two point mutations
which lead to a change of C111 to W. The impact of this mutation is not known. We also
examined cj1429c since its function is unknown and we found it was expressed in both the
WT and the cj1319::CAT mutant.
Change in LOS composition leads to the identification of secondary mutations in
cj1319::CAT
We found that the mutant had a reduced amount of galactose in the LOS, consistent with
the truncation we observed by SDS-PAGE and silver staining. Through sequencing phase
variable genes in the LOS cluster (Table 6), we found that the truncation was due to a point
mutation in a β-1,3-galactose transferase gene, cj1139, which leads to an immature stop in
translation and thus no functional transferase is made (Linton et al., 2000). Thus the
truncation of the LOS is not caused by the cj1319 mutation, which is further supported by
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finding the same mutation in the cj1319comp_RSP which also produces truncated LOS.
Interestingly, we found another point mutation in cj1144/45, encoding a putative α1,4
galactosyltransferase whose precise function is unknown, however, it has been found
associated with alterations in the LOS composition (Semchenko et al., 2012). This gene
was found in the ‘OFF’ state in WT, but in the ‘ON’ state in the mutant, suggesting that
the cj1319 mutant expresses a galactosyltransferase not expressed in the WT. However, it
does not appear to be compensating for the loss of Cj1139 based on the composition
analysis of the LOS. Therefore, it is not clear what phenotypic change this mutation created
in the cj1319 mutant. We found the same truncated phenotype in the cj1319comp_RNP
and cj1319comp_ONP, further emphasizing that this truncation is due to phase variation
that occurred while the cj1319::CAT mutant was generated and is unrelated to cj1319. In
light of this discovered phase variation, a new cj1319::CAT mutant was generated and the
above phase variable genes were sequenced and verified to match that of the WT. However,
as these variations were detected at the latest stages of this work, the cj1319::CAT mutant
with these variations was used in all the phenotypic analyses presented in this work.With
the three complement strains, we were able to conclude whether or not each phenotype
studied was related specifically to Cj1319 or not.
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Table 6. Phase variation of LOS and CPS genes.
gene

WT

cj1319::CAT

cj1319comp_RSP

cj1139

Poly-8G = ON

Poly-9G = OFF

Poly-9G = OFF

cj1144/45

Poly-9G = OFF

Poly-10G = ON

Poly-10G = ON

cj1426c

Poly-10G= ON

Poly-10G= ON

Poly-10G= ON

*C111W

*C111W

Poly-10G= ON

Poly-10G= ON

cj1429c

Poly-10G= ON
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Effect of cj1319 inactivation on SDS, polymyxin B and serum
resistance

Truncations of the LOS usually affects SDS and polymyxin B sensitivity (Naito et al.,
2010), thus we sought to determine if the loss of the terminal galactose residue resulted in
increased susceptibility of the cj1319::CAT mutant to these compounds. We did not find
any significant difference in the sensitivity of the mutant to SDS or polymyxin B (MIC of
0.01% and 25 µg/mL respectively).
Capsule has been shown to play an important role in serum resistance (Keo et al., 2011),
and recently the modified heptose of the capsule was shown to play an important role in
this function (Wong et al., 2015). We determined that the cj1319::CAT mutant produced
more high molecular capsule weight chains compared to the WT. Although we later
determined that this phenotype was not related to cj1319, but rather to a secondary
mutation, we investigated the effect of active serum on the cj1319::CAT mutant.
Interestingly, despite the abundance of capsule, we found that our mutant was significantly
more sensitive to killing by the serum compared to WT (P<0.05). We could restore this
phenotype to WT in the cj1319comp_RNP strain, signifying that this phenotype was
specific to cj1319.
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Figure 19. The cj1319 knockout mutant is significantly more sensitive to active
serum compared to WT.
Bacteria were incubated with or without the addition of active horse serum for 2.5 hours at
37ᵒC and then serially diluted and plated for CFU enumeration. The graph displays the
mean of three independent experiments performed in duplicate wells and spot plated in
triplicate. * P<0.05, ** P<0.01, and ***P<0.001 by two-way ANOVA. ns. Not significant.
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Effect of cj1319 on motility

An important feature and virulence factor of C. jejuni is motility which is affected by
general N-protein glycosylation (Vijayakumar et al., 2006). In addition, mutants of
enzymes playing a role in flagellin O-glycosylation often have defects in flagellin
production, export, and/or flagella formation (Ewing et al. 2009; Goon et al. 2003). We
verified this through testing cj1121c::CAT and cj1294::CAT and their complemented
strains respectively in a soft agar stabbing assay. We found the mutants were not motile
and the complement strains partially restored motility (Figure 20A). Since Cj1319 could
have a role in protein glycosylation, we examined also examined motility in the cj1319
mutant. We found no defect in flagellin production as per anti-flagellin Western blot
(Figure 20B), no defect in flagella assembly as per electron microscopy (Figure 20C), and
no defect in motility compared to WT as per stabbing in semi-solid agar (Figure 20A). The
cj1319comp_RSP was oddly nonmotile when cj1319::CAT had no motility defect. This
complement still made full length flagella as determined by EM (Figure 20C). It was
apparent that complement constructs with the strong promoter were not optimal due to only
partial restoration of motility in cj1121ccomp_RSP and cj1294comp_RSP and abolishment
of motility in cj1319comp_RSP. Thus we constructed cj1319comp_RNP and
cj1319comp_ONP as detailed in section 3.2, which both express cj1319 under the
regulation of its native promoter. Interestingly, both these complements showed motility
defects, although not as drastic as cj1319comp_RSP, whereas WTcj1319comp_RNP and
WTcj1319comp_ONP had no defects in motility. This highlights the importance of the
stoichiometry of Cj1319. Furthermore, we did not find any difference in the ability of the
cj1319::CAT mutant or any of its complement strains to autoagglutinate (data not shown),
a feature of C. jejuni that has been shown to be correlated with flagellar expression (Misawa
and Blaser, 2000).
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Figure 20. Cj1319 does not play an integral role in motility or flagellum production.
(A) Motility halo measurements on 0.3% agar plates (n=6 for all strains except
cj1319comp_RNP, cj1319comp_ONP and their respective WT controls where n=2).
Statistical analysis was done by one-way ANOVA. Same letters indicate no significant
difference with P>0.05. Different letters indicate significant difference with P<0.05. (B)
Western blot analysis of flagellins purified by mechanical shearing. PonceauS Red stain of
total proteins (top panel) and anti-flagellin Western blot (bottom panel). MW, molecular
weight. (C) Electron micrographs of WT (19,000x magnification), cj1319 knockout mutant
(10,500x magnification) and cj1319comp_RSP (49,200x magnification). Black arrows
point to flagella.
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Mass spectrometry analysis of WT C. jejuni NCTC 11168
flagellins by HCD-MS2

As we observed that the cj1319 complement strains have motility defects despite
assembling normal flagella, we reasoned this may be due to aberrant flagellar
glycosylation. Since Cj1319 has been implicated in an in vitro pathway for making
legionaminic acid for flagellar glycosylation (Schoenhofen et al., 2009), dysregulation of
cj1319 expression could lead to altered glycosylation profiles. However, as mentioned
previously, there is no in vivo data supporting a role for Cj1319 in legionaminic acid
synthesis, nor had legionaminic acid been shown to decorate C. jejuni flagellins at the onset
of this study. Furthermore, flagellin glycopeptide data for C. jejuni NCTC 11168 was very
limited until the latest stages of our study (Ulasi et al., 2015). Therefore, we performed an
extensive MS analysis of the WT flagellins of this strain in parallel with cj1319::CAT and
cj1319comp_RSP.
To analyze the flagellin glycopeptides of C. jejuni NCTC 11168, the flagella were sheared
off the bacterial surface mechanically and concentrated by ultracentrifugation. Bands
corresponding to flagellins were excised from SDS-PAGE gels and subjected to in-gel
trypsinolysis for MS analysis. The portion of the flagellins that is proposed to be heavily
glycosylated, based on sequence alignments with C. jejuni 81-176 and C. coli VC167,
comprises three large tryptic peptides of 2826, 3036 and 4294 Da in flagellin A,
corresponding to residues 339-336, 388-420, and 421-463 respectively (Figure 21). The
recovery of such large peptides and of their even larger glycosylated forms after in-gel
trypsinolysis was anticipated to be low. Thus, after extraction of the tryptic peptides, the
gel pieces were further treated with chymotrypsin to reduce the sizes of remaining peptides
and maximize extraction. Both sets of peptides were analyzed separately by LC-MS and
HCD-MS2. This method, not previously used for flagellins, allows to concomitantly detect
oxonium ions derived from sugars, acquire peptide sequence, and map glycosylation sites
(Segu and Mechref, 2010). Glycopeptides were identified by manual addition of the mass
of each sugar found in the metabolome of C. jejuni NCTC 11168 (Table 2) into PEAKS
software as variable modifications and by manual search for characteristic oxonium ions.
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Figure 21. Amino acid sequence of flagellin A from C. jejuni NCTC 11168
summarizing glycopeptide and protein coverage data determined by this study and
available at onset of this study.
Blue font: peptides covered in nonglycosylated form (this study). Red font: glycopeptides
covered (this study). Black font: peptides not detected (this study). Yellow highlight:
glycosylation sites previously determined in C. jejuni NCTC 11168 (Zampronio et al.,
2011). Underline: conserved amino acid found glycosylated in C. jejuni 81-176 (Thibault
et al., 2001). Bold: conserved amino acid found glycosylated in C. coli VC167 (Logan et
al., 2002). Black box: Large tryptic peptides predicted to be heavily glycosylated.
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Using this approach, we were able to detect 7 different glycopeptides from the WT, five of
which

were

in

multiple

glycoforms

(Table

7).

The

peptide

T464T465AFGVKDETAGVTTLK for example, was found unmodified (Figure 22A) and
modified

by

sugar

masses

consistent

with

Pse5Ac7Am/Leg5Am7Ac,

or

Pse5Ac7Ac/Leg5Ac7Ac (Figure 22B and C). It was also found modified by either one of
Pse5AcGriMe7Ac or Pse5AcGriMe7Am (Figure 22D and E) as previously reported
(Zampronio et al. 2011). This peptide was additionally found carrying an unknown sugar
of 372.145 Da (Figure 23A), as a peak at 373.160 m/z signifying a potential sugar oxonium
ion was observed for this glycopeptide. We were able to identify the glycosylation site
through the presence of b-ions (peptide fragments originating from sequential losses of
amino acids from the C- terminus) which, compared with b-ions of the unmodified peptide,
comprise the additional mass of a sugar. For example, two ions at 518.243 m/z (b2 +
315.143 Da) and 589.281 m/z (b3 + 315.143 Da) are consistent with TT and TTA each
carrying Pse5Ac7Am/Leg5Am7Ac, respectively (Figure 22B). This indicates that
glycosylation occurs on T464 or T465. Glycosylation was also mapped at the same two
positions for all other glycoforms of this peptide (Figure 22C, D, E and Figure 23A). As
the glycosylation occurred at the N-terminus, no y-ions (originating from sequential losses
of amino acids from the N- terminus) were observed carrying a sugar.
Similarly, the peptide IS181TSGEVQF was also found in four different glycoforms
(Appendix B, Figure 47 and Figure 23B) and we mapped the glycosylation to residue S181
as determined by the ion of 516.265 m/z (b2 + 315.143 Da) for modification by
Pse5Ac7Am/Leg5Am7Ac (Appendix B, Figure 47A), 590.307 m/z (b2 + 389.180 Da) for
modification by Pse5AcGriMe7Am (Appendix B, Figure 47B), and 591.283 m/z (b2 +
390.164 Da) for modification by Pse5AcGriMe7Ac (Appendix B, Figure 47C). A longer
peptide, encompassing IS181TSGEVQF, was found modified by an unknown sugar of
372.145 Da, but found consistently modified at S181 by detection of the fragment ion
1321.640 m/z (b9 + 372.145 Da), although modification on T182 could not be excluded for
this glycoform (Figure 23B).
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Table 7. Summary of glycopeptide data collected in C. jejuni NCTC 11168 from this
study showing the extensive microheterogeneity of flagellin glycosylation.
Peptide sequence

a

WT

cj1319::CAT

cj1319comp_RSP

Peptide not
detected

Peptide not
detected

b

ISTSGEVQF

c

VVISTSVGTGL

d

NDGKDILISGSNLSSAGF

GVVLGGYSSVSAYMSSAGSG
FSSGSGYSVGSGK
NYSTGF

Peptide not
detected

SQFATMK

TTAFGVKDETAGVTTLK

Peptide not
detected

Peptide not
detected

e

a

Glycosylation sites were determined as, or narrowed down to, the bold underlined
residues.
b

Additionally detected as FETGGRISTSGEVQFTLK

c

Additionally detected as VVISTSVGTGLGALADEINKNADK and
VVISTSVGTGLGALADEINK
d

Additionally detected as DILISGSNLSSAGFGATQFI SQASVSLR,
NDGKDILISGSNLSSAGFGATQFISQASVSLR, and DILISGSNLSSAGF
indicates two glycans detected on this peptide – one at S5 or S7 and one at S10 or
S11
e

Also found unmodified in all strains

Sugars are simplified in symbol form as described in table 2 in addition to: unknown
putative sugar 372.154 m/z ( ).
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Figure 22. HCD-MS2 analysis of a WT flagellin peptide showing multiple
glycoforms and nonglycosylated form.
(A) Unmodified peptide. The same peptide glycosylated with (B) Pse5Ac7Am or
Leg5Am7Ac (

315.143 Da), (C) Pse5Ac7Ac or Leg5Ac7Ac (

Pse5AcGriMe7Am (

389.180 Da), and (E) Pse5AcGriMe7Ac (

316.127 Da), (D)

390.164 Da). For all

figures, the respective oxonium ion for each sugar is represented on the spectra using the
same symbol with a (+) sign and important ions representing peptide + sugar masses are
highlighted on spectra.
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Figure 23. HCD-MS2 analysis showing three peptides carrying an additional mass of
372.145 Da ( ), indicative of a possible novel glycan in NCTC 11168.
(A)

TTAFGVKDETAGVTTLK,

(B)

FETGGRISTSGEVQFTLK,

VVISTSVGTGLGALADEINK with the oxonium ion (

373.16 m/z).

and

(C)
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The peptide VVIS207T208SVGTGL was also found carrying five different sugars
individually, including the unknown 372.145 Da sugar (Appendix B, Figure 48 and Figure
23C) and out of its four potential O-glycosylation sites, we narrowed the glycosylation site
down to S207 or T208 for two of its glycoforms based on its b5 ion (Appendix B, Figure
48B and C) and to S207 based on the b4 ion for another glycoform (Figure 23C).
Overall, a total of three different peptides were found carrying the unknown sugar of
372.145 Da (Figure 23), each showing the same oxonium ion peak at m/z 373.160, showing
several ions arising from the combined mass of a b ion and this unknown sugar mass, and
in one example also showing a 372.145 Da mass difference between the modified and
unmodified full peptides (Figure 23A). We pursued the identification of this sugar by
targeted third-stage MS (MS3) of the 373.160 m/z ion (Appendix B, Figure 49). A number
of diagnostic ions were observed, namely an ion at 89.002 m/z that is typical of a singly
positively charged sugar backbone (C6O1 of mass 87.995 Da), an ion at 74.060 m/z that
potentially corresponds to the CH3-CHOH-CH-NH portion of a CH3-CHOH-CH-NH-COCH3 side chain, mass 73.053 Da, carrying a single positive charge as previously reported
(Logan et al., 2009), an ion at 59.050 m/z that potentially stems from a singly positively
charged N-acetyl side chain (CH3-CO-NH, mass 58.029 Da), and two ions at 134.060 m/z
and 180.066 m/z which were reported as C1-C9 sugar backbone ions found in Pse5Ac7Ac
and Pse5Am7Ac (Thibault et al., 2001). Of note, in our MS2 spectra, this 372.145 Da sugar
candidate was often found associated with a 391.172 m/z ion (Pse5AcGriMe7Ac), whose
break down also releases a 373.160 m/z ion, which prevented us from making a definitive
assignment of its identity. Notwithstanding its precise identity, this sugar modification
confers further heterogeneity to the flagellins and its biological relevance will be worth
investigating.
Moreover, we found the peptide NDGKDILIS343GS345NLS348S349AGF carrying four
different combinations of two sugars at once (Appendix B, Figure 50). The 1529.749 m/z
(b12

+

315.143

Da)

ion

representing

NDGKDILIS343GS345

carrying

Pse5Ac7Am/Leg5Am7Ac and the 783.355 m/z (y5 + 315.143 Da) ion representing
S348S349AGF carrying Pse5Ac7Am/Leg5Am7Ac in one of the glycoforms (Appendix B,
Figure 50A) show that glycosylation occurs at one site comprised of S343 or S345 and at
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a second site comprised of S348 or S349. This was consistently shown to be the case with
another glycoform (Appendix B, Figure 50C) and two partially mapped glycoforms
(Appendix B, Figure 50B and D).
Compared to the tryptic digest alone, the addition of chymotrypsin allowed the detection
of two additional glycosylated peptides, NYSTGF and SQFATMK (Appendix B, Figure
51). Their glycosylation was mapped to the serine residue based on the 680.294 m/z (b3 +
315.143 Da) ion, consistent with NYS carrying Pse5Ac7Am/Leg5Am7Ac, and the 605.278
m/z (b2 + 389.180 Da) ion, consistent with SQ carrying Pse5AcGriMe7Am. The sequential
digest also improved the quality of the data by providing shorter glycopeptide fragments
which aided the interpretation of many of the spectra.
We detected a large mass of 5193.280 Da, resulting from the tryptic digest alone, whose
HCD-MS2 spectrum shows oxonium ions 316.150, 317.130 and 330.166 m/z indicative of
Pse5Ac7Am/Leg5Am7Ac, Pse5Ac7Ac/Leg5Ac7Ac and Leg5AmNMe7Ac, respectively,
as well as ion 373.159 m/z corresponding to the unknown sugar (Figure 24A). Large ions
showing sequential losses of 315.143 Da and 316.127 Da were determined by manual
analysis to correspond to residues G388 to K420 (3036.3891 Da), which form one of the
predicted highly glycosylated peptides indicated in Figure 21. Our manual analysis allowed
us to assign the mass of 3982.777 Da to this peptide carrying a total of two
Pse5Ac7Am/Leg5Am7Ac (315.143 Da) and one Pse5Ac7Ac/Leg5Ac7Ac (316.127 Da).
The additional sugar oxonium ions and extra unassigned mass of the 5193.280 Da
glycopeptide that those fragments originated from suggest more extensive glycosylation,
however we did not detect fragment ions above 3982.777 Da to further characterize this
peptide.
Similarly, we found the same peptide (based on unmodified b and y ions) present as a
different glycoform (5231.382 Da), with the strong oxonium ion of 330.166 m/z in addition
to large ions showing a loss of 329.159 Da indicative of Leg5AmNMe7Ac (Figure 24B).
This shows that the peptide fragment is modified by at least one Leg5AmNMe7Ac residue.
We could not fully characterize this fragment which is thus annotated as “partial peptide”.
This spectrum also shows oxonium ions of 316.150, 317.130 and 373.160 m/z indicative
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of Pse5Ac7Am/Leg5Am7Ac, Pse5Ac7Ac/Leg5Ac7Ac and the unknown 372.145 Da
species respectively. Overall, the large mass and sugar oxonium ions further highlight the
highly glycosylated nature of this peptide. Importantly, these results show for the first time
glycopeptide evidence that WT C. jejuni NCTC 11168 flagellins carry the
Leg5AmNMe7Ac modification, thus directly demonstrating that legionaminic acid is used
for flagellin glycosylation in this strain. As mentioned previously, this is based on the fact
that the 5AmNMe7Ac modification is unique to legionaminic acid.
Noteworthy, we did not find any peptide modified with O-acetyl pseudaminic acid, Nacetyl glutamic pseudaminic acid derivative or dihydroxypropionyl pseudaminic acid
derivative, three sugars shown to modify the flagellins of C. jejuni 81-176. Additionally,
every glycopeptide found was not detected in an unglycosylated form except for one
(Figure 22A).

150

Figure 24. A highly glycosylated peptide shown carrying Leg5AmNMe7Ac (
329.159 Da).
(A) Manual analysis of a HCD-MS2 spectrum identifying the peptide carrying
Pse5Ac7Ac/Leg5Ac7Ac ( 316.127 Da), Pse5Ac7Am/Leg5Am7Ac ( 315.143 Da),
Leg5AmNMe7Ac, and the unknown putative sugar ( 372.145 Da). (B) Manual analysis
of the HCD-MS2 spectrum of a second glycoform of this peptide, highlighting the
modification by Leg5AmNMe7Ac.
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The cj1319 knockout mutant glycosylates its flagellins with
Leg5AmNMe7Ac
In C. coli VC167, a knockout mutant of a cj1319 homologue was found to produce
significantly more CMP-Leg5Ac7Ac compared to WT (McNally et al. 2007). If a cj1319
mutant of C. jejuni also exhibited the same phenotype, this would further demonstrate
flagellin glycosylation by legionaminic acid in C. jejuni and would exclude Cj1319 from
the legionaminic acid synthesis pathway. Thus we investigated the presence of
legionaminic acid on the flagellins of our cj1319 mutant. We showed that this mutant had
no defects in flagellin production, export, and assembly nor in motility (Figure 20), and
thus the flagellins purified from the mutant were processed and analyzed by MS as
described for WT. We found that the cj1319 mutant still glycosylates its flagellins with all
the same modifications as determined in the WT (Table 7). Importantly, we also detected
Leg5AcNMe7Ac (329.159 Da) on four different peptide sequences, contributing to four of
the total 23 glycoforms detected in this mutant (Figure 25, Table 7). The addition of
Leg5AcNMe7Ac to these peptides did not otherwise change the glycosylation sites as
highlighted by ions representing peptide fragments with the bound sugar (Figure 25A, B
and D). These results show that legionaminic acid can be used for flagellin glycosylation
without drastically altering the global flagellin glycosylation pattern and that Cj1319 is not
required for legionaminic acid synthesis, although it does affect its incorporation onto
flagellins.
To assess if this phenotype was specific to cj1319, we complemented cj1319 in cis using a
strong constitutive promoter to ensure the expression of Cj1319. The flagellins of this
complemented strain were analyzed using the same method and the glycopeptide data are
summarized in Table 7. We only detected Leg5AmNMe7Ac on one peptide in this strain,
compared to four peptides in the cj1319 knockout mutant but readily detected peptides
glycosylated by pseudaminic acid and its derivatives, suggesting successful (although
partial) complementation. This shows that the enhanced incorporation of legionaminic
acid on the flagellins of the cj1319 knockout mutant is indeed due to Cj1319 specifically.
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Figure 25. HCD-MS2 analysis of the cj1319 knockout mutant reveals four different
peptide sequences glycosylated with Leg5AmNMe7Ac (
(A)

ISTSGEVQF,

(B)

329.159 Da).

VVISTSVGTGLGALADEINK,

NDGKDILISGSNLSSAGFGATQFISQASVSLR

(additionally

modified

Pse5Ac7Ac/Leg5Ac7Ac ( 316.127 Da)), and (D) TTAFGVKDETAGVTTLK.

(C)
with
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Legionaminic acid synthesis in L. pneumophila has been demonstrated in vitro using the
neuraminic acid synthesis enzymes on UDP-bacillosamine, which is produced by the Nglycosylation pathway in C. jejuni (Glaze et al., 2008). These enzymes are homologous to
the C. jejuni enzymes used for making the sialic acid of LOS. Although deemed highly
unlikely, we acknowledged that these enzymes may compensate for the lack of Cj1319, if
Cj1319 normally is involved in making legionaminic acid, by using UDP-bacillosamine
produced by the N-glycosylation pathway. If so, we expect there would be an increase in
the expression of these enzymes that would allow them to compete for UDP-bacillosamine
and result in making legionaminic acid. Therefore, we used qRT-PCR to measure the level
of expression of these sialic acid synthesis genes in the WT and cj1319::CAT strains. No
significant difference was determined in the level of expression of these genes between the
two strains (Figure 26). Thus there was no apparent compensatory mechanism occurring.
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Figure 26. Fold change in sialic acid synthesis genes in the cj1319::CAT mutant
compared to WT as determined by qRT-PCR.
Genetic organization of the genes targeted for the qRT-PCR analysis is depicted (not drawn
to scale). The interstrain change in gene expression compared to the WT is reported in the
table shown. The fold change in expression was determined from two biological replicates,
each tested in duplicate. The brackets indicate 2(ΔΔCT-SD) and 2(ΔΔCT+SD), where SD
represents the standard error propagated through the fold calculations. No significant
difference was determined by Student’s t test.
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Investigation of the role of Cj1319 in non-flagellar protein
glycosylation
We determined that Cj1319 does not have a role in capsular heptose modification based on
enzymology studies and that it is not required for legionaminic acid synthesis. Therefore,
we hypothesized that Cj1319 likely plays a role in non-flagellar protein glycosylation. To
address this, we screened cell free extracts of the cj1319::CAT mutant compared to those
of the WT and the cj1121c::CAT and cj1294::CAT protein glycosylation pathway mutants.
To increase the resolution of the screening, cell free extracts were fractionated into soluble
and membrane proteins. The membranes were further divided into inner membrane and
outer membrane fractions based on the differential solubility of the inner membrane in the
detergent N-laurylsarcosine. We labelled glycoproteins with biotin hydrazide post mild
periodate-based oxidation and the proteins were separated by SDS-PAGE and analyzed by
Western blot using fluorescently labelled streptavidin (Figure 27). We did not observe any
striking difference in the glycoprotein profiles of cj1319::CAT compared to WT in any of
the protein fractions using this method. However, an important observation to note is that
the cj1121c::CAT mutant’s glycoprotein profile only differed to the WT in the outer
membrane proteins, where glycoproteins at ~50-52 kDa are missing in this mutant, but are
restored upon complementation (Figure 27D). It is also interesting to note that cj1294::CAT
is missing a major outer membrane protein of ~60-62 kDa which is consistent with the
flagellins, however, this protein is not restored to the outer membrane upon
complementation. The same protein in the cj1319::CAT mutant is more abundant and
reactive with biotin hydrazide compared to the WT and its complement.
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Figure 27. Western blot analysis of the glycoprotein profiles of C. jejuni strains
using biotin hydrazide labelling.
Representative blots of glycoprotein profiles of (A) soluble proteins, (B) total membrane
proteins, (C) inner membrane proteins, and (D) outer membrane proteins pre-labelled with
biotin hydrazide. The bracket indicates area where differences were perceived in the outer
membrane samples. Detection was accomplished using fluorescently labelled streptavidin.
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The prior glycoprotein detection method did not perceive differences between the cj1121
mutant and the WT although we know Cj1121c is part of the N-glycosylation pathway
which glycosylates over 60 proteins, both soluble and membrane proteins (Scott et al.,
2011). Thus we could conclude that the biotin hydrazide labelling method was either
labelling more than just glycoproteins or that there were glycoproteins beyond those
modified by the general N-glycosyltaion pathway that were masking the signals
disappearing in the cj1121c mutant. Therefore, we used the soybean-agglutinin (SBA)
lectin which was originally used to detect the N-glycosylated proteins in C. jejuni by
Western blot (Young et al., 2002). This lectin binds terminal α- and β-GalNAc residues
which are found in the N-linked heptasaccharide. Similar to the biotin hydrazide labelling
method, we did not perceive any obvious difference between the cj1319 mutant and the
WT (Figure 28). In cj1121c::CAT, we still observed many glycoprotein bands and only
glycoproteins at ~50-52 kDa are missing in the membrane fraction, but restored upon
complementation (Figure 28B).
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Figure 28. Western blot analysis of glycoprotein profiles of C. jejuni strains using
anti-SBA.
Representative blots of glycoprotein profiles of (A) soluble proteins and (B) total
membrane proteins using anti-SBA for the detection of glycoproteins containing terminal
GalNAc. The bracket indicates area where differences were perceived in the membrane
samples.
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GDP-mannose can be used to make GDP-fucose through the action of a dehydratase and a
3,5-epimerase/4-reductase. If Cj1319 can dehydrate GDP-mannose, it is possible that
fucose would be the end product on the Cj1319 pathway and serve for protein
glycosylation. Although we had determined enzymatically that Cj1319 could not use GDPmannose as a substrate, we had concurrently tested for the presense of fucosylated proteins
in C. jejuni using two fucose binding lectins, BambL (Audfray et al., 2012) and PAII-L
(Mitchell et al., 2005), in Western blot analysis of protein fractions. Interestingly, both
lectins were able to bind some soluble proteins, but no membrane proteins (Appendix B,
Figure 52). However, in agreement with our enzymatic assays, we found no differences
between the fucosylated glycoprotein profiles of the WT and cj1319 mutant. Similarly, we
screened for heptose modified proteins using a heptose binding lectin, BC2L-A (Marchetti
et al., 2012), by Western blot. However, this lectin did not bind to any proteins (data not
shown). This lectin could also not bind the modified heptose of the capsule as per Western
blot (data not shown) and thus we concluded that this lectin is specific to unmodified
heptose and was not suitable for detection of modified heptoses that could be produced by
the Cj1319 pathway. However, to our knowledge, such a lectin does not exist and since we
did not find a role for Cj1319 in heptose modification enzymatically, we did not pursue
this analysis further.
Although we were limited by the resolution of the 1D Western blot analysis of glycoprotein
profiles, we were able to conclude that there were glycoproteins modified by a pathway
other than the general N-protein glycosylation pathway as marked by the analysis of the
cj1121c mutant. In addition, although we did not perceive any differences in glycoprotein
profiles of the cj1319 mutant compared to WT, we could not exclude the possibility that
enzymes of the other two protein glycosylation pathways may act to compensate for the
loss of Cj1319 or vice versa. To determine if this could occur, we used qRT-PCR to
measure the level of gene expression of protein glycosylation genes and cj1319 in the
cj1319 mutant compared to WT and the two protein glycosylation pathway mutants,
including their respective complemented strains. There were no notable changes in gene
expression in any of the genes tested among the strains, and thus no compensatory
mechanism could be inferred (Figure 29). Importantly, these results show that in the
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complementation was successful at the level of gene expression, as all three complement
strains show high levels of gene expression, owing to the promoter of OmpE.

166

Figure 29. Fold changes of protein glycosylation pathway genes in our strains of
interest compared to WT as determined via qRT-PCR.
Genetic organization of the genes targeted for the qRT-PCR analysis is depicted (not drawn
to scale). The interstrain change in gene expression is reported in the table shown as a heat
map of low to high gene expression compared to the WT. The fold change in expression
was determined from three biological replicates, each tested in duplicate in the case of
cj1319::CAT and cj1319comp_RSP or one biological replicate tested in duplicate for the
other strains. The brackets indicate 2(ΔΔCT-SD) and 2(ΔΔCT+SD), where SD represents the
standard error propagated through the fold calculations. No significant difference was
determined by Student’s t test.
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Effect of cj1319 inactivation on sensitivity to nitrosative and
oxidative stress

Despite not finding the biochemical role of Cj1319 in C. jejuni, we sought to determine the
role of this protein in the interaction of C. jejuni with environmental or host stressors. A
PhD thesis by Blackwell, 2010 (Dr. Charles Penn, University of Birmingham) suggests
that cj1319 and surrounding genes are regulated by Nssr, which regulates the response to
nitric oxide. Although the work remains unpublished, it is interesting that genes involved
in synthesizing sugars may be regulated in reponse to nitric oxide. Therefore, we sought to
determine the effect of nitrosative stress in our strains of interest. Nitric oxide radicals were
produced from sodium nitrite at different concentrations in media pH-adjusted to 5.0. The
bacteria were allowed to incubate in this media for 30 min and then serially diluted and
spot-plated for CFU counts. As a negative control, cells were incubated in the same media
without any sodium nitrite. We did not find any significant difference among strains in
their sensitivity to nitrosative stress (Figure 30).
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Figure 30. cj1319::CAT and protein glycosylation mutants do not differ in their
sensitivity to nitrosative stress compared to WT.
Data represent the means of six independent experiments for the WT and knockout mutants
and two independent experiments for the complement strains, all performed in duplicate
wells and spot plated in triplicate. Two-way ANOVA showed no significant difference
among strains.
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Since C. jejuni is microaerophilic, oxidative stress poses an important burden on its ability
to survive both in the external environment and within the host. Therefore, we tested the
susceptibility of cj1319::CAT and protein glycosylation mutants to oxidative stress
compared to WT. We performed this as a long term assay whereby diffusible discs with
different concentrations of hydrogen peroxide were placed on the surface of freshly
inoculated agar and zones of inhibition were measured after 24 h (Figure 31A). Short term
survival was assessed by incubating cells with different concentrations of hydrogen
peroxide for 30 min and then serially diluting and plating for CFU enumeration (Figure
31B). We found no difference in the long term sensitivity of the strains to oxidative stress
and similarly no difference in the short term sensitivity except for cj1121c::CAT which
was more susceptible to stress at higher concentrations of H2O2, however, this was an
observed trend that was not determined to be statistically significant by two-way ANOVA.
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Figure 31. Susceptibility of C. jejuni strains to oxidative stress.
(A) Long term assay measuring zone of inhibition of the hydrogen peroxide discs. Data
represent the mean of six independent experiments using three discs per strain. No
significant difference was found among strains by two-way ANOVA. (B) Short term assay
measuring the survival of strains in the presence of different concentrations of hydrogen
peroxide. Data represent the means of six independent experiments for the WT and
knockout mutants and two independent experiments for the complement strains, all
performed in duplicate wells and spot plated in triplicate. Two-way ANOVA showed no
significant difference among strains.
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Effect of cj1319 inactivation on biofilm production

Biofilm production makes use of an extracellular polymeric matrix to protect the cells
within the biofilm (Joshua et al., 2006). It remains unclear what this matrix is composed
of, but there has been support for DNA and an α-dextran (Brown et al., 2015; Jowiya et
al., 2015; Svensson et al., 2014) It is possible that protein glycosylation pathways
contribute to producing this matrix as it has been reported that C. jejuni produces the
heptasaccharide for protein N-glycosylation as a free soluble form, unattached to protein,
in response to osmotic stress (Nothaft et al., 2009). In some bacteria, protein glycosylation
mutants have been shown to have defects in biofilm formation. In C. jejuni, it has been
shown that a mutant of the legionaminic acid pathway, cj1324, is defective in biofilm
formation (Howard et al., 2009). Therefore, we decided to determine if our mutants played
a role in biofilm formation. We tried a plethora of different plastic multiwell dishes in order
to increase throughput of the assay, however, no biofilms were observed on any plastic
tested and thus we resorted to using borosilicate glass tubes which are typically used for C.
jejuni biofilm studies. Additionally, since it is known that C. jejuni shows enhanced biofilm
formation in aerobic conditions (Reuter et al., 2010), we compared both aerobic and
microaerobic conditions for biofilm formation. As some of the strains are nonmotile, we
further tested the effect of shaking in both aerobic and microaerobic conditions. The cells
were allowed to incubate for 60 h in either of these conditions and tubes were then washed
in water and biofilms were stained with crystal violet. We determined that the cj1319::CAT
mutant showed enhanced biofilm formation compared to WT under static aerobic
conditions (Appendix D, Figure 53). Therefore, we pursued these conditions for further
experimentation.
We performed a time course over six days, whereby we evaluated biofilm formation on
days three to six for WT, cj1319::CAT and the two protein glycosylation pathway mutants.
We determined that only cj1319::CAT was significantly different from the WT as it showed
enhanced biofilm formation (Figure 32A).
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In order to determine if this phenotype was due to the disruption of cj1319 specifically, we
tested the complement strains in the same manner (Figure 32B). Interestingly, whereas
cj1319comp_RSP did not restore the phenotype to that of the WT, cj1319comp_RNP and
cj1319comp_ONP

did

restore

this

phenotype.

WTcj1319comp_RSP,

WTcj1319comp_RNP and WTcj1319comp_ONP all produced biofilms comparable to the
WT.
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Figure 32. Biofilm formation is enhanced in the cj1319::CAT mutant.
(A) Biofilm formation comparison of cj1319::CAT with WT and protein glycosylation
mutants. Data represent the means of three independent experiments performed in
triplicate. (B) Comparison of biofilm formation of cj1319::CAT with its three respective
complement strains and controls. Biofilm formation was measured for each strain every
day for three to six days. These data represent the average of 9 independent experiments
performed in triplicate for WT and cj1319::CAT, 3 for cj1319comp_RSP and
WTcj1319comp_RSP, 6 for cj1319comp_RNP and WTcj1319comp_RNP, and 4 for
cj1319comp_ONP and WTcj1319comp_ONP. Statistical analysis was performed by twoway ANOVA. Same letters indicate no significant difference with P>0.05. Different letters
indicate significant difference with P<0.05. Stars indicate significance compared to WT.
* P<0.05, ** P<0.01, ***P<0.001 and ****P<0.0001.
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3.4

Interaction of cj1319::CAT mutant with eukaryotic

cells and eukaryotes
Rationale: Glycosylated structures have been shown to be important for interaction of
bacteria with eukaryotic cells, colonization and infection in animal models (Ishijima et al.,
2011; Vijayakumar et al., 2006). Thus, we sought to explore the role of protein
glycosylation in these three events. We examined the cj1319::CAT mutant as we
hypothesize Cj1319 plays a role in protein glycosylation, in addition to each of the N- and
O-protein glycosylation pathway knockout mutants.

Interaction of C. jejuni strains with Acanthamoeba castellanii

C. jejuni is a microaerophilic organism and thus atmospheric conditions stress these
bacteria and ultimately lead to their death. Therefore, mechanisms of survival in
environments external to their natural bird and cattle reservoir or human gut environemt
are important for their transmissibility among hosts. It has been found that C. jejuni can
survive within amoeba as well as externally in their presence as the amoeba provide a
tolerable microenvironment by utilizing the majority of the local oxygen (Bui et al., 2012a,
2012b). To determine if Cj1319 and protein glycosylation plays a role in internal survival
in amoeba, we conducted an internalization and short term survival assay with our mutants.
We initially monitored the survival at 2.5, 5 and 24 hours post infection, however, very
few bacterial counts if any were recovered after 5 hours and none at 24 hours post infection.
Therefore, we performed experimental replica for 0 and 2.5 hours post infection only. Since
Triton X-100 is used to lyse the amoeba prior to serial dilutions for bacterial enumeration,
and the assay is performed in a defined buffer void of nutrition and performed at room
temperature under normal atmospheric conditions, all of which are stressful for C. jejuni,
we additionally tested the effect of this detergent under these conditions on our bacterial
strains to determine if there were any differences in susceptibility that would influence the
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CFU counts recovered between strains (Appendix B, Figure 54). Although Triton X-100
did result in killing a small portion of the bacteria, the effect was consistent among strains.
We determined that cj1319::CAT did not differ significantly compared to the WT in either
internalization or short term survival ability (Figure 33). Similarly, all three of the cj1319
complement strains behaved the same as WT. On the contrary, the two protein
glycosylation mutants were not able to internalize and survive to the same extent as seen
at 0 h post infection. This impairment could be partially restored in their respective
complement strains. These two strains were often below the limit of detection at 2.5 hours
post infection, or trace bacterial counts could be recovered, and thus the extent of their
survival could not be determined accurately, although it was clear that their survival ability
was impaired compared to WT.
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Figure 33. Short term survival of C. jejuni strains in Acanthamoeba castellanii.
The internal survival of C, jejuni strains in A. castellanii was assessed over a period of 2.5
hours. (A) Amoeba were incubated in 24-well tissue culture plates for 2 hours prior to
incubation with C. jejuni strains for 2 hours. Gentamycin was used to kill bacterial cells
external to the amoeba and then bacteria were lysed immediately (0 h post infection) or 2.5
hours after antibiotic treatment (2.5 h). Bacteria were enumerated by serial dilutions and
CFU counting calculated to CFU/mL. (B) Internal bacterial survival at 0 and 2.5 h post
infection. (C) The inoculum was measured prior to incubation of the bacteria with the
amoeba (Inoculum) and at the end of the experiment (Viability control). Experiments were
conducted using triplicate wells/strain/time point and bacteria were enumerated by serial
dilutions performed in duplicate and spot plating performed in triplicate. The data represent
the average of six independent experiments for WT and cj1319::CAT, five for
cj1319comp_RSP and WTcj1319comp_RSP, three for cj1121c::CAT, cj1294::CAT,
cj1319comp_RNP, WTcj1319comp_RNP, cj1319comp_ONP, and WTcj1319comp_ONP,
and two for cj1121ccomp_RSP, cj1294comp_RSP, WTcj1121ccomp_RSP and
WTcj1294comp_RSP. No significant differences were determined by two-way ANOVA
or Student’s t-test.
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Interaction of C. jejuni strains with intestinal cells and
macrophages

The mechanism of C. jejuni invasion of intestinal or macrophage cells is still under
investigation, whereby evidence supporting aspects of both the ‘zipper’ and ‘trigger’
mechanisms have been found, thus indicating the mechanism by which C. jejuni invades
is novel and requires further study or depends on the strain like so many other phenotypes
(Ó Cróinín and Backert, 2012). It is possible that surface glycosylation including that of
glycoproteins may be part of this novel mechanism. Therefore, we examined the interaction
of our mutants with Caco-2 intestinal cells, an immortalized human cell line, and RAW
264.7 macrophages (mouse origin).
Once C. jejuni reaches the intestine of humans, it interacts with the mucins and eventually
invades intestinal cells (Young et al., 2007). To determine if Cj1319 plays a role in this
process, we performed an adhesion and invasion assay of Caco-2 intestinal cells. As in the
amoeba assay, Triton X-100 is used to lyse the intestinal cells prior to serial dilutions for
bacterial enumeration, but in this case the bacteria were incubated in cell culture media rich
with nutrients and at 37ᵒC under close to favourable atmospheric conditions (5% CO2), so
we assessed the effect of this detergent on our strains within this assay as well (Appendix
B, Figure 55 ). Similarly, Triton X-100 did result in killing of a small portion of bacteria
and the effect was consistent among strains. However, in this case we found that the strains
replicated during the assay as a result of nearly optimal growth conditions such that the
effect of the Triton X-100 killing was negligible when compared to that of the inoculum.
We did not observe a significant difference in the ability of cj1319::CAT to adhere and
invade Caco-2 intestinal cells compared to the WT (Figure 34). We found that the
cj1121c::CAT mutant was slightly impaired in adhesion and invasion compared to the WT.
Although it was not statistically significant, the trend is in agreement with previously
published work (Vijayakumar et al., 2006). The cj1294::CAT mutant had not been
previously tested and we did not find a significant difference or any trend between this
mutant and WT.
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Figure 34. Comparison of C. jejuni strains ability to adhere to and invade into Caco2 intestinal cells.
The adhesion and invasion of C, jejuni strains of Caco-2 intestinal cells was assessed after
5 hours of incubation. Total adhesion and invasion was assessed by CFU enumeration of
bacterial counts prior to treating the wells with gentamycin and invasion only was
determined through enumeration of bacteria post treatment with gentamycin. The inoculum
was measured prior to incubation of the bacteria with the amoeba (Inoculum) and at the
end of the experiment (Viability control). Experiments were conducted in using triplicate
wells/strain and bacteria were enumerated by serial dilutions performed in duplicate and
spot plating performed in triplicate. The data represent the average of 4 independent
experiments.
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Similar to our Caco-2 cell study, we sought to determine if Cj1319 and protein
glycosylation plays a role in adhesion and invasion of macrophage. C. jejuni are able to
survive within macrophages although the mechanism is unknown (Kiehlbauch et al.,
1985), however, this appears to be strain specific and host specific (Wong et al., 2015).
The glycosylation may also have a role in internal survival.
We performed an adhesion assay at a low temperature to prevent macrophages from
engulfing the bacteria which would interfere with our results. We did not find any
significant difference or trend among strains in their ability to adhere to the macrophage
(Figure 35A). To determine if there are any differences in the ability of the mutants to
invade the macrophage, we examined internalization of the strains after incubation with
the macrophage for 2 or 4 hours (Figure 35B). The duration of the incubation had no effect
on recovery of internalized bacteria, signifying that that intracellular killing is
counterbalanced by the entry rate. We also did not find a difference among strains in the
recovery of internalized bacteria. Finally, we measured internal survival over a period of 5
hours at 2.5 hour intervals (Figure 35C). No significant difference was observed between
the cj1319::CAT mutant and the WT or among strains at any time point. The only exception
was the cj1121::CAT mutant which was impaired in its ability to survive short term within
macrophages as detection was typically below the limit of detection at 5 hours post
infection. This phenotype was recovered in cj1121ccomp_RSP.
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Figure 35. Interaction of C. jejuni strains with RAW 264.7 macrophage.
(A) Adhesion of C. jejuni strain to macrophage. Results represent the means of three
independent experiments performed in triplicate wells, duplicate serial dilutions and
triplicate spot plating for all strains. (B) Infection time course of 2 and 4 hours. (C) Internal
survival time course up to 5 hours post infection. Bacteria were enumerated by serial
dilutions and CFU counting calculated to CFU/mL. The inoculum was measured prior to
incubation of the bacteria with the amoeba (Inoculum) and at the end of the experiment
(Viability control). Experiments for B and C were conducted using triplicate
wells/strain/time point and bacteria were enumerated by serial dilutions performed in
duplicate and spot plating performed in triplicate. The data represent the average of 4
independent experiments for WT and knockout mutants and 3 for the complement strains,
and one for the complement controls in WT. The experimental scheme of each assay is
represented above the bar graphs. No statistical significance was determined by two-way
ANOVA, one-way ANOVA, or Student’s t-test.
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Infection of Galleria mellonella with C. jejuni strains

In order to assess the role of protein glycosylation in an in vivo infection model where
innate immunity is involved, we employed Galleria mellonella larvae as an insect infection
model that has been validated for the study of C. jejuni (Champion et al., 2010; Senior et
al., 2011). It was necessary to optimize the dose of the WT inoculum in order to match the
larvae killing rate of 100% reported in these studies. Since the WT strain that has been
reported in these assays so far is a hyper virulent variant of our NCTC 11168 strain (NCTC
11168-H), the dose needed to be increased. We determined that preincubation of cells in
broth for 4 hours at 37°C followed by suspending these cells in saline and using a dose of
10 ul of ~109 cells/mL for injecting larvae is optimal.
We determined that the cj1319::CAT mutant was ~30% significantly less effective at
killing the larvae compared to the WT (Figure 36). This phenotype could be restored upon
complementation in cj1319comp_RSP. Even more strikingly, the cj1121c::CAT mutant
was found to be ~60% less efficient at killing the larvae and this phenotype could also be
complemented with cj1121ccomp_RSP. On the contrary, the cj1294 mutant did not differ
significantly from WT in its ability to kill the larvae. These results signify the importance
of Cj1319 and Cj1121c in virulence in this infection model.
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Figure 36. Galleria mellonella show a 30% increase in survival after infection with
the cj1319::CAT mutant and a 45% increase in survival after infection with the
cj1121c::CAT mutant compared to those infection with WT or the cj1294::CAT
mutant.
G. mellonella were challenged with 10 µl of ~109 cells/mL of bacteria. Data represent
percentage of larvae that survived after 24h of infection with each of the indicated strains
(n=3, 10 larvae/strain/n). * P<0.05, ***P<0.001 by one-way ANOVA.
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The cj1319::CAT mutant shows enhanced chicken
colonization

Based on our finding that the cj1319 knockout mutant modifies its flagellins with more
Leg5AcNMe7Ac compared to WT, we sought to determine if this excess legionaminic acid
incorporation on the flagella would enhance colonization of chickens, since a previous
study showed that a cj1324 knockout mutant that lacked legionaminic acid production as
per metabolomic analysis showed reduced colonization in this model (Howard et al. 2009).
Two-day old chicks were challenged orally with either WT or cj1319 mutant and the
bacterial load in the ceacum was measured after five days. There was a significant (P<0.05)
increase in the ability of the knockout mutant to colonize the chicks compared to WT
(Figure 37). We have previously published that the cj1121c mutant is unable to colonize
chickens (Vijayakumar et al., 2006). We did not test the cj1294 mutant in this system
because we infer it will also be attenuated since it is nonmotile. Furthermore, a cj1293
mutant (Cj1293 preceeds Cj1294 in the O-glycosylation pathway) was completely
attenuated in this model (Creuzenet, 2004).
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Figure 37. The cj1319 knockout mutant has significantly enhanced chicken
colonization compared to WT.
Two day old chicks were orally gavaged with 107 CFU, and their caecal content
in C. jejuni was determined after 5 days by CFU counting of plated caecal homogenate.
Significant difference compared to WT is indicated by *(P<0.05) as determined by the
Mann-Whitney test. Courtesy of Dr. Dozois (Zebian et al., 2015).
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3.5

Discovery of a novel Helicobacter pylori outer

membrane glycoprotein
Evidence of Ley modified proteins
The O-antigen of LPS in pathogenic gram negatives typically plays an important role in
virulence. The O-antigen of H. pylori is made of Lewis blood group mimics and plays a
role in immune evasion in the early stages of infection (Appelmelk et al., 1996, 1997;
Moran et al., 2002; Negrini et al., 1996). Later in infection, the host may form antibodies
against the O-antigen, however, these antibodies cross react with the highly similar host
blood group antigens. It has been shown in other bacteria, such as P. aeruginosa, that pilins
can be glycosylated with the O-antigen produced by the LPS synthesis pathway (Castric et
al., 2001; DiGiandomenico et al., 2002). We and others have previously demonstrated the
presence of multiple glycoprotein candidates in H. pylori NCTC 11637 (Champasa et al.,
2013; Hopf et al., 2011). Therefore, we hypothesized that it is possible for H. pylori to
glycosylate outer membrane proteins with Lewis groups which could be exposed to the
outside and potentially contribute to the host-pathogen interaction.
H. pylori NCTC 11637 expresses Ley in its LPS
We chose to test this hypothesis by examining strain NCTC 11637 for the production of
Ley- and Lex-modified glycoproteins since this strain was shown to produce these two
Lewis O-antigens (Appelmelk et al., 1998; Merkx-Jacques et al., 2004). The expression of
Lewis O-antigens is phase variable whereby the expression of fucosyltransferases may be
switched on or off by slipped strand mutagenesis (Nilsson et al., 2006; Skoglund et al.,
2009; Wang et al., 2000), leading to the generation of variable O-antigen serotypes with
varying degrees of completion (Appelmelk et al., 1999; Wang et al., 1999, 2000). Ley is a
four sugar glycan, (Fuc α (1,2)-Gal β (1,4)-[Fuc α (1,3)]GlcNAc β-) and Lex resembles Ley
but lacks the terminal fucose (Figure 38). To assemble Ley O-antigen chains, two
fucosyltransferases are required to add fucose to the Gal β (1,4)-GlcNAc β- main chain,
whereas Lex only requires one fucosyltransferase. Strain NCTC encodes for three
fucosyltransferases where FutA and FutB are α (1, 3/4) fucosyltransferases and FutC is an
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α (1, 2) fucosyltransferase (Appelmelk et al., 1999). FutA preferentially transfers fucose to
internal Gal β (1,4)-GlcNAc β- units and FutB preferentially transfers fucose to this unit at
the terminus of the O-antigen chain. Through sequencing, we determined that our NCTC
11637 strain contained shorter poly C tracts in futA (10 bases versus 13) and in futB (9
bases versus 13 bases) than reported for strain 26695. futC had the same 14-base poly C
tract as strain 26695. These results indicated that both FutA and FutC were in frame, and
therefore could fulfill their function to concurrently support Ley and Lex production,
whereas FutB was out of frame. To determine if these Lewis groups incorporated into the
LPS in strain NCTC 11637 under our laboratory growth conditions, we analyzed the
amount, pattern and nature of LPS by SDS-PAGE and silver staining and Western blot
analysis using anti- Ley and Lex antibodies (Figure 39). Strain 26695 expresses both Ley
and Lex antigens and was used as a positive control. We determined that strain NCTC
11637 expresses Ley, but not Lex in its LPS.
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Figure 38. Schematic representation of the structures of Ley and Lex.
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Figure 39. Analysis of the lipopolysaccharide of H. pylori strains NCTC 11637 and
26695 by SDS-PAGE and detection by silver staining or anti-Lewis Western
blotting.
The LPS was extracted by SDS solubilization and proteins eliminated by proteinase K
treatment before SDS-PAGE. The LPS was detected by silver staining (A), and anti-Ley
(B) or anti-Lex (C) Western blotting. / indicates no sample loaded. (Credit to R. Ford, MSc).
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Discovery of outer membrane Ley glycoprotein candidate
H. pylori cells were lysed and the soluble cytoplasmic and periplasmic proteins were
separated from the membranes by ultracentrifugation. These membranes were screened for
Ley glycoproteins by SDS-PAGE and anti- Ley Western blot using LPS of strain 26695 as
a positive control (Figure 40). In order to distinguish signal arising from Ley of the LPS
present in the membranes from that arising from Ley modifying proteins, we additionally
treated half of the samples with proteinase K. Thus, signals disappearing after proteinase
K treatment compared to signals present in untreated samples indicate the presence of Ley
modified protein candidates. One anti-Ley reactive band that was sensitive to proteinase K
treatment was observed at ~30-33 kDa. The total membranes were further treated with the
detergent N-laurylsarcosine in order to solubilize the inner membrane proteins and these
proteins were separated from the outer membrane proteins by ultracentrifugation (Filip et
al., 1973; Hopf et al., 2011). By similar analysis, the candidate glycoprotein of 30-33 kDa
was found to localize to the outer membrane. Of note, the soluble protein fraction was also
screened in a similar manner, however, no Ley positive proteins were observed.
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Figure 40. Identification of glycoproteins reactive with anti- Ley antibodies in the
membrane fraction of H. pylori strain NCTC 11637.
Total membranes were prepared by ultracentrifugation of mechanically disrupted cells and
the proteins were analysed by SDS-PAGE with detection by Ponceau S Red staining (A),
anti- Ley (B), and anti-Lex Western blotting (C). Outer membranes (OM) were analyzed
similarly (D). To facilitate distinguishing between proteins and LPS, the samples were
treated with proteinase K (+ PK) or not (- PK) prior to loading on SDS-PAGE gels. The
LPS of strain 26695 served as a positive control for anti- Ley Western blots. The bracket
highlights the 30-33 kDa area that reacts with anti- Ley Western blotting and is sensitive to
proteinase K treatment.
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In order to identify this Ley glycoprotein candidate and show that it is indeed glycosylated
with Ley, we needed to enrich and purify this candidate to facilitate detection and allow
thorough MS analysis of its glycosylation. However, there were a number of difficulties in
this case. Firstly, the outer membrane proteins cannot be solubilized without a detergent or
chaotropic agent that is incompatible with downstream mass spectrometry applications.
Secondly, the LPS co-purifies with the outer membrane and it is not possible to separate
the LPS from the outer membrane proteins without solubilizing the proteins.
We reasoned that it was not necessary to analyze the whole glycoprotein candidate to prove
its glyosylation. Based on the hydrophilic and bulky nature of the Ley motif, glycopeptides
were expected to be surface exposed which in turn would make them extractable directly
from the outer membranes by protease digestion. This approach overcomes the issues of
protein solubility and the presense of LPS. Therefore, outer membranes were treated with
trypsin in order to release exposed tryptic peptides into the supernatant. These soluble
peptides were separated from the membrane by ultracentrifugation. The supernatant
containing the solubilized tryptic peptides, including those potentially carrying sugars, was
analyzed by SDS-PAGE and anti- Ley Western blot (Figure 41). The procedure was
efficient at releasing four Ley reactive peptide bands (Lane 1, Figure 41A and B), whereby
the largest two were further sensitive to proteinase K digestion in the presense of detergent
(Lane 2, Figure 41B), indicating that they were derived from a protein. The two smaller
Ley reactive peptides remained resistant to trypsin digestion even in the presence of the
detergent signifying that they may not contain the cleavage sites for trypsin, or that the
attached sugar motif prevents accessibility of the protease, or that they may have originated
from released LPS (although it is unlikely).
As these Ley reactive peptides were not pure and too large (>10 kDa) for MS analysis, the
tryptic peptides were separated by SDS-PAGE, stained with Coomassie blue, and the four
peptide bands of interest before Tween-20 and protease digestion were exised and digested
with trypsin. The peptides were extracted from the gel and analyzed by MS.
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Figure 41. Analysis of outer membrane tryptic peptides by anti- Ley Western blot.
SDS-PAGE analysis of total outer membrane tryptic peptides (Lane 1) and outer membrane
tryptic peptides further treated with trypsin in the presence of Tween-20 (Lane 2) stained
with Ponceau S Red (A), and anti- Ley blot (B) shows four Ley positive bands around 12
kDa, indicated by the arrows, two that are sensitive to further tryptic digestion in the
presence of Tween-20.
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Enrichment of glycopeptides by affinity chromatography
In order to further enrich Ley carrying glycopeptides, we used affinity chromatography. An
anti-Ley antibody column would be ideal, however, due to the high cost of this antibody,
we opted for a relatively inexpensive, though less specific, lectin column. We used BambL,
a lectin from B. cenocepacia which is able to bind terminal α (1, 3) fucose of Ley. This
lectin was expressed and purified from E. coli. To confirm that this lectin could bind Ley,
we coupled the lectin to biotinyl-N-hydroxy-succinimide ester. Purified LPS from H. pylori
strain SS1 was analyzed by Western blot using biotin-labelled BambL and fluorescentlylabelled streptavidin and compared to an anti- Ley Western blot of the same sample
(Appendix B, Figure 56). It was concluded that BambL does bind Ley and thus we
proceeded in coupling this lectin to a sepharose column to extract the Ley carrying peptides
from the total soluble outer membrane tryptic peptide sample. Bound glycopeptides were
eluted with mannose which competes with immobilized glycopeptides for BambL binding.
The eluate was assumed to be enriched with glycopeptides and was analyzed by LC-MS
and HCD-MS2 as done previously (Zebian et al., 2015).

Identification of the glycoprotein candidate as HopE (HP0706)
by MS
Our glycoprotein candidate is hypothesized to carry a Ley motif which consists of four
sugars as depicted in Figure 38, thus increasing the complexity of the MS analysis. An
ionization energy sufficient to fragment the glycopeptide bond (the bond between the
peptide and glycan), peptidic bonds (along the peptide chain) and glycosidic bonds (along
the glycan) is necessary in order to obtain information on both the glycan and peptide
composition. As glycan bonds (and the glycopeptide bond) are more labile compared to
peptidic bonds, a lower energy is needed to fragment the glycan, however, lower energies
will not suffice to fragment the peptide in the case of glycopeptides, as the energy is
consumed by glycosidic fragmentation. Therefore, higher energy is required to fragment
both the peptide and glycan, however, higher energies may also lead to over fragmentation

208

of the glycan which prevents the visualization of sugar oxonium ions that serve as signature
ions for glycosylation in MS spectra. Therefore, we used HCD-MS2 at low, medium, and
high energies to obtained data for both glycan and peptide.
The extracted tryptic peptides (enriched through BambL lectin column or not)
representing both unmodified peptides and Ley carrying peptides were processed through
LC-MS and HCD-MS2. The data were analyzed with PEAKS software by de novo
sequencing and database searching. The analysis incorporated the search for select
variable PTMs including Ley and its fragments, which were calculated based on the
structure shown in Figure 38 (Table 4, Materials and Methods). Spectra were also
manually inspected for sugar oxonium ions, internal peptide fragment ions, and signature
sugar losses between fragment ions.
We identified a triply charged ion of 904.1143 m/z with a total mass of 2709.32 Da whose
de novo generated sequence partially matched a sequence from Helicobacter outer
membrane protein HopE (Figure 42B). Upon in silico digestion of this protein with trypsin,
the sequence of the full tryptic peptide was determined to be FLSAGPNATNLYYHLK.
Furthermore, we were able to manually match the ions present in our spectra to the b and
y ions calculated from this sequence (Appendix B, Table 11). This peptide was also found
as a triply charged ion of 603.64 m/z, with a total mass of 1807.93 Da, matching the
theoretical mass of the peptide, indicating that this ion represents a peptide which is not
post-translationally modified (Figure 42A). Thus, the 2709.32 Da version of this peptide
carries an additional mass of 901.39 Da, which is large enough to encompass the Ley
structure, 657.25 Da, in addition to an unknown component of 244.14 Da. We obtained
optimal peptide fragmentation at high energy HCD, but no obvious sugar related ions were
detected (Figure 42B). At low energy HCD, we obtained poor peptide fragmentation,
however, we observed an ion of 902.48 m/z, indicating a potential oxonium ion of the full
901.39 Da glycan (Figure 42C). This indicates that this additional mass occurs as one
glycan chain at one amino acid site as opposed to Ley at one site and the unknown 244.14
Da at another site. Furthermore, we also found this glycopeptide in the sample that could
bind to the BambL lectin, thus supporting that this glycopeptide is fucosylated. As we could
not assign the most abundant ion at 1120.58 m/z to this peptide, we investigated the
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possibility that a second ion co-isolated with our peptide of interest. Examination of the
LC chromatogram showed that two other peptides of similar m/z (904.11+/- 2 Da) coeluted with our glycopeptide: 904.9728 m/z (+2 charge) corresponding to the
unglycosylated FLSAGPNATNLYYHLK peptide and 904.1152 m/z (+3 charge)
corresponding to the peptide GGFIALSQMGDANASIPTPQPVYYR carboxymethylated
at D or M (+57 Da) from the urease subunit A. Upon close inspection of the spectra and
compiling information from all scans of the 904.11 +/- 2 Da m/z ion, we determined that
the ions 1120.58 and 922.48 m/z can be assigned to y ions of the urease peptide, and the
1808.94 m/z ion may represent contributions from both the FLSAGPNATNLYYHLK
glycopeptide and its nonglycosylated form (stemming from the 904.9728 +2 charge ion).
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Figure 42. HCD-MS2 analysis of a peptide from HopE shown in both unglycosylated
and glycosylated forms with Ley and unknown linker.
(A) Unmodified peptide 603.64 m/z. (B) High energy HCD of glycosylated peptide, 904.11
m/z (+3 charge), where no sugar related ions were detected and the sequence of the full
deglycosylated peptide was observed. (C) Low energy HCD of glycosylated peptide
highlighting the entire deglycosylated peptide and ions corresponding to peptide fragments
carrying sugars as well as the full glycan oxonium ion at 902.48 m/z indicated by (+

).

Key ions are highlighted on the spectra. Ions corresponding to the urease peptide are
indicated in bold font.
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Table 8. Glycopeptide fragment ion assignment in MS2 spectra.
Ion

Peptide and its mass

Attached sugar and its mass

(m/z)

(Da)

(Da)

1328.64

SAGPN

Ley + Unknown

427.19

657.25 + 244.14

AGPNATNLY

Ley + Unknown

902.44

657.25 + 244.14

SAGPNATNLYYHLK
1531.77

Ley + Unknown

1803.90

2433.21

Ion type

c7 - c2

c12 - c3

z14

657.25 + 244.14
2580.28

FLSAGPNATNLYYHL

Ley + Unknown

1678.84

657.25 + 244.14

c15 - H
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As the fragmentation observed in the HCD-MS2 spectra of Figure 42 did not offer enough
information to assign the glycosylation site(s), we used LC-MS and alternating CID- and
ETD-MS2 in order to identify the glycosylation site(s). Whereas ETD is used for
glycosylation site determination since it does not cleave the glycopeptide bond, the ions
generated are typically c and z ions as opposed to b and y ions which are obtained from
CID and HCD, thus the alternation of ETD with CID was chosen to facilitate the analysis.
Thus we first analyzed the CID spectra by a simple comparison to the low energy HCD
spectra in Figure 42 to facilitate peptide sequence assignment and subsequently facilitate
the analysis of the ETD spectra.

Furthermore, we noted the fragmentation of the

unmodified peptide, triply charged ion 603.64 m/z by ETD to facilitate the analysis of its
glycosylated counterpart (Figure 43A). The glycopeptide, triply charged 904.11 m/z ion
fragmented less efficiently by ETD (Figure 43B) in comparison to its unmodified
counterpart (Figure 43A), whereby the fragmentation mainly occurred at the extremities of
the peptide. We thus observed mostly internal ions, all carrying the extra full glycan mass
of 901.39 Da as noted on the spectrum, with details to ion assignments in Table 8. As the
fragmentation was not optimal, we did not obtain enough ions of the c and z series of our
peptide of interest in order to be confident in our internal ion assignments. However, the
observed ions precisely matched our calculated internal peptide fragments to two decimal
places. This was beneficial as it allowed us to putatively map the glycosylation to N247,
suggesting potentially novel N-glycosylation in H. pylori. This was inferred from the
internal peptide fragments SAGPN and AGPNATNLY (both with the full glycan attached)
at 1328.64 and 1803.90 m/z respectively, whereby the first eliminates the T as being the
glycosylation site and the latter similarly eliminates the S, provided that glycosylation was
not heterogenous, occurring either on S or T.
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Figure 43. ETD spectra of the HopE peptide in both unglycosylated and
glycosylated forms.
(A) ETD of the unglycosylated peptide, 603.64 m/z. (B) ETD of the glycosylated peptide,
904.11 m/z. The full glycan is denoted by (

).
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Confirmation that HopE is modified with Ley
The Helicobacter outer membrane protein, HopE (~29 kDa), consistenly would migrate in
the same MW range as that of Ley glycoprotein candidate protein observed in Figure 40.
Upon structural modelling of this protein, we determined that the glycopeptide found by
MS is predicted to be part of a surface exposed loop (Figure 44), which is consistent with
its release upon trypsinolysis of intact non solubilized outer membranes. Furthermore, this
supports the hypothesized ability of this Ley glycosylated protein to participate in evasion
of the host immune surveillance. In order to further confirm that the identified peptide
belongs to HopE and is indeed modified with Ley, we constructed a hopE knockout mutant
and analyzed the LPS and outer membranes by anti- Ley Western blot compared to the WT.
We confirmed that this mutant still produces Ley LPS by both Western blot and sequencing
of the phase variable fucosyltransferase genes (data not shown). We examined the outer
membranes for Ley reactivity as previously done and found that the ~30-33 kDa protein
band reactive with anti- Ley antibody in the WT sample that was absent in the hopE
knockout mutant (Figure 45). Thus by MS analysis of WT and Western blot analysis of
this knockout mutant, we conclusively showed that H. pylori glycosylates the outer
membrane protein HopE with Ley, supporting our hypothesis that H. pylori can glycosylate
proteins with the O-antigen for LPS.
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Figure 44. Structural model of HopE highlighting in purple the extracellular loop
found to carry a Ley motif based on MS analysis.
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Figure 45. Analysis of hopE::CAT mutant outer membrane proteins for Ley
reactivity shows a Ley reactive band missing in the mutant.
Panel A shows total proteins stained with Ponceau S Red. Panel B shows the anti- Ley
Western blot. The + and – signs indicate that the samples were treated with proteinase K
or not respectively. The star (*) indicates the Ley reactive band in the WT which is absent
in the mutant.
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Chapter 4

4

Discussion

4.1 The role of Cj1319 in C. jejuni
In this work, we completed a comprehensive analysis of Cj1319 of C. jejuni NCTC 11168.
We used an enzymology approach in parallel with phenotypic analyses of a cj1319
knockout mutant. We were unable to determine its precise function as per enzymology,
however, we did find an important role for this enzyme in virulence. Moreover, we
conclusively excluded this enzyme from having a role in making capsular modified heptose
or legionaminic acid for flagellin glycosylation which were proposed functions of this
enzyme at the onset of our work.

Biochemical function of Cj1319

Cj1319 is a predicted sugar nucleotide dehydratase and enzymes with this function have
been shown to initiate glycosylation pathways important for bacterial virulence in C. jejuni,
H. pylori, and P. aeruginosa among others (Creuzenet, 2004; Creuzenet and Lam, 2001;
Creuzenet et al., 2000; Schoenhofen et al., 2006). Thus there is potential for this enzyme
to initiate a glycosylation pathway that would also impact the virulence of C. jejuni. Since
this enzyme is homologous to GDP-mannose and GDP-manno-heptose dehydratases, we
examined its activity on these two substrates. GDP-manno-heptose is the precursor in the
pathway for heptose modification for capsule synthesis in C. jejuni NCTC 11168 which is
only partially deciphered (Figure 3) (McCallum et al., 2013). The oxidase of the pathway
has yet to be determined and, although we reasoned Cj1319 may function as the oxidase,
since C-4 oxidation is also a function of C4, C6 dehydratases, we did not find that Cj1319
fulfills this function. Aside from being part of the main pathway for modifying the heptose
for capsule, it is possible that Cj1319 would instead use the same precursor, but the
dehydrated product would then be aminated and N-acetylated by the actions of Cj1320 and
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Cj1321 respectively, which are encoded by the cj1319 locus. Similarly, we did not find
that this was the case.
As Cj1319 was not found to be the oxidase of the heptose modification pathway for
capsule, other oxidase candidates need to be explored. However, there is no evident oxidase
candidate for sugar nucleotide modification in the genome of C. jejuni based on
bioinformatics. A screening approach to identify the oxidase could be performed. This may
be achieved by fractionation of C. jejuni cell extracts and screening for activity of these
fractions on GDP-manno-heptose whereby activity can be monitored by CE. The active
protein fraction can then be further fractionated by ion exchange chromatography and the
active fraction analyzed by mass spectrometry in order to determine the identities of the
proteins in that fraction. Of these proteins, the most probable enzyme candidates can then
be cloned and tested for oxidase activity on the said substrate. This is not an ideal approach
due to the preciousness of GDP-manno-heptose. This sugar nucleotide is not available
commercially and can only be synthesized enzymatically using four different enzymes to
modify the D-sedoheptulose-7-phosphate as a precursor which is available commercially,
but very costly (Kneidinger et al., 2001).
We determined that the 3-O-methyltransferase of the capsular heptose modification
pathway is Cj1419 which does not methylate GDP-manno-heptose, but can methylate the
surrogate dehydrated product produced through the activity of DdahA. Cj1319 did not use
the resulting sugar, thus we could conclude that Cj1319 does not use a 3-O-methylated
derivative of GDP-manno-heptose. Further studies can be pursued to determine if Cj1419
can act on other intermediates of the pathway and to analyze the kinetics of the reactions.
It seems likely that this enzyme is less efficient than enzymes of the main pathway as we
only observed ~50% conversion to the methylated intermediate after a 3 hour reaction
compared to full conversion of GDP-manno-heptose to its dehydrated intermediate in 15
minutes. In addition to the fact that none of the enyzmes in this pathway require a
methylated substrate, this would explain the heterogeneity in methylation of the final
modified heptose product incorporated into the capsule.
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Since the surrogate intermediate of the heptose modification pathway generated as a result
of using DdahA, rather than the true C4 oxidase, is dehydrated, thus lacking its OH at C6,
no activity for Cj1426 could be found in the surrogate pathway. Thus, when the C4 oxidase
of this pathway is determined, the native 4-keto intermediate of this pathway can be
generated which has a hydroxyl at C6. This will allow us to determine if Cj1426 is the true
6-O-methyltransferase for this pathway. In the case we do find it has a role in this pathway,
we will be able to assess its substrate specificity. We could test Cj1319 on its product to
determine if Cj1319 can use the 6-O-methylated product as its substrate. However, as the
expression of Cj1426 is phase variable owing to the presence of a poly-G tract within
cj1426c, and the expression of Cj1319 is not phase variable, it is not likely that Cj1319
would primarily use the product of Cj1426.
To determine the substrate of Cj1319, it is possible to extract the sugar nucleotide pool
from cell free extracts of WT C. jejuni and screen for Cj1319 activity on these extracts.
The sugar nucleotide extracts from WT and cj1319 knockout mutant may also be compared
by MS or CE to determine if a sugar nucleotide is accumulated in the cj1319 mutant. If so,
the metabolite of interest can be purified by anion exchange chromatography and identified
by MS. We have attempted this and did not find any metabolite accumulated in the cj1319
mutant, however, we also did not find any metabolite accumulated in the cj1430 mutant
that was used as a positive control. Cj1430 is the second enzyme in the pathway for
capsular heptose modification, so one could expect an accumulation of GDP-mannoheptose in this mutant. However, a probable negative regulator of the pathway, WcaG, has
been studied extensively and because this enzyme reduces the first oxidized intermediate
of the pathway, it is likely that this prevents the accumulation of the pathway precursor
(Figure 3) (McCallum et al., 2011). A similar mechanism may exist for the Cj1319 pathway
as well. The substrate of Cj1319 may be unstable and thus is only present at a small
concentration and so this substrate was undetected in our CE analysis. In addition, it may
have also degraded completely as a result of the extraction conditions. Finally, the
extraction methods tested may not be optimal for the extraction of the sugar nucleotide of
interest, as different metabolites show different extraction efficiencies under different
methods (Faijes et al., 2007).
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GDP-mannose can be converted to up to four different sugars depending on the enzyme
function following dehydration (Albermann and Piepersberg, 2001; Mäki et al., 2002; Wu
et al., 2001). These four sugars have been shown to be important for virulence and include
GDP-fucose. Although we did not find activity of Cj1319 on GDP-mannose, we did detect
a number of glycoproteins using the fucose binding lectins BambL and PAII-L by Western
blot. This suggests that C. jejuni NCTC 11168 may fucosylate some proteins, either as a
single sugar or as a part of an oligosaccharide. However, for this to occur, there must be a
GDP-mannose dehydratase encoded by the genome of this strain, but the only protein
homologous to the E. coli GMD in our strain is Cj1319. Alternative to synthesizing GDPfucose from GDP-mannose, it is possible that C. jejuni may uptake fucose and would then
transfer it to proteins. Although C. jejuni can uptake L-fucose, this bacterium uses it as an
energy source and thus not likely for protein glycosylation (Stahl et al., 2011). In addition,
a fucosyltransferase would be needed to transfer the fucose onto proteins, which has not
been noted to date. Additionally, as we only found glycoproteins binding these two lectins
in the soluble protein fraction, these proteins would not be exposed to the host so it is not
clear what role fucosylated proteins would play in C. jejuni virulence unless these proteins
are secreted either as Cia proteins that can be secreted through the flagellar apparatus or by
means of outer membrane vesicles (Elmi et al., 2012; Konkel et al., 2004). It is possible
that these lectins may not have bound to fucose, but to another related sugar since these
lectins have relaxed specificity in their binding (Audfray et al., 2012; Mitchell et al., 2005).
Although these findings hint that there are yet novel glycoproteins to be discovered in C.
jejuni, these particular ones are not related to Cj1319 as the two lectins were able to bind
to the same proteins in the cj1319 knockout mutant as in the WT.
We did not find any changes in glycoprotein profiles between the cj1319 knockout mutant
compared to WT via Western blotting with lectins or biotin hydrazide labelling of
glycoproteins. However, we did find that the cj1121c::CAT mutant (Cj1121c is part of the
N-glycosylation pathway responsible for glycosylation of over 60 proteins (Scott et al.,
2011)) still expresses a large number of glycosylated proteins based on both biotin
hydrazide labelling and the SBA lectin which was originally used to detect N-protein
glycosylation in C. jejuni. Therefore, there must be another glycosylation pathway
modifying these proteins in the absence of Cj1121. Thus, the cj1121c::CAT mutant can be
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used as a tool to analyze its glycoproteins by mass spectrometry as performed previously
on WT C. jejuni (Scott et al., 2011). This will reveal the glycan or sugar(s) modifying these
proteins which in turn will shed light on what type of enzymes would be required for
synthesis of this/these sugar(s). By doing so, this glycosylation may be traced back to
Cj1319. Furthermore, as we know that the cj1121c::CAT mutant is nonmotile although it
produces full length glycosylated flagella (Vijayakumar et al., 2006), the flagellin
glycopeptides of this mutant can be analyzed by mass spectrometry as we have
demonstrated (Zebian et al., 2015), in order to determine if the lack of motility is caused
by a change in the glycosylation pattern of the flagellins of this mutant. Furthermore, a
double mutant of cj1121c and cj1319 can be generated to determine if glycosylation is
abrogated.

Mass spectrometry analysis of flagellin glycopeptides in C.
jejuni reveals the incorporation of legionaminic acid
As a major contribution in our study, we performed a comprehensive glycopeptide analysis
of the C. jejuni NCTC 11168 flagellins using HCD-MS2. We found evidence of the first
glycopeptide carrying Leg5AcNMe7Ac in the WT, observing both the loss of its 329.159
Da signature mass and the presence of its oxonium ion at 330.166 m/z. We found seven
glycopeptides (in their shortest digested form), five of which could be glycosylated by only
one sugar at a time and one which could be glycosylated by two sugars at a time, each
occupying a different site. In total, we found 22 different glycoforms of flagellin peptides
in the WT. Two of the glycopeptides found could carry up to five different sugars
(separately). Further showing the extensive heterogeneity of glycosylation are two
glycopeptides from the cj1319::CAT mutant which could be glycosylated by six different
glycans. This heterogeneity offers a wide combinatorial power of glycosylation patterns
that produce flagellins with potentially different antigenic properties. Such properties may
contribute to immune evasion and pathogenesis beyond the already established role of
glycosylation in flagellin production and flagella function such as motility (Goon et al.
2003; Hitchen et al. 2010).
The extensive micro-heterogeneity found in the glycosylation of these peptides was a novel
finding compared to prior reports available at onset of our studies and which indicated up
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to two sugars per glycopeptide in other C. jejuni strains or in other bacteria in general
(Logan et al., 2002; Thibault et al., 2001; Zampronio et al., 2011). Our wild-type data were
corroborated by a study published during the final stages of preparation of this manuscript
which also reported extensive heterogeneity of flagellin glycosylation in strain NCTC
11168 (Ulasi et al. 2015), including in the amino acid region 387 to 463 of flagellin A that
is highly glycosylated and has been missed from all prior analyses. This extended coverage
was obtained by coupling FAIMS ETD with proteinase K digestion in the Ulasi study and
by coupling HCD with a double trypsin and chymotrypsin digest in our work. Overall, the
same glycopeptides were identified and mapped but the Ulasi study revealed an additional
glycopeptide spanning residues 427-456 as well as additional sugars on peptides 421-426
and 457-463 while our study showed the presence of a new sugar of 372.145 Da on three
peptides, and most importantly our study is the only one providing unambiguous proof of
the existence of legionaminic acid on flagellins.
Overall, both studies consistently highlight the high level of heterogeneity of flagellin
glycosylation in C. jejuni strain NCTC 11168 and highlight the complexity of glycopeptide
analysis whereby a combination of complex methods is necessary to capture the complete
repertoire of glycopeptides. While ETD is usually considered ideal to map posttranslational modifications, HCD had been used successfully to map glycosylation sites
modified by GalNAc using y-ions (Segu and Mechref, 2010). Our work shows that HCD
is very efficient at detecting peptides glycosylated by complex bacterial sugars and shows
that mapping glycosylation sites is also possible using b-ions. It is very likely that HCD
coupled with proteinase K would also have revealed an extensive number of flagellin
glycopeptides in a single experiment. This also suggests the possibility of uncovering novel
glycans/glycopeptides using this method in strains that were analyzed using prior methods.
To identify the potential new sugar observed at 372.145 Da, MS3 analyses were performed.
While these analyses identified several diagnostic fragments for a sugar backbone and for
side chains commonly found on sugars, its identity as a new sugar can not be ascertained
because of the concomitant presence of a 391.172 m/z ion in MS2 spectra that releases
common fragments upon MS3 analysis (Logan et al., 2009). Thus 372.145 Da may have
arisen from fragmentation of the 390.164 Da sugar during the MS2 step. If different, this
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sugar may contribute to this strain’s pathogenicity and further increase the level of
heterogeneity found in this strain. This finding additionally stresses the need for elucidating
the functions of genes comprising C. jejuni’s flagellin glycosylation island in order to
identify the enzymes responsible for generating this sugar.

Cj1319 is not required for legionaminic acid synthesis

In addition, we addressed the controversial role of Cj1319 in legionaminic acid synthesis
by determining that Cj1319 is not required for legionaminic acid synthesis through the
glycopeptide analysis of flagellins from the cj1319 mutant. We showed that the enhanced
detection of legionaminic acid on this mutant’s peptides is specifically due to Cj1319, as
determined by partial restoration of the WT phenotype in the complemented strain. Partial
complementation is not unusual for glycosylation-related genes as cross-talk between
glycosylation pathways and regulatory effects may occur (Demendi and Creuzenet, 2009;
Howard et al., 2009; Wong et al., 2015).
Furthermore, the phenotypes we observed for the cj1319 mutant were in contrast with the
phenotypes reported for a cj1324 knockout mutant of the legionaminic acid synthesis
pathway (Howard et al. 2009). The C. coli homologue of Cj1324 is responsible for the
conversion of CMP-Leg5Ac7Ac to CMP-Leg5Am7Ac (Figure 8) (McNally et al., 2007).
Consistently, inactivating cj1324 in C. coli or in C. jejuni does not affect synthesis of CMPlegionaminic acid, but prevents further production of acetamidino derivatives (Howard et
al., 2009; McNally et al., 2007). On the contrary, a C. coli mutant of the Cj1319 homologue
makes more CMP-Leg5Ac7Ac as per metabolomic analysis (McNally et al. 2007). This is
likely also the case in our cj1319 mutant in the C. jejuni NCTC 11168 background since
we observed enhanced incorporation of Leg5AcNMe7Ac on the flagellins by MS analysis.
Finally, whereas the C. jejuni cj1324 mutant had reduced chicken colonization compared
to WT (Howard et al. 2009), our cj1319 mutant showed enhanced chicken colonization.
This phenotypic comparison supports that Cj1319 is not required for legionaminic acid
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synthesis, but may rather negatively regulate legionaminic acid production via scavenging
of the GDP-GlcNAc precursor and potentially rerouting it to the synthesis of another sugar.
This implies that another dehydratase yet to be identified fulfills the role currently assigned
to Cj1319 in the GDP-based legionaminic acid synthesis pathway, or that UDP-based
legionaminic acid synthesis occurs when Cj1319 is absent. This latter explanation is
unlikely as very little legionaminic acid could be obtained in vitro using the GDPdiacetamidobacillosamine modifying enzymes (Cj1328, Cj1327 and Cj1331) on UDPdiacetamidobacillosamine (Schoenhofen et al., 2009). There remains the possibility that
their Cj1141-Cj1143 homologues that are normally dedicated to sialic acid production for
LOS synthesis would fulfill this function, however, our qRT-PCR analysis of these genes
in the cj1319::CAT mutant suggests that this likely does not occur. Analysis of the many
genes of the flagellin glycosylation island that remain uncharacterized to date may assist
in understanding the mechanism of this potential negative regulation.
In vitro biochemical pathways can be misleading as, despite their specificity, sugarnucleotide modifying enzymes can be used artificially in vitro in pathways that they do not
belong to biologically. For example, the N-acetyltransferase Cj1123c from the general
protein N-glycosylation pathway can also acetylate an intermediate of the pseudaminic
acid synthesis pathway for flagellin O-glycosylation (Demendi and Creuzenet, 2009)
although both pathways have been shown to be independent by mutagenesis studies (Goon
et al., 2003; Vijayakumar et al., 2006). Further evidence of cross-talk between both
pathways was also demonstrated for the initiating enzymes Cj1120c and Cj1293c
(Creuzenet, 2004; Guerry et al., 2007).

The role of Cj1319 in C. jejuni

Knockout mutants in C. jejuni are routinely created by insertional gene inactivation with
an antibiotic resistance cassette. This leads to some polarity effects on surrounding genes
in an operon when the promoter of the antibiotic cassette is stronger than that of the native
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promoter of downstream genes. This can be avoided by addition of a transcriptional
terminator downstream of the antibiotic resistance cassette, however, this would stop
transcription of the downstream genes in operon. We did not introduce a terminator
sequence into the mutant constructs for this reason. As such, we observed that the
downstream genes were upregulated in our cj1319::CAT mutant, although this was not
deemed significant by Student’s t test. To our knowledge, there has been no system
developed for in-frame deletion mutants with no insertional antibiotic cassette for C. jejuni
and thus we were unable to avoid this effect. However, in order to assess that the
phenotypes we detected in our cj1319::CAT mutant were indeed due to the loss of Cj1319
and not due to polarity and pleiotropic effects, we designed three different complements in
our study. Because complementation in trans by use of a shuttle vector results in unstable
strains in which the vector is rapidly lost through repeated culturing, all three complement
constructs were prepared on a suicide vector which was transformed into C. jejuni and
inserted into the genome by homologous recombination to create stable strains.
Specifically, integration was engineered into a redundant tRNA site. As detailed in section
3.2, the two additional complement strains were developed due to inability to complement
the biofilm, capsule, and LOS phenotypes with cj1319comp_RSP. This was thought to be
due to either the overexpression of Cj1319, other mutations or a combination of both which
may vary depending on the phenotype studied. The capsule and LOS were found to be
altered due to phase variation of genes within the LOS or capsule biosynthesis clusters.
The enhanced biofilm phenotype in the cj1319 knockout mutant was concluded to be due
to the cj1319 mutation. This was interpreted based on the ability to complement this
phenotype with cj1319comp_RNP and cj1319comp_ONP. As we could not complement
this phenotype with cj1319comp_RSP, this indicates that overexpression of cj1319
inferred from qRT-PCR caused complications. The bulk of the overexpressed protein may
precipitate and thus result in limited amounts of soluble and active Cj1319 available which
may have been sufficient to complement some phenotypes but not others. We ruled out
growth rate, motility and flagella as being the causes for the increased biofilm production
since cj1319comp_RNP and cj1319comp_ONP grow at the same rate as cj1319::CAT,
cj1319comp_RSP is nonmotile yet still makes enhanced biofilms, and cj1294::CAT which
lacks flagella formed biofilms comparable to WT. The enhancement in biofilm formation
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in the cj1319::CAT mutant only occurred under aerobic static conditions and did not occur
under shaking conditions or microaerobic conditions. This suggests that oxidative stress
may affect the mutant more than the WT, however, we did not find that the two strains
differ significantly in their sensitivity to oxidative stress. There must be another stressor
that this mutant is susceptible to which causes it to form biofilms more readily. As shaking
abolished this effect, this suggests that the biofilm created by the cj1319 mutant may be
more fragile in its early stages compared to the WT and so the shaking slows down the rate
of biofilm formation in the mutant.
The loss of motility of the cj1319comp_RSP strain and partial loss of motility in the
cj1319comp_RNP and cj1319comp_ONP strains remain an enigma that may be
investigated. We know the cj1319comp_RSP produces and assembles flagella which are
glycosylated similarly to WT based on our ability to shear this structure from the cells, EM
analysis and our mass spectrometry analysis. We could clearly see that this complement
still makes normal (bi)polar flagella. There was no striking difference in the amount of
flagella sheared among the strains, no evidence of truncated flagella formation, or lateral
flagella formation which has been shown to occur in some C. jejuni mutants and impair
motility (Balaban et al., 2009). Therefore, it is most likely that there is some change that
occurred in this strain that affected the flagellar motor proteins or proteins involved in
flagellar regulation.
From our analyses, we can conclude that Cj1319 is not required for synthesis of capsular
or LOS sugars, nor is it required for legionaminic acid synthesis. We did find however, that
it may have a negative regulatory role on legionaminic acid expression as a legionaminic
acid derivative was detected more readily in the cj1319 knockout mutant. Although we
could not detect any glycoproteins dependent on Cj1319 for glycosylation based on our
analysis of glycoprotein profiles via Western blot, it is possible that Cj1319 is responsible
for glycosylation of proteins involved in legionaminic acid synthesis and/or export. These
Cj1319 dependent glycoproteins would be repressors of legionaminic acid synthesis and/or
export, whose activity is dependent on their glycosylation. Thus, in the absence of Cj1319,
they would no longer be glycosylated and thus would no longer be able to perform their
repressor role. This would then explain the effect of the complement strains on motility
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since there is an upregulation of cj1320 and cj1321 which would mean an upregulation of
the whole predicted Cj1319 pathway. Since there is an over expression of cj1319 in
cj1319comp_RSP, there is an increase in the glycosylation of repressor proteins by this
pathway which could shut down motility. In the cj1319comp_RNP, there is only an
increase in cj1320 and cj1321 which limits the increase in glycosylation and thus less
repressor proteins would be glycosylated compared to the prior complement strain, and
thus motility is only partially lost. It is presumed the same would apply to the
cj1319comp_ONP strain, since this strain has a kanamycin resistance cassette just
upstream of cj1320 which may also result in an upregulation of its transcription and also
that of cj1321.

Importance of Cj1319 in the interactions with eukaryotic cells
and eukaryotes

We determined that Cj1319 was not important for interactions of C. jejuni NCTC 11168
with A. castellanii. On the other hand, both protein glycosylation pathway mutants were
impaired in their survival within these protists, suggesting that both general protein
glycosylation with the N-linked heptasaccharide and flagellar glycosylation were essential
for survival. Whereas the enhanced killing of cj1121::CAT may be due to its increased
susceptibility to oxidative stress, the cj1294::CAT mutant did not differ in its sensitivity to
this stressor compared to WT. The lack of motility was ruled out as the causative factor
due to the cj1319comp_RSP mutant which was nonmotile but did not differ from WT in
its survival within the amoeba. Thus it appears that the glycosylation of the flagella may
play a role in prolonging survival of C. jejuni within amoeba. However, at this stage we do
not know by what mechanism this may occur.
An important difference between the interaction of C. jejuni with chickens compared to
humans is that C. jejuni invades human intestinal cells more than chickens’ (Young et al.,
2007), signifying that this phenomenon is key to understanding what triggers this chicken
commensal to become pathogenic in humans. It is possible that human intestinal cells have
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receptors that interact with surface glycoproteins expressed by C. jejuni which allow for
its internalization. Although Cj1319 did not appear to have any effect on adherence or
invasion of the cell lines tested, the N-protein glycosylation pathway was evidently
important in invasion of Caco-2 cells (Vijayakumar et al., 2006) and macrophages. Since
a large number of proteins are glycosylated by this pathway, this was not surprising. As
the number of bacteria from each strain recovered from macrophage was not affected by
infection time, this suggests that the strains were being killed by macrophage at a constant
rate compared to the internalization rate. Similarly, the strains were not internalized at
different rates, which suggests that the initial internalization was mostly influenced by the
macrophage phagocytosing the bacteria. As we demonstrated that cj1319::CAT was not
significantly different compared to WT in its sensitivity to both nitrosative and oxidative
damage which are encountered in the phagosome or secreted into the media by the
macrophage, it was not surprising that the mutant survived the internalization to the same
extent as the WT. Consistently, the cj1121::CAT mutant was more susceptible to oxidative
stress which explains its impaired survival in this system.
In the insect model of infection, Cj1319 and Cj1121c were clearly important for killing G.
mellonella. Motility and flagellar glycosylation were ruled out as factors influencing
virulence in this model as the nonmotile cj1294::CAT mutant did not differ from WT in its
ability to kill the larvae. In G. mellonella, the innate immune response is very similar to
that of mammals and acts as a first line of defense (Browne et al., 2013). This includes
eight types of hemocytes, including a phagocytic cell type called a plasmatocyte,
circulating in the hemolymph throughout the insect’s body. Furthermore, these insects also
have a humoral response whereby they secrete anti-microbial peptides, melanin,
complement-like proteins, and products of proteolytic pathways to combat pathogens.
Since our cj1319::CAT mutant was more sensitive to killing by serum containing these
effectors, this indicates that the larvae could clear this mutant faster and in turn they were
able to survive better upon challenge with cj1319::CAT. This was interesting since the
excess capsule produced by this mutant which should protect it from serum killing failed
to do so (Keo et al., 2011). This suggests that Cj1319 has an important role in serum
resistance which even excess capsule cannot compensate for. Athough we did not test
cj1121c::CAT for serum susceptibility, this may also be the reason for enhanced survival
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of the larvae challenged with this mutant. As such, the glycosylation resulting from both
Cj1319 and Cj1121 pathways is important for evading killing by complement or antimicrobial peptides.
As legionaminic acid has been largely associated with livestock isolates from chicken,
bovine, and ovine origin (Champion et al. 2005), this modification may be used by
Campylobacter to enhance colonization in livestock. Since more legionaminic acid
decorates the cj1319 mutant’s flagellins compared to WT, this provided an opportunity to
assess whether enhanced legionaminic acid presented on flagellins offered an advantage
with regards to chicken colonization. We showed that our mutant did indeed colonize
chicken caecum significantly better than the WT with ~1.1 log difference between both
strains. The complemented strain was not tested in this system in light of the partial
complementation highlighted by the flagellin analysis which, combined with the variability
of the in vivo assay and the relatively small difference between wild-type and mutant,
would likely prevent reaching statistical significance even upon using a very large number
of chicks. The enhanced colonization seen in the mutant may not be solely attributed to the
increased legionaminic acid incorporation on flagellins, but may also be due to the
currently unknown specific function of Cj1319 that is lacking in this mutant. Further
research needs to be done to understand this complex glycosylation machinery and how
this complexity contributes to the virulence of C. jejuni, its ability to colonize poultry and
its ability to survive in seemingly unsuitable growth environments during transmission.

Concluding remarks
In conclusion, although cj1319 did not appear to have a significant role in interactions with
the tested cells lines, we showed that it does have an important role in vivo, whereby it
affects both colonization and infection potential. Protein glycosylation, particularly the Nglycosylation pathway, appears to have an important role in colonization and virulence and
survival in macrophage. Studies extended to human macrophages and to chicken epithelial
cells and macrophages may be performed in order to address the potential role of Cj1319
in host specificity. This can be done using the new cj1319::CAT mutant clone void of point
mutations in the LOS genes. The level of different cytokines produced by these cell lines
can also be examined as it is possible that Cj1319 indirectly alters the immune response
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which may explain why we observe less larvae killing upon challenge with this mutant
compared to WT. Larvae immune cells may be extracted and cultured to examine the
interactions of C. jejuni strains on these primary immune cells to shed light on the
mechanism behind the decreased virulence in both cj1319::CAT and cj1121c::CAT
mutants.
We have generated three complement strains with respective control strains which allow
us to distinguish effects resulting from our desired mutation from those generated by
randomly occurring phase variations. To facilitate future analyses, we have produced a new
cj1319::CAT mutant that we have confirmed is not a LOS phase variant. This mutant can
be utilized for future experimentation as misleading phenotypes arising due to the LOS
truncation and excess capsule will be absent.

4.2 Protein glycosylation in H. pylori

The major findings presented in this work are the discovery of a Ley-modified outer
membrane glycoprotein HopE and potential N-linked glycosylation. This was achieved
through a series of anti-Ley Western blotting for initial detection, extraction of
glycopeptides by trypsinolysis treatment of outer membranes coupled with SDS-PAGE
and/or lectin chromatography, and the combination of three modern MS fragmentation
methods. The significance of these findings is discussed below.
We are the first group who performed MS analysis of an intact glycopeptide from an H.
pylori glycoprotein and were able to map the glycosylation site with the glycan remaining
attached to the peptide using ETD-MS2. This analysis of an intact glycopeptide is in
contrast with the analysis of the H. pylori flagellin subunits, FlaA and FlaB (Schirm et al.,
2003). FlaA was shown to carry seven Pse5Ac7Ac residues and FlaB could carry up to 10
of these sugars, each at a unique S/T residue, however, the mapping of the glycosylation
sites was determined through a comparison of glycosylated and chemically deglycosylated
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flagellin peptides following extensive peptide digestion. Similarly, the other glycoproteins
in H. pylori were identified on the basis of MS analysis of the sugars released from protein
samples (Hopf et al., 2011) or MS analysis of glycoproteins after chemical deglycosylation
(Champasa et al., 2013). Noteworthy, neither of these studies had identified HopE as a
glycoprotein candidate. This can be explained simply by the prior study only analyzing the
soluble protein fraction by MS and not including Ley or the newly identified 244.14 Da
linker in the MS analysis inclusion list during data analysis of released sugars. The latter
study did look at outer membrane proteins but used azide-labelled free GlcNAc which acts
as a metabolic intermediate for making UDP-GlcNAz, which becomes incorporate into
glycoproteins (Vocadlo et al., 2003). This labelled GlcNAz variant is used as a basis for
tagging these unknown proteins with a FLAG-His-tag via the reaction between the azide
and a phosphine that had been incorporated into the FLAG-His-tag. β-elimination was used
to release O-linked sugars and these proteins were analyzed by mass spectrometry. Since
the GlcNAc of Ley is linked to both fucose and galactose, ligation with the FLAG-His-tag
is likely inhibited or much less efficient due to steric hindrance. This is provided that
GlcNAz would be incorporated into Ley. Thus the Ley modified HopE remained undetected
in these studies.
Although the N-glycosylation consensus sequence was thought to consist of (D/E)-X-NX-(S/T) (where X≠P) in bacteria (Kowarik et al., 2006), this no longer appears to be the
case as the sequence of N-X-(S/T) (where X≠P) was found to be sufficient in some bacteria
(Schwarz and Aebi, 2011; Schwarz et al., 2011b). The glycopeptide mapped to HopE
contains NAT, belonging to the minimal consensus sequence, which suggests potential for
this peptide to be modified by Lewis Y via N-glycosylation. However, there remains the
possibility that the peptide is O-glycosylated at either S or T. It was not possible to
determine the precise site of glycosylation due to the co-elution of a peptide from the urease
subunit A protein which was abundantly found in our samples. Urease is constitutively
highly expressed in H. pylori and has been shown to associate with outer membranes
(Phadnis et al., 1996). The urease peptide was found to be carboxymethylated as a result
of the alkylation performed prior to tryptic digestion and thus in order to prevent this
peptide from co-eluting and co-isolating with the HopE peptide of interest in the future, no
alkylation will be performed in vitro. Furthermore, to map the glycosylation site, the
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potential glycosylated residues may be mutated by site-directed mutagenesis. The
recombinant protein can be analyzed for glycosylation in order to definitively assign the
modified residues conclusively.
The enzymes for LPS synthesis in H. pylori have been shown to be evolutionarily related
to those required for protein N-glycosylation in other bacteria such as the Pgl enzymes
encoded by C. jejuni (Hug et al., 2010). In both protein glycosylation and LPS synthesis,
oligosaccharides or polysaccharides are assembled onto the lipid carrier undecaprenol
pyrophosphate (UndPP) (Hug and Feldman, 2011). To date, most bacteria producing
glycans linked to UndPP have been shown to use these glycans either for protein
glycosylation or as the O-antigens for LPS, but not for both. P. aeruginosa and A.
actinomycetemcomitans are exceptions that use UndPP-linked glycans for both protein
glycosylation and LPS synthesis (Faridmoayer et al., 2007; Tang and Mintz, 2010). In these
cases, whereas the O-antigen ligase for incorporation of the UndPP-linked glycan onto the
core oligosaccharide of LPS is known, the protein responsible for transfer of the glycan
onto proteins remains unknown. We also have yet to determine the oligosaccharyl
transferase responsible for transfer of the Ley motif onto HopE. In light of the discovery of
the yet to be characterized 244.14 Da linker, it is possible that this linker is the key
determinant in which O-antigen chains are transferred onto the LPS core versus those that
are transferred by the unknown Oligosaccharyl transferase for protein glycosylation.
The identification of an outer membrane protein glycosylated with Ley signifies the
importance of molecular mimicry in H. pylori colonization and infection since we have
shown that it is extended beyond the O-antigen of the LPS. The localization of this
glycoprotein to the outer membrane further suggests a role for this protein in interactions
with the host and the potential for modulation of the immune response. Indeed, several
studies have shown the importance of HopE in immune activation and its antigenic
properties. HopE purified from H. pylori was shown to stimulate cytokine production,
including tumour necrosis factor alpha, interleukin 6 (IL-6), IL-8, interferon gamma and
granulocyte macrophage colony stimulating factor, from monocytes and lymphocytes in
vitro, whereby the release of cytokines was dependent on the concentration of HopE and
the duration of incubation with this porin (Tufano et al., 1994). This porin was also found
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in all clinical isolates from asymptomatic carriers and duodenal ulcer and gastric cancer
patients, along with BabA and Omp11 (Carlsohn et al., 2006). This is not surprising due to
its conserved nature among H. pylori strains. HopE was ranked as the fourth best candidate
antigen as a vaccine target in an analysis of the ANTIGENome of H. pylori (Meinke et al.,
2009). Further studies to understand the role of glycosylation on the function of HopE as
an immune modulator can be conducted comparing recombinant HopE expressed and
purified from E. coli, which would be unglycosylated due to the lack of Ley synthesis
machinery, and HopE purified from H. pylori, which would be found in both glycosylated
and potentially unglycosylated forms, in their ability to stimulate cytokine production from
immune cells. Alternatively, upon determination of the glycosylation site of HopE, this
residue can be changed by site-directed mutagenesis to prevent glycosylation while
keeping the protein structure (Miller et al., 2004).
HopE, originally called Omp15 (Outer membrane protein 15), is the name denoted for
HP0706, a member of the Helicobacter outer membrane porins (Hops) (Doig et al., 1995;
Tufano et al., 1994), which are conserved among H. pylori strains, but not in other
Helicobacter spp. (Doig and Trust, 1994). This protein is one of the more abundant outer
membrane proteins and is a non-specific, large, water-filled channel, with a conductance
of 1.5 nS in 1.0M KCl that is present as a homotrimer in the outer membrane (Doig et al.,
1995), signifying the potential for a wide variety of molecules to be transported through
this porin. Porins from gram negatives are comprised of β-barrels unique to bacteria, save
those found in mitochondria and chloroplasts (Walther et al., 2009) and have been shown
to be immunogenic, such as those expressed by Salmonella typhimurium and E. coli
(Galdiero et al., 2012; Liu et al., 2012a). Glycosylation may mask the immunogenic
epitopes. There is no identified porin-specific signaling receptor on host cells, however,
porins are considered as pathogen associated molecular patterns that may be recognized by
a number of host cell receptors. There has been evidence of interactions of porins with
toll-like receptor 1 (TLR-1), TLR-2, and TLR-6 (Banerjee et al., 2008; Galdiero et al.,
2004; Massari et al., 2002, 2006), however, since there are a broad range of porins, these
interactions do not appear to be specific. The porins of a number of gram negatives have
been shown to have a ring of positively charged residues on their extracellular surfaceexposed side, which has been shown to interact with the negatively charged LPS to
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maintain stability in the membrane (Ferguson et al., 2000; Zeth et al., 2000). In addition,
the TLR-1/2 heterodimer has been shown to have two predominantly negatively charged
ectodomains, which mediate recognition of bound ligands (Jin et al., 2007), and thus it has
been proposed that the nonspecific electrostatic interactions between the positively charged
ring of porins and the negatively charged ectodomains of the TLR receptors may be the
basis for recognition and signal transduction in host cells (Galdiero et al., 2012). Based on
this, it is possible that the glycosylation of HopE by Ley not only modulates the immune
response through molecular mimicry, but may also serve to block the interaction between
HopE and TLRs, thus preventing immune activation by these glycoproteins. Since we
detected nonglycosylated versions of the HopE glycopeptide, it is possible that not all
molecules are glycosylated. These unglycosylated versions of HopE may still activate the
immune response, but perhaps the glycosylation of some HopE molecules functions to
dampen the response.
HopE is the first H. pylori porin to be shown to be glycosylated. In general, only two other
bacterial porins have been shown to be glycosylated to date. The C. jejuni MOMP porin is
O-glycosylated with a glycan chain of three GalNAc and one galactose residue and this
glycosylation was shown to influence the conformation of the protein such that it improves
binding to histo-human blood group antigens (Mahdavi et al., 2014). Importantly, the
glycosylation was observed to occur at T268, which is in a surface exposed loop as we found
in HopE. In P. aeruginosa, the porin OrpD was shown to be sialylated and this modification
caused increased resistance to β-lactam uptake, thus hinting to a novel mechanism for
antibiotic resistance (Khatua et al., 2014). Thus it is possible that the glycosylation of HopE
also contributes to antibiotic resistance.
In summary, we showed that HopE is glycosylated with the O-antigen Ley, a highly novel
finding as this indicates that H. pylori can glycosylate proteins with Lewis O-antigens
which were presumed to be exclusively associated with LPS. This also shows that
glycosylation in this bacterium is linked to the LPS synthesis pathway. Further studies are
needed to determine the precise relationship between the two processes in which the key
lies in the identification of the oligosaccharyl transferase responsible for transfer of the Oantigen chain to proteins. Another important finding was that this novel glycosylation was
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found to occur through an unknown linker of 244.14 Da. It is presumed that this is a sugar,
however, further analysis is required to determine its structure and subsequently the origin
of this molecule. We have found a potentially important role for HopE in enhancing host
mimicry during H. pylori infection based on the role assigned to Ley motifs in previous
literature and thus it is well worth investigating the role that glycosylation with Ley has on
the immunogenicity of HopE and its importance in colonization and infection of the
stomach.

4.3

General discussion

This work examined aspects of protein glycosylation in both C. jejuni and H. pylori in
relation to the synthesis of different glycolipids. In C. jejuni, we focused on studying
Cj1319 to uncover a novel protein glycosylation pathway which may share a precursor
with the heptose modification pathway for capsule synthesis. On the other hand, in H.
pylori, we had preliminary data suggesting that proteins may be glycosylated with the LPS
O-antigen. Thus, although our analysis was performed on two different microorganisms,
we had a similar focus in both. Protein glycosylation is a complex process that is studied
at three levels: the glycosylation pathways, the glycoproteins, and the function of
glycosylation. Our work in C. jejuni focused on the first and third areas of study, whereas
in H. pylori the work focused on the second. If we had been successful in determining the
pathway of Cj1319 through the identification of its substrate, we would have proceeded to
identify the glycoproteins in a similar manner as done in H. pylori. Thus, combining the
work performed in both bacteria provided a continuum of the methodology undertaken for
studying protein glycosylation.
In C. jejuni, we dispelled the assumptions that Cj1319 plays a role in modification of the
heptose found in the capsule. Although we rejected our original hypothesis that Cj1319
provides a link between capsule synthesis and protein glycosylation, we did not exclude or
examine if the capsular K-units may be incorporated onto proteins as has been shown to
occur in A. baumannii (Lees-Miller et al., 2013). We showed that even in the absence of
the general N-protein glycosylation pathway, C. jejuni still glycosylates a significant
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number of proteins and that the glycosylation of these proteins was not dependent on
Cj1319. Therefore, nothing excludes the possibility that at least some of these
glycoproteins may be glycosylated by capsule K-units. However, being independent of
Cj1319, this was not a focus of this work. Importantly, we showed that although Cj1319
can be used in a pathway for making legionaminic acid in vitro, this was not the case in
vivo. Instead, we found that Cj1319 likely plays a role in negative regulation of
legionaminic acid synthesis since more legionaminic acid was detected on the flagellins of
the cj1319 knockout mutant. This increase in legionaminic acid expression was correlated
with an increase in chicken colonization, thus showing the importance of this modification
for interaction of C. jejuni with its host. The role of Cj1319 in C. jejuni virulence was
shown to be significant in the insect model of infection, highlighting that it is worth
investigating the basis of attenuation of the cj1319 knockout mutant in this system.
We found a link between LPS synthesis and protein glycosylation in H. pylori by showing
that the outer membrane protein HopE is glycosylated by the Ley O-antigen of the LPS.
We showed this through a comprehensive MS analysis of a HopE glycopeptide that was
found to be modified with Ley. The importance of this glycosylation may also be
investigated in the future to determine the role that this glycosylation has on both the
protein function and its interaction with the host.
We report novel findings related to protein glycosylation in these bacteria. Our study
highlights that many glycoproteins in C. jejuni have yet to be identified. This further
indicates that there are protein glycosylation pathways beyond the general N-protein
glycosylation pathway and the flagellar O-glycosylation pathway. The discovery of Leymodified HopE in H. pylori provides new insight into mechanisms that this pathogen uses
to evade the host immune response and persist in long term colonization.
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Table 9. Primers used in this study.
Primer name

Primer sequence

Cloning
CJ1319P1

AGGGTCCATGGATGGAAAGGGTGAG

CJ1319P2

GCGTCGGATCCTTAAACATTATAAAGCTCGC

272

CJ1319P3

GTGGGTACCGTGCTAGATACTTGCGAG

CJ1319P4

ATGCTAGGGCCCCGCTTGTTGAGGTGTGGA

CJ1319P9

GGAAGACCATATGGATGGAAAGGGTGA

CJ1319P10

ATAGTTTCGCGGCAACATTATAAAGCTCGCTT

CJ1319P13

GCCTCGAATTCTTAAACATTATAAAGCTCGC

CJ1319P14

AAGACGGATCCATGGATGGAAAGGGTGAG

CJ1319P16

TAATTTTTGACAAGGAGAATTCTCATGAGAAATATTTTAGTTACAGGTG

CJ1319P17

CACCTGTAACTAAAATATTTCTATGAGAATTCTCCTTGTCAAAAATTA

CJ1319P18

ATAAAAGCGAGCTTTATAATGTTTAAGAAACCCAGCGAACCATTTGAG

CJ1319P19

CTCAAATGGTTCGCTGGGTTTCTTAAACATTATAAAGCTCGCTTTTAT

Aph3-p3-NcoI

AGGTACCATGGTGACATCTAAATCTAGGTACT

Cj1319p25-NdeI

TGGGAATTCCATATGAACATTATAAAGCTCGCTTTTATAATTTTC

16s-Rev-Bglll

GAAGATCTGGAGGTGATCCAACCGC

1318Pr-Bglll

GAAGATCTAAAGTTGAAACTCATAGTATATGGCTTT

Aph3-For-His-NdeI

TGGGAATTCCATATGCACCACCACCACCACCACTGGATAAACCCAGCG
AACCATTTG

CJ1320P1

AGGGTCCATGGGCATGTTTAAAAAAGAAATTTCTTTTATAAAAAGTCT

CJ1320P2

GCGTCGGATCCTCATTCCTTTTTATTTGCTATTCTAACG

16S rRNA Top

GGGGTACCCTGGAACTCAACTGACGCTAA

Primer – KpnI
23S rRNA Bottom
NotI

ATAAGAATGCGGCCGCTCTTGCACATTGCAGTCCTA

CJ1419P1

AGGTACCATGGGCATGCAAAAACTAGTAGAACAA

CJ1419P2

GCGTCGGATCCTTATATTTTTTTAGCACTCCAAC

CJ1426P1

AGGTACCATGGGCATGAAAAAAGAACAATTGGAAGTATTA

CJ1426P2

GCGTCGGATCCTCATATCCAATCAAGTAAAATATTTTG

Sequencing
HP0379P1

GAATCTTGGGGGCGTTATTGG

HP0379P2

CCGGTGTAAAACACTCGTTTAG

273

HP0651P1

GGTGGTTTGCTTCAGCGGAG

HP0094P1

CAACACCTCCCCAAGCTAGT

HP0094P2

CAAGATTGCATGAGCAGCATG

qPCR
CJ1142P1

TGCATGGTGATAGAGTGGAGC

CJ1142P2

GATTTCTCATCTTCACCCATTTGT

CJ1141P1

TAGATGCGGCCAAAAGAGCA

CJ1141P2

ACCAAACCTTGCTTCTCTACAT

CJ1142P1

CCTGCCATACAAAGAGGTGT

CJ1142P2

ATAAGCCACTCATCTTGCGGT

CJ1121RT-F

AAACCTCCATTTGCGCTACG

CJ1121RT-R

TCACCACTTCAGGTGGAGGTA

CJ1294RT-F

ATTTTGCGGGCAATAGCGTT

CJ1294RT-R

CCACAGCCCCACCTTCAAAA

CJ1319RT-F

TTTATCCACACCTCAACAAGCG

CJ1319RT-R

GGTGTTAAAAGGGCGTGCAA

CJ1318RT-F

ACCGAGGCTTATGGAGGAAATG

CJ1318RT-R

TGGTTCCTTCTATCCTTGCTCC

CJ1320RT-F

GCCCTACATGAGCCTTGCTT

CJ1320RT-R

ATATGAAGGGCTGCTGTGCC

CJ1321RT-F

AGGACAAGGGGTTATAGTGTGTC

CJ1321RT-R

GCAAGGCAACAGGCTAACTC

CJ1419RT-F

AGCCTGTTGCTCTAACCCAG

CJ1419RT-R

GTCGCTGATATCGGTGCAGG

CJ1426RT-F
TTATCGACATAAAGCATCTTGTAAAAAA
CJ1426RT-R
ATTGATAATCATCAGCAAGCTAGGAA
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CJ1120RT-F

AGTTCTCCCCCTTTTGCGAT

CJ1120RT-R

TGCTTGTGTGCGTTTTGGTA

CJ1293RT-F

TTAATCACGGGCGGAACAGG

CJ1293RT-R

CACATCACGCATAGCAGCAC

CJ1427RT-F
CCGCATGCACTTTATCGATCCCA
CJ1427RT-R
CTGATATTATTATTCCTCTAGCTGCT
CJ1428RT-F
CAAGCGGTTGCTAAATTTTTTAAAGAA
CJ1428RT-R
AAATCACCTTGAAATAAATATTCCTCTT
CJ1429RT-F
GCTTGTACCAAAGTAATTGTATTCTC
CJ1429RT-R
GAATAGGTGGTAATGGAGATGGTG
CJ1430RT-F
CAGATGGAATTAAATTTAAGCATGACA
CJ1430RT-R

TGGTGGTAATAAAATAAGTTGCTGATT

AcetylRT-F
TAGCCCCAATCCTTGCACAAGCT
AcetylRT-R

AATGTCTTGATCGTCATATGAAAACAA

275

Figure 46. Expression and purification of Cj1319 tagged clones.
SDS-PAGE stained with Coomassie blue showing the induced expression of Cj1319
from four expression clones and highlighting that expression was successful with
Cj1319-CHis and Cj1319-NGST (A). The pure Cj1319-CHis elution fractions stained
with Coomassie blue (B) and detected by anti-His Western blot (C). Analysis of Cj1319NGST purification and thrombin cleavage by SDS-SDS-PAGE and Coomassie blue
staining.
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Table 10. Compositonal analysis of the LOS and capsule by GC-MS of C. jejuni WT
and cj1319::CAT.
WT
(mol %)

cj1319::CAT
(mol %)

WT
Ratio of sugars
to GalNAc

cj1319::CAT
Ratio of sugars to
GalNAc

Galactose (Gal)

29.4

25.2

4.39

3.32

Glucose (Glc)

13.4

14.0

2

1.84

6.7

7.6

1

1

(NANA)

6.7

6.3

1

0.83

Heptose

18.3

19.7

2.73

2.59

KDO

22.1

22.8

3.30

3

GlcA

22.7

22.8

1.6

1.52

Modified heptose

11.7

7.8

0.82

0.52

GalNAc

14.2

15.0

1

1

Ribose

51.4

54.4

3.6

3.6

Sugar

LOS

N-Acetyl
Galactosamine
(GalNAc)
Neuraminic acid

Capsule
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Figure 47. HCD-MS2 analysis of WT glycopeptide showing multiple glycoforms.
(A) Peptide modified with Pse5Ac7Am/Leg5Am7Ac ( 315.143 Da). (B) Peptide
modified with Pse5AcGriMe7Am (
Pse5AcGriMe7Ac ( 390.164 m/z).

389.180 m/z). (C) Peptide modified with
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Figure 48. HCD-MS2 analysis of WT glycopeptide showing multiple glycoforms.
(A) Peptide modified with Pse5Ac7Am/Leg5Am7Ac ( 315.143 Da). (B) Peptide
modified with Pse5Ac7Ac/Leg5Ac7Ac ( 316.127 Da). (C) Peptide modified with
Pse5AcGriMe7Am (
390.164 m/z).

389.180 m/z). (D) Peptide modified with Pse5AcGriMe7Ac (
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Figure 49. Targeted MS analysis of the 372.145 Da (

) modification.

(A) HCD-MS2 of peptide TTAFGVK carrying the 372.145 Da modification seen as ion at
373.160 (

). (B) HCD-MS3 of the 373.160 m/z ion acquired from HCD-MS2 data. Key

ions are noted and potential chemical formulas are indicated where applicable.
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Figure 50. HCD-MS2 analysis of WT glycopeptide glycosylated with two sugars
showing multiple glycoforms.
(A) Peptide modified with two residues of Pse5Ac7Am/Leg5Am7Ac ( 315.143 Da). (B)
Peptide modified with Pse5Ac7Ac/Leg5Ac7Ac ( 316.127 Da) and
Pse5Ac7Am/Leg5Am7Ac. (C) Peptide modified with two residues of Pse5AcGriMe7Am
( 389.180 Da). (D) Peptide modified with Pse5AcGriMe7Ac ( 390.164 Da) and
Pse5AcGriMe7Am.
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Figure 51. HCD-MS2 analysis of two WT glycopeptides only found after a sequential
digest with trypsin followed by chymotrypsin.
(A) Peptide modified with Pse5Ac7Am/Leg5Am7Ac ( 315.143 Da). (B) Peptide
modified with Pse5AcGriMe7Am (

389.180 Da).
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Figure 52. BambL and PAII-L lectin blots of soluble proteins.
Analysis of soluble protein with (A) PAII-L and (B) BambL by Western blot using
strepatividin.

283

OD550nm

Biofilm formation of C. jejuni strains on
borosilicate glass
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
aerobic

aerobic with
shaking
cjWT

cj1319

microaerobic
cj1121c

cj1294

microaerobic with
shaking

284

Figure 53. Biofilm formation of C. jejuni strains 60 hours under aerobic or
microaerobic conditions with or without shaking.
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Figure 54. Effect of Triton X-100 on C. jejuni strains in amoeba assay.
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Figure 55. Effect of Triton X-100 on C. jejuni strains in Caco-2 cell assay.
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Table 11. Monoisotopic fragment ions of the peptide FLSAGPNATNLYYHLK.

Table produced through the Fragment Ion Calculator tool on
http://db.systemsbiology.net/.
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Figure 56. BambL binds to Ley of H. pylori SS1. (Credit to A. Oberc).

287

Curriculum Vitae

Name:

Najwa Zebian

Post-secondary

Western University

Education and

London, Ontario, Canada

Degrees:

May 2011-April 2016
Ph.D candidate

Western University
London, Ontario, Canada
Sept. 2007-April 2011
BMSc Honours Specialization in Microbiology and Immunology

Honours and

Terry Beveridge Poster Award -2015

Awards:

(Canadian Society of Microbiology)
$500.00

Dr. Frederick W. Luney Graduate Travel Award -2013, 2014, 2015
Department of MNI, Western University
$1000.00
Ontario Graduate Scholarship – 2012-2013 & 2014-2015
$15,000.00

Graduate Thesis Research Award -2012, 2013
Western University
$850
Western Graduate Research Scholarship - 2011 – 2016

288

Western University
$7,500.00/year
Western Scholarship of Excellence – 2007
$1500.00

Related Work

Teaching Assistant

Experience

Western University
M&I 3610F: Microbiology Laboratory
Sept 2014- Dec 2016

Teaching Assistant
The University of Western Ontario
M&I 2100A: Biology of Prokaryotes
Sept 2012- Dec 2013

Publications:
Zebian, N., Merkx-Jacques, A., Pittock, P.P., Houle, S., Dozois, C.M., Lajoie, G.A., and
Creuzenet, C. (2015). Comprehensive analysis of flagellin glycosylation in
Campylobacter jejuni NCTC 11168 reveals incorporation of legionaminic acid and its
importance for host colonization. Glycobiology cwv104.
Hopf, P.S., Ford, R.S., Zebian, N., Merkx-Jacques, A., Vijayakumar, S., Ratnayake, D.,
Hayworth, J., and Creuzenet, C. (2011). Protein Glycosylation in Helicobacter pylori:
Beyond the Flagellins? PLoS One 6, e25722.

Oral and Poster Presentations:
1- Nov 6, 2015: Poster presentation for Infection and Immunity Research Forum
Title: A comprehensive study of Sbe1 reveals incorporation of legionaminic acid in the
flagellins, a regulatory role on capsule synthesis and a role in virulence of Campylobacter
jejuni
Authors: Najwa Zebian, Paula P. Pittock, Gilles A. Lajoie, and Carole Creuzenet

289

2- June 15-18, 2015: Poster presentation for student competition at the Canadian
Society of Microbiology - WINNER
Title: The role of Sbe1 in protein glycosylation and capsule synthesis
Authors: Najwa Zebian, Paula P. Pittock, Gilles A. Lajoie, and Carole Creuzenet
3- April 1, 2015: Poster presentation for London Health Research Day
Title: The role of Sbe1 in flagellin glycosylation and capsule synthesis
Authors: Najwa Zebian, Paula P. Pittock, Gilles A. Lajoie, and Carole Creuzenet
4- Nov 6, 2014: Poster presentation for Infection and Immunity Research Forum
Title: Investigation of the role of a sugar biosynthetic enzyme in flagellar glycosylation
and capsule synthesis
Authors: Najwa Zebian, Paula P. Pittock, Gilles A. Lajoie, and Carole Creuzenet
5- March 18, 2014: Poster presentation for London Health Research Day
Title: SBE1 and its role in the virulence of Campylobacter jejuni
Authors: Najwa Zebian and Carole Creuzenet
6- Feb 10, 2014: Poster presentation for CDDW – Main conference
Title: Investigating the function of SBE1 and its potential link to the virulence of
Campylobacter jejuni
Authors: Najwa Zebian and Carole Creuzenet
7- Nov 1, 2013: Poster presentation for Infection and Immunity Research forum
Title: Investigating the function of SBE1 and its potential link to the virulence of
Campylobacter jejuni
Authors: Najwa Zebian and Carole Creuzenet
8- March 19, 2013: Poster presentation for London Health Research Day
Title: sbe1: A novel sugar biosynthetic enzyme involved in protein glycosylation in
Campylobacter jejuni
Authors: Najwa Zebian and Carole Creuzenet
9- March 1-4, 2013: Poster presentation for CDDW – main conference
Title: Determining the function of a novel sugar biosynthetic enzyme and its role in the
pathogenesis of Campylobacter jejuni
Authors: Najwa Zebian and Carole Creuzenet

290

10- Feb 27-28, 2013: Oral Presentation for CDDW –Research Topics
Title: Determining the function of a novel sugar biosynthetic enzyme and its role in the
pathogenesis of Campylobacter jejuni
Authors: Najwa Zebian and Carole Creuzenet
11- Nov 30, 2012: Poster presentation for Infection and Immunity Research Forum
Title: Determining the function of a novel sugar biosynthetic enzyme and its role in the
pathogenesis of Campylobacter jejuni
Authors: Najwa Zebian and Carole Creuzenet
12- March 20, 2012: Poster presentation for London Health Research Day
Title: Characterization of two putative glycoproteins in Helicobacter pylori
Authors: Najwa Zebian and Carole Creuzenet
13- Nov 4, 2011: Poster presentation for Infection and Immunity Research Forum
Title: Protein glycosylation in Helicobacter pylori
Authors: Najwa Zebian and Carole Creuzenet

